

STAES Bart OFFICE

From: Inga Jesinghaus <jesinghaus@abnr.de>
Sent: 25 September 2013 14:01
Subject: Postponement of the decision in the European Parliament on the TPD
Attachments: ABNR_letter_postponement TPD.pdf; ABNR_Positionen_7_2013_english.pdf

Dear Member of the European Parliament,

please find attached a letter of the German Smoke-Free Alliance (Aktionsbündnis Nichtraucher - ABNR) concerning the postponement of the decision of the European Parliament on the Tobacco Products Directive (TPD) as well as the Tobacco industry lobbyism.

Please find enclosed also our detailed “Position on the Proposal for the Tobacco Products Directive” as presented in March 2013.

Best Regards,

Inga Jesinghaus

Inga Jesinghaus
Referentin

Aktionsbündnis Nichtraucher e.V. (ABNR)
c/o Bundesvereinigung Prävention und Gesundheitsförderung e. V. (BVPg)
Heilsbachstr. 30
D-53123 Bonn
Telefon: +49 (0) 228 987 27 18
Fax: +49 (0) 228 64 200 24
Mobile: +49 (0) 151 17 22 78 99
jesinghaus@abnr.de
www.abnr.de

STAES Bart OFFICE

From: Office DGP Berlin <office@dgpberlin.de>
Sent: 24 September 2013 14:35
To: QUISTHOUDT-ROWOHL Godelieve; DARTMOUTH William; ABELA BALDACCHINO Claudette; AGNEW John Stuart; ALBRECHT Jan Philipp; ALFANO Sonia; ALFONSI François; ALLAM Magdi Cristiano; ALVARO Alexander; ALVES Luís Paulo; ANDERSDOTTER Amelia; ANDERSON Martina; ANDREASEN Marta; ANDRES BAREA Josefa; ANDRIEU Eric; ANDRIKIENE Laima Liucija; ANGELILLI Roberta; ANGOURAKIS Charalampos; ANTINORO Antonello; ANTONESCU Elena Oana; ANTONIOZZI Alfredo; ARIAS ECHEVERRIA Pablo; ARLACCHI Pino; ARSENIS Kriton; ASHWORTH Richard; ATKINS Robert; ATTARD-MONTALTO John; AUCONIE Sophie; AUDY Jean-Pierre; AUKEN Margrete; AYALA SENDER Inés; AYLWARD Liam; AYUSO Pilar; BACH Georges; BADIA i CUTCHET Maria; BAGÓ Zoltán; BAL YTIS Zigmantas; BALDASSARRE Raffaele; BALDINI Marino; BALZ Burkhard; BALZANI Francesca; BÁNKI Erik; BARRACCIU Francesca; BARTOLOZZI Paolo; B SESCO Elena; BASTOS Regina; BATTEN Gerard; BAUER Edit; BEARDER Catherine; BECKER Heinz K.; BELDER Bastiaan; BELET Ivo; BÉLIER Sandrine; BENARAB-ATTOU Malika; BENDTSEN Bendt; BENNAHMIA Jean-Luc; BENNION Phil; BERES Pervenche; BERLATO Sergio; BERLINGUER Luigi; BERMAN Thijs; BERRA Nora; BERTOT Fabrizio; BESSET Jean-Paul; BICEP Jean-Jacob; BIELAN Adam; BILBAO BARANDICA Izaskun; BINEV Slavi; BIZZOTTO Mara; BLINKEVI I T Vilija; BLOOM Godfrey; BODU Sebastian Valentin; BOEGE Reimer; BOKROS Lajos; BONANINI Franco; BONSIGNORE Vito; BORGHEZIO Mario; BORISSOV Preslav; BORSELLINO Rita; BORYS Piotr; BORZAN Biljana; BO TINARU Victor; BOULLAND Philippe; BOVÉ José; BOWLES Sharon; BOZKURT Emine; BRADBOURN Philip; BRANTNER Franziska Katharina; BRATKOWSKI Arkadiusz Tomasz; BREZINA Jan; BROK Elmar; BRONS Andrew Henry Wiliam; BRZOBOHATÁ Zuzana; BUFTON John; BULLMANN Udo; BUŠI Zdravka; BÜTIKOFER Reinhard Hans; BUZEK Jerzy; CABRNOCH Milan; CADEC Alain; CALLANAN Martin; CAMPBELL BANNERMAN David; CANCIAN Antonio; CAPOULAS SANTOS Luis Manuel; CARONNA Salvatore; CARVALHO Maria Da Graça; CASA David; CASHMAN Michael; CASINI Carlo; CASPARY Daniel; CASTEX Françoise; CAVADA Jean-Marie; CERCAS Alejandro; EŠKOVÁ Andrea; CHATZIMARKAKIS Jorgo; CHICHESTER Giles; CHILDERS Nessa; CHOUNTIS Nikolaos; CHRISTENSEN Ole; CHRYSOGELOS Nikos; CLAEYS Philip; CLARK Derek Roland; CLIVETI Minodora; COCHET Yves; COELHO Carlos; COFFERATI Sergio Gaetano; COHN-BENDIT Daniel; COLLIN-LANGEN Birgit; COLMAN Trevor; COMI Lara; CORAZZA BILDT Anna Maria; CORNELISSEN Marije; CERCAS Alejandro; CORREIA DE CAMPOS António Fernando; CORTÉS LASTRA Ricardo; COSTA Silvia; COSTELLO Emer; COTTIGNY Jean-Louis; COZZOLINO Andrea; CRAMER Michael; CRETU Corina; CREUTZMANN Jürgen; CRONBERG Tarja; CROWLEY Brian; CUSCHIERI Joseph; CUTA George Sabin; CYMA SKI Tadeusz; CZARNECKI Ryszard; DAERDEN Frederic; D NCIL Vasilica Viorica; DANELLIS Spyros; DANJEAN Arnaud; DANTIN Michel; DATI Rachida; DAUL Joseph; DAVID Mário; chris@chrisdaviesmep.org.uk; DE ANGELIS Francesco; DE BACKER Philippe; DE CASTRO Paolo; DE GRANDES PASCUAL Luis; DE JONG Dennis; DE KEYSER Véronique; DE LANGE Esther; DE MARTINI Susy; DE MITA Luigi Ciriaco; DE SARNEZ Marielle; DE VEYRAC Christine; DE VILLIERS Philippe; DEHAENE Jean-Luc; DEL CASTILLO Pilar; DELLI Karima; DELVAUX Anne; DEMESMAEKER Mark; DESIR Harlem; DESS Albert; DEUTSCH Tamás; DEVA Nirj; PATRÃO NEVES Maria do Céu; DODDS Diane; DOMENICI Leonardo; DONSKIS Leonidas; DORFMANN Herbert; DROUTSAS Dimitrios; DUFF Andrew; DURANT Isabelle; DUŠEK Robert; DÍAZ DE MERA GARCÍA-CONSUEGRA Agustín; EHLER Christian; EHRENHAUSER Martin; EICKHOUT Bas; EL KHADRAOUI Saïd; ELLES James; ENCIU Ioan; ENGEL Frank; ENGSTRÖM Christian; EPPINK Derkjan; ERNST Cornelia; ERTUG Ismail; ESSAYAH Sari; ESTARAS FERRAGUT Rosa; ESTRELA Edite; EVANS Jill; FAJMON Hynek; FAJON Tanja; FALBR Richard; FARAGE Nigel; FÄRM Göran; FEIO Diogo; Prof. Dr. med. Martin Kohlhäufel; FERNANDES José Manuel; FERREIRA João; FERREIRA Elisa; FIDANZA Carlo; FISAS AYXELA Santiago; FJELLNER Christofer; FLAŠÍKOVÁ BE OVÁ Monika; FLAUTRE Hélène; FLECKENSTEIN Knut; FONTANA Lorenzo; FORD Victoria Grace; FOSTER Jacqueline; FOX Ashley; FRAGA ESTÉVEZ Carmen; FRANCO Gaston; FRIGO Franco; GABRIEL Mariya; GAHLER Michael; GÁL Kinga; GALLAGHER Pat the Cope; GALLO Marielle; GÁLL-PELCZ Ildikó; GARCÉS RAMÓN Vicente; GARCÍA-HIERRO CARABALLO Dolores; GARCÍA-PEREZ Iratxe; GARDIAZÁBAL RUBIAL Eider; GARDINI Elisabetta; guiseppe.gargani@europarl.europa.eu; GARRIGA POLLEDO Salvador; GAUZÈS Jean-Paul; GEBHARDT Evelyne; GEIER Jens; GERBRANDY Gerben-Jan; GERINGER DE OEDENBERG Lidia Joanna; GIANNAKOU Marietta; GIEGOLD Sven; GIEREK Adam; GIRLING Julie; GLANTE Norbert; GLATTFELDER Béla;

To: GODMANIS Ivars; GOEBBELS Robert; GOERENS Charles; GOLLNISCH Bruno; GOMES Ana Maria; GÖNCZ Kinga; GOULARD Sylvie; THUN UND HOHENSTEIN Ró a Maria Gräfin von; GRAESSLE Ingeborg; GREZE Catherine; GRIESBECK Nathalie; GRIFFIN Nick; GRÓBARCZYK Marek Józef; GROSCHE Mathieu; GROSSETETE Françoise; GRZYB Andrzej; GUALTIERI Roberto; GUERRERO SALOM Enrique; GUILLAUME Sylvie; GURMAI Zita; GUSTAFSSON Mikael; GUTIÉRREZ PRIETO Sergio; GUTIERREZ-CORTINES Cristina; GYURK Andras; HADJIGEORGIOU Takis; HÄFNER Gerald; HALL Fiona; HÄNDEL Thomas; HANDZLIK Malgorzata; HANKISS Ágnes; HANNAN Daniel; HARBOUR Malcolm; HARKIN Marian; HARTONG Lucas; HASSI Satu; HÄUSLING Martin; HEDH Anna; Eduardraulhellvig@europarl.europa.eu; HELMER Roger; HENIN Jacky; HERCZOG Edit; HERRANZ GARCIA Esther; HIBNER Jolanta Emilia; HIGGINS Jim; HIRSCH Nadja; HOANG NGOC Liem; HOHLMEIER Monika; HÖKMARK Gunnar; HONEYBALL Mary; HORTEFEUX Brice; HOWITT Richard; HUEBNER Danuta Maria; HUDGHTON Ian; HUGHES Stephen; HYUSMENOVA Filiz Hakaeva; IACOLINO Salvatore; IBRISAGIC Anna; ILCHEV Stanimir; IMBRASAS Juozas; IN'T VELD Sophie; IOTOVA Iliana Malinova; IOVINE Vincenzo; Inaki.irazalbalbeitiafernandez@europarl.europa.eu; IRIGOYEN PÉREZ María; ITURGAIZ ANGULO Carlos; IVAN C t lin-Sorin; JAAKONSAARI Liisa; JÄÄTTEENMÄKI Anneli; JADOT Yannick; JAHR Peter; JÁRÓKA Lívía; JAZŁOWIECKA Danuta; J DRZEJEWSKA Sidonia El bieta; JEGGLE Elisabeth; JENSEN Anne E.; JIMENEZ-BECERRIL BARRIO Teresa; JOHANSSON Kent; JOLY Gro Eva; JORDAN Romana; JØRGENSEN Dan; JUVIN Philippe; KACIN Jelko; KACZMAREK Filip; KADENBACH Karin; KALFIN Ivailo; KALINOWSKI Jarosław; KALNIETE Sandra; KAMALL Syed; KAMI SKI Michał Tomasz; KAMMEREVERT Petra; KARAS Othmar; KARIM Sajjad; KARI Š Krišj nis; KASTLER Martin; KAZAK Metin; KELAM Tunne; KELLER Franziska; KELLY Seán; KIIL-NIELSEN Nicole; KIRILOV Evgeni; KIRKHOPE Timothy; KLEVA KEKUŠ Mojca; KLINZ Wolf; KLUTE Jürgen; KOCH Dieter-Lebrecht; KOCH-MEHRIN Silvana; KOHLICEK Jaromír; KOLARSKA-BOBI SKA Lena; KOPPA Maria Eleni; KORHOLA Eija-Riitta; KÓSA Ádám; KÖSTINGER Elisabeth; KOUMOUTSAKOS Georgios; KOVÁCS Béla; KOVATCHEV Andrey; KOWAL Paweł Robert; KOZLIK Sergej; KOZŁOWSKI Jan; KOŽUŠNÍK Edvard; KRATSA-TSAGAROPOULOU Rodi; KREHL Constanze Angela; KREISSL-DORFLER Wolfgang; KUHN Werner; KUKAN Eduard; KURSKI Jacek; LA VIA Giovanni; LAMASSOURE Alain; LAMBERT Jean; LAMBERTS Philippe; LAMBSDORFF Alexander Graf; LANDSBERGIS Vytautas; LANGE Bernd; LANGEN Werner; LE BRUN Agnès; LE GRIP Constance; LE HYARIC Patrick; LE PEN Jean-Marie; LE PEN Marine; LEGUTKO Ryszard Antoni; LEHNE Klaus-Heiner; LEICHTFRIED Jörg; LEPAGE Corinne; LIBERADZKI Bogusław; LICHTENBERGER Eva; LIOTARD Kartika Tamara; LISEK Krzysztof; LOCHBIHLER Barbara; LØKKEGAARD Morten; LOPE FONTAGNÉ Veronica; LÓPEZ AGUILAR Juan Fernando; LÓPEZ ISTÚRIZ Antonio; LÖSING Sabine; LÖVIN Isabella; LUDFORD Sarah; LUDVIGSSON Olle; LUHAN Petru Constantin; ŁUKACIJEWSKA El bieta Katarzyna; LULLING Astrid; LUNACEK Ulrike; LYON George; LYUBCHEVA Marusya; MACOVEI Monica Luisa; MALETI Ivana; MALINOV Svetoslav Hristov; MANDERS Toine; MANKA Vladimir; MANN Thomas; MARCINKIEWICZ Bogdan Kazimierz; MARINESCU Marian-Jean; MARTIN David; MARTIN Hans-Peter; MARTINEZ Miguel Angel; MASIP HIDALGO Antonio; MASTALKA Jiri; MASTELLA Clemente; MATERA Barbara; MATHIEU HOUILLON Véronique; MATIAS Marisa; MATO Gabriel; MATULA Iosif; MAYER Hans-Peter; MAYOR OREJA Jaime; MAZEJ KUKOVI Zofija; MAZZONI Erminia; MCAVAN Linda; MCCARTHY Arlene; MCCLARKIN Emma; McGUINNESS Mairead; MCINTYRE Anthea; MCMILLAN-SCOTT Edward; MEISSNER Gesine; MÉLENCHON Jean-Luc; MELO Nuno; MENENDEZ DEL VALLE Emilio; MERKIES Judith A.; MESSERSCHMIDT Morten; MÉSZÁROS Alajos; METSOLA Roberta; MEYER Willy; MICHEL Louis; MICHELS Martina; MIGALSKI Marek Henryk; MIKOLASIK Miroslav; MILANA Guido; MILLÁN MON Francisco; MIRSKY Alexander; MITCHELL Gay; MIZZI Marlene; MÖLZER Andreas; MORAES Claude; MOREIRA Vital; MORGANTI Claudio; MORIN-CHARTIER Elisabeth; MORK NAIT -MIKUL NIEN Radvil ; MORVAI Krisztina; MOTTI Tiziano; MULDER Jan; MUÑIZ DE URQUIZA María; MURPHY Paul; MUSCARDINI Cristiana; MYNÁ Vojt ch; NARANJO ESCOBAR Juan; NATTRASS Michael Henry; NEUSER Norbert; NEVE ALOVÁ Katarína; NEWTON DUNN Bill; NEYNSKY Nadezhda; NEYTS-UYTTEBROECK Annemie; NICHOLSON James; NICOLAI Norica; NICULESCU Rare -Lucian; NIEBLER Angelika; NILSSON Jens; NITRAS Sławomir; NUTTALL Paul; OBERMAYR Franz; OBIOLS I GERMA Raimon; OJULAND Kristiina; OLBRYCHT Jan; OLEJNICZAK Wojciech Michał; OMARJEE Younous; OOMEN-RUIJTEN Ria; ORTIZ VILELLA Eva; ORY Csaba; OUZKY Miroslav; OVHIR Siiri; PACK Doris Gisela; PADAR Ivari; PAKARINEN Riikka; PAKSAS Rolandas; PALECKIS Justas Vincas; PALIADELI Chrysoula; PALLONE Alfredo; PANAYOTOV Vladko Todorov; PANAYOTOVA Monika; PANZERI Pier Antonio; PAPAPOPOULOU Antigoni; PAPANIKOLAOU Georgios; PAPANASTAMKOS Georgios; PARGNEAUX Gilles; PARVANOV Antonia; PASCU Ioan Mircea; PAŠKA Jaroslav; PATRICIELLO Aldo;

To: PAULSEN Marit; PERELLO RODRIGUEZ Andres; PETERLE Alojz; PETROVI JAKOVINA Sandra; PICULA Tonino; PIEPER Markus; PIETIKÄINEN Sirpa; PIOTROWSKI Mirosław; PIRILLO Mario; PIRKER Hubert; PITSILLIDES Andreas; PITTELLA Gianni; PLENKOVI Andrej; POC Pavel; PODIMATA Anni; PONGA Maurice; POREBA Tomasz Piotr; mail@bernd-posselt.de; POETTERING Hans-Gert; POUPAKIS Konstantinos; PREDÁ Cristian Dan; PRENDERGAST Phil; PRODI Vittorio; PROTASIEWICZ Jacek; PROUST Franck; PROVERA Fiorello; RANGEL Paulo; RANSDORF Miloslav; RAPKAY Bernhard; RAPTI Sylvana; REGNER Evelyn; REMEK Vladimir; REPO Mitro; REUL Herbert; RIERA MADURELL Teresa; RIES Frédérique; RINALDI Niccolò; RIQUET Dominique; RIVASI Michèle; RIVELLINI Crescenzo; ROATTA Jean; ROCHEFORT Robert; RODUST Ulrike; ROHDE Jens; ROITHOVA Zuzana; ROMERO LÓPEZ Carmen; ROMEVA i RUEDA Raül; RONZULLI Licia; ROSBACH Anna; ROSSI Oreste; ROUCEK Libor; RUBIG Paul; RUBIKS Alfreds; RUEHLE Heide; ŠADURSKIS K rlis; SAIFI Tokia; SALAFRANCA José Ignacio; SALATTO Potito; SALAVRAKOS Nikolaos; SALVINI Matteo; SÁNCHEZ PRESEDO Antolín; SANCHEZ-SCHMID Marie-Thérèse; SARBU Daciana Octavia; SARGENTINI Judith; SARTORI Amalia; SARVAMAA Petri; SARYUSZ-WOLSKI Jacek; SASSOLI David-Maria; SAUDARGAS Algirdas; SAVISAAR-TOOMAST Vilja; SCHAAKE Marietje; SCHALDEMOSE Christel; SCHLYTER Carl; SCHMIDT Oille; SCHOLZ Helmut; SCHÖPFLIN György; SCHROEDTER Elisabeth; SCHULZ Martin, President; SCHULZ Werner; SCHWAB Andreas; SCOTTA' Giancarlo; SCURRIA Marco; SEDÓ I ALABART Salvador; SEEBER Richard; SEHNALOVÁ Olga; SENYSZYN Joanna; SEVERIN Adrian; SIEKIERSKI Czesław; SILAGHI Ovidiu Ioan; SILVESTRIS Sergio Paolo Francesco; SIMON Peter; SIMPSON Brian; SINCLAIRE Nikki; SIPPEL Birgit; SIWIEC Marek; SKINNER Peter; SKRZYDLEWSKA Joanna Katarzyna; SKYLAKAKIS Theodoros; SMITH Alyn; SMOLKOVÁ Monika; SÓGOR Csaba; SØNDERGAARD Søren Bo; SONIK Bogusław; SOPHOCLEOUS Sophocles; SOSA WAGNER Francisco; SOUSA Alda; SPERONI Francesco Enrico; STADLER Ewald; STAES Bart; STASSEN Laurence; STASTNY Peter; STAVRAKAKIS Georgios; STEINRUCK Jutta; STEVENSON Struan; STIER Davor; STIHLER Catherine; STOLOJAN Theodor Dumitru; STOYANOV Dimitar; STREJCEK Ivo; STRIFFLER Michele; STURDY Robert; ŠUICA Dubravka; SURJAN Laszlo; SVENSSON Alf; SWINBURNE Jacqueline Kay; SWOBODA Hannes; SZAJER Jozsef; SZEGEDI Csanád; SZYMANSKI Konrad; TABAJDI Csaba; TAKKULA Hannu; T N Sescu Claudiu Ciprian; TANNOCK Charles; TARABELLA Marc; TARAND Indrek; TATARELLA Salvatore; TAVARES Rui; TAYLOR Rebecca; TAYLOR Rebecca; TEIXEIRA Nuno; TERHO Sampo; THEIN Alexandra; THEOCHAROUS Eleni; THEURER Michael; THOMAS Isabelle; THOMSEN Britta; THYSSEN Marianne; IC U Silvia Adriana; TIROLIEN Patrice; TOIA Patrizia; T KÉS László; TOMAŠEVSKI Valdemar; TOMAŠI Ruža; TORVALDS Nils; TOŠENOVSKÝ Evžen; TOUSSAS Georgios; TRAUTMANN Catherine; TREMATERRA Gino; TREMOSA i BALCELLS Ramon; TRIANTAPHYLIDIS Kyriacos; TRÜPEL Helga; TRZASKOWSKI Rafał; TSOUKALAS Ioannis A.; TURMES Claude; TURUNEN Emilie; TZAVELA Niki; UGGIAS Giommara; ULVSKOG Marita; UNGUREANU Traian; URUTCHEV Vladimir Andreev; VADIM Tudor Corneliu; VAIDERE Inese; VAJGL Ivo; V LEAN Adina Ioana; VALJALO Oleg; VAN BAALEN Johannes Cornelis; VAN BREMPT Kathleen; VAN DALEN Peter; VAN DE CAMP Wim; VAN DER KAMMEN Patricia; VAN DER STOEP Daniel; VAN NISTELROOIJ Lambert; VAN ORDEN Geoffrey; VANHECKE Frank; VATTIMO Gianni; VAUGHAN Derek; VERGIAT Marie-Christine; VERGNAUD Bernadette; VERHEYEN Sabine; VERHOFSTADT Guy; VIDAL-QUADRAS Alejo; VITKAUSKAITE BERNARD Justina; VLASAK Oldrich; VLASTO Dominique; VOSS Axel; VULJANI Nikola; WAŁ SA Jarosław; WATSON Graham; WEBER Henri; WEBER Manfred; WEBER Renate; WEIDENHOLZER Josef; WEILER Barbara; WERTHMANN Angelika; WESTLUND Asa; WESTPHAL Kerstin; WIELAND Rainer; WIKSTRÖM Cecilia; WILLMOTT Glenis; WINKLER Hermann; WINKLER Iuliu; WŁOSOWICZ Jacek Władysław; WOJCIECHOWSKI Janusz; WORTMANN-KOOL Corien; YAÑEZ-BARNUEVO GARCÍA Luis; YANNAKOUDAKIS Marina; ZABORSKA Anna; ZHRADIL Jan; ZALA Boris; ZALBA BIDEGAIN Pablo; ZALEWSKI Paweł; ZAMFIRESCU Dan Dumitru; ZANICCHI Iva; ZANONI Andrea; ZASADA Artur; ZDANOKA Tatjana; ZELLER Joachim; ZEMKE Janusz; ZERIBI Karim; ZIJLSTRA Auke; ZILE Roberts; ZIMMER Gabriele; ZIOBRO Zbigniew; ZUBER Inês; ZVER Milan; ZWIEFKA Tadeusz

Cc: Anja Flender; Robert Loddenkemper; 'Tobias Welte'

Subject: Voting on Tobacco Product Directive

Attachments: 2013-09-24_Tobacco Product Directive.pdf

Dear members of the European Parliament,

please find attached a letter from the German Respiratory Society concerning the voting on the Tobacco Product Directive.

Sincerely yours,

Friederike Röder
Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V.
Stralauer Platz 34
10243 Berlin

Tel: 030 29 36 - 27 01

Fax: 030 29 36 - 27 02

Email: office@dgpberlin.de

STAES Bart OFFICE

From: Charles Hamshaw-Thomas <Charles@e-lites.co.uk>
Sent: 20 September 2013 18:17
To: Charles Hamshaw-Thomas
Subject: 100 Words On E-Cigarettes: safe, popular and effective - so let's ban them!

- **August 2013:** Goldman Sachs says "e-cigarettes are by far the most credible alternative to cigarettes"
- **September 2013:** The Lancet publishes research demonstrating e-cigarettes are at least as good as nicotine patches at reducing smoking
- **October 2013:** MEPs vote to impose legislation that destroys nearly all e-cigarette businesses

Is this the future? If medicinal regulation is approved on 8 October, MEPs will be effectively banning a product which health professors say is safe, bankers say is popular and academics say is effective. Europe's 12 million e-cigarette users ask MEPs to look at this expert evidence before voting on life and death...

Charles Hamshaw-Thomas, Legal & Corporate Affairs Director for E-Lites

Notes:

Winning the battle against Tobacco

- "We have increased conviction that consumption of e-cigs could surpass consumption of conventional cigs within the next decade." [Wells Fargo, June 2013](#)
- "...the first real possibility that cigarette smoking could be phased out" Professor Ann McNeill, Kings College London [Reuters, September 2013](#)
- E-cigarettes are "the most significant development in the history of the organised tobacco industry, stretching back some 200 years," [Canaccord Genuity, July 2013](#)
- Tobacco company shares downgraded due to e-cigarette growth: [The Guardian, July 2013](#)
- E-cigarettes help smokers to quit even when they are not motivated: [Polosa Study, June 2013](#)

Reducing smoking faster than Pharmaceutical Products

- "E-cigarettes are by far the most credible alternative to tobacco cigarettes" [Goldman Sachs, August 2013](#)
- "E-cigarettes are more effective than nicotine patches" [The Independent, September 2013](#) quoting [Bullen, Lancet, September 2013](#)
- "Nicotine replacement therapy products represent a classic example of the stifling effect of medicinal regulation. There have been no major improvements since they were introduced 30 years ago" [Hajek, Lancet, July 2013](#)
- "The world should welcome the electronic cigarette" [The Economist, March 2013](#)
- "Regulating them as medicines is a really bad idea. It is extremely expensive. The only players able to afford medicinal licensing will be big tobacco. They will have no interest in developing them further." Professor Peter Hajek on BBC, Sept 2013

Safe - e-cigarettes do not cause harm, regulation needs only to be light

- "The chemicals in e-cigarettes pose no health concern for users or bystanders" [Drexel University, August 2013](#)
- "The chemicals that make cigarettes dangerous are either absent in electronic cigarettes or present only in trace concentrations" [Lancet, July 2013](#)
- "The study indicates no apparent risk to human health from e-cigarette emissions" [Inhalation Toxicology, October 2012](#)
- "The risk is negligible, and compared with smoking there is no contest" [Professor Robert West, University College London, July 2013](#)

- “If all the smokers in Britain stopped smoking cigarettes and started smoking e-cigarettes we would save 5 million deaths” Professor John Britton, Royal College of Physicians, February 2013

Legal:

- Medicinal regulation is “a very extreme and intrusive form of regulation” that is likely to be annulled Legal Opinion, July 2013 from Sir Francis Jacobs KCMG QC, former Advocate-General to the European Court of Justice

E-Lites:

This is the main brand of Zandera Ltd, the UK’s largest e-cigarette company and believes tight regulation of product quality and safety is important



E-Lites

Charles Hamshaw-Thomas | Director of Legal & Corporate Affairs
+ 44 (0) 7715 091 254 | + 44 (0) 1527 573 492 | www.E-Lites.co.uk
Zandera Ltd, 18 Buntsford Park Road, Bromsgrove, Worcestershire B60 3DX

This email and any attachments to it may be confidential and are intended solely for the use of the individual to whom it is addressed. Any views or opinions expressed are solely those of the author and do not necessarily represent those of Zandera Ltd/E-Lites. If you are not the intended recipient of this email, you must neither take any action based upon its contents, nor copy or show it to anyone. Please contact the sender if you believe you have received this email in error.



[Check out our latest advert on YouTube!](#)

This email has been scanned by the Symantec Email Security.cloud service.
Provided by ATG-IT - www.atg-it.co.uk

STAES Bart OFFICE

From: droomvlucht@zonnet.nl
Sent: 20 September 2013 17:26
To: VERHOFSTADT Guy
Subject: Een vriendelijk verzoek voor 8 oktober.

Geachte Lezer,

Op 8 oktober wordt gestemd over de nieuwe tabaksrichtlijnen en wil graag Uw aandacht vragen voor het volgende.

E-roken (Dampen) is hetzelfde als koffie en alcohol= een genotsmiddel. Het is geen medicijn zoals al bewezen is en als het zo slecht voor de mens zou zijn zoals men beweert in de regering waarom zou je er dan met een goed geweten een medicijn van willen maken.

Ik ben niet ziek en heb geen "medicijn" nodig ik wil gewoon lekker dampen en genieten van al de smaakjes waar ik uit kan kiezen. Ik hoef er niet voor naar de winkel want alles is online te koop in goede webshops wat ik graag zo zou willen blijven zien, aangezien mijn lichamelijke beperkingen.

Het is moreel heel verkeerd als men alcohol en koffie in een winkel/online kan kopen en de e-rookwaren niet.

Daar komt nog bij en dat vind ik persoonlijkst het ergste, dat de echte sigaret waar op het pakje staat dat het DODELIJK is gewoon in de winkel/online te koop is en de aanzienlijk minder schadelijke e-sigaret verboden zou worden.

Ik wil U dus vragen om TEGEN het volgende te stemmen:

1- Amendement 71 om de e-sigaret onder de geneesmiddelenwet te laten vallen.

Wij als Damper gemeenschap willen graag dat het blijft zoals het nu is en hoort te zijn : een genotsmiddel, wel met controle op veiligheid en kwaliteit.

Dank U voor het lezen van mijn email en ik hoop van harte dat U mijn vraag in overweging wil nemen met het belang van de algemene volksgezondheid voor ogen, want als de e-sigaret verboden wordt, zullen 100.000-den mensen gedwongen worden terug te grijpen naar de normale DODELIJKE sigaret en ik kan me niet voorstellen dat iemand dat op zijn/haar geweten wil hebben.

Hoogachtend,
Monika Oord

STAES Bart OFFICE

From: Schmitt, Susanne <su.schmitt@dkfz-heidelberg.de>
Sent: 18 September 2013 10:00
To: Schmitt, Susanne
Cc: Schunk, Susanne
Subject: Delay of the Tobacco Products Directive - Information of the German Cancer Research Center
Attachments: Letter DKFZ to all MEP September 2013.pdf

Dear Ladies and Gentlemen of the European Parliament,

In preparation of the vote on the Tobacco Products Directive we send you a letter of Prof. Dr. med. Dr. h.c. Otmar D. Wiestler, chairman and scientific member of the management board of the German Cancer Research Center.

If you have any further queries, please do not hesitate to contact us.

Sincerely yours

Dr. Martina Pötschke-Langer

STAES Bart OFFICE

From: celialiu@sky-sz.net
Sent: 18 September 2013 08:19
To: COHN-BENDIT Daniel; HARMS Rebecca; EVANS Jill; CORNELISSEN Marije; EICKHOUT Bas; LUNACEK Ulrike; RIVASI Michèle; ROMEVA i RUEDA Raül; TURMES Claude; TSETSI Paraskevi; DENKINGER Joachim; LINAZASORO José Luis; ALFONSI François; AUKEN Margrete; BRANTNER Franziska Katharina; CRAMER Michael; GIEGOLD Sven; GREZE Catherine; HÄFNER Gerald; HASSI Satu; HÄUSLING Martin; JADOT Yannick; LAMBERT Jean; LICHTENBERGER Eva; LÖVIN Isabella; RUEHLE Heide; SARGENTINI Judith; STAES Bart; TAVARES Rui; TRÜPEL Helga; CORNELIUS Steven; DIMITROVS Aleksejs; silvio.falcon; INGELAERE Frank; MUIR Lachlan; UYTTERSROT Katrien; WYLIE Daniel; APOTEKER Arnaud; ARHELGER Malte; AUTH Kristian; BALTIME Nelly; BEECKMANS Paul; BELTRAME Francesca; BENTOLILA Karen; BERGAMASCHI Paolo; BROCHARD Aurélie; BURSI Camilla; CHABAUD Frédérique; CHALENCON Delphine; CUTARELLI Claudio; DEVELAY Laurent; DI FILIPPO Gerard; DRIEUX Willy; DUGNIOLLE Laurence; DULLAERT Jean-Pierre; EARLE Michael; FISERA Raphael; GAROBY Roccu; GAUDOT Edouard; GIMENEZ Marc; GRUDZIELSKI Stany; HAAS Marie Anne Sophie; HALMOS Berta; HEIDER Tobias; HERLOFSEN Veronica; HILDWEIN-SCHEELE Andrea; HORSTKOETTER Elisabeth; HUNDSDORFER Stefanie; JOSEFSSON Erik; JUNG Diana; KEMP David; KOEHLER Martin; KOELLER Tom; KRIKORIAN Gaëlle; KUPPERS Gaby; KUTTEN Jean; KWAN Claire; LEBERLE Heike; LEHTONEN Terhi; LORENZEN Hannes; LOSADA Sebastian; MEYER Sabine; MEYRL Sonja; MIGLIOLI Chiara; MORE O'FERRALL Richard; MORRISON David; MURRAY Grace; NOWAKOWSKI Andrzej; PADILLA OLIVARES Francisco Javier; PERLI Silver; PIERINI Jean-Bernard; PINZER Verena; POGLIANI Silvia; PRUMMEL Hendrik; RAQUET Michel; RECINELLA Daniela; REICHSTEIN Ruth; REINHART Simone; RIHOVSKY Hana; SCHMITT Michael; SCHOLZE Philine; SELLIER Guillaume; SGRAZZUTTI Susanne; SIDENIUS Christine; SINGHOFEN Axel; STONE Sarah; STORZ Gesa; TREPANT Ines; TSAKLANGANOS Georgia; WEIXLER Helmut; ZERROUK Isabelle; VAN BALLEGOOIJ Wouter; WALELIGN Tsiguereda; YURTTAGUL Ali; ZERGER Corinna
Cc: callyyang; tobykang
Subject: SKY E-Cigarette all Category Quotation Sheet-20130824
Attachments: SKY E-Cigarette all Category Quotation Sheet-20130824.pdf

Dear Buyer,

How are you?

I'm Celia from Shenzhen Sky Corporation Co.,Ltd

We are professional manufacturer for electronic cigarette..

Our products cover mini e-cigarette rechargeable kit,disposable,cartomzier,battery,CE4,CE5,510 kit,ego-c etc.

Attached is our quotation sheet for your reference.

Selling point:

- 1.Competitive price with high quality;
- 2.All our products are full inspection with reject ratio below 1%;
- 3.Short production period and delivery 3~15;
- 4.OEM/ODM is welcome

Looking forward our cooperation!

Thanks and Best regards

Celia

E-mail: celialiu@sky-sz.net

Tel : +86-755-85284033

Fax: +86-755-85284033-808

Mobile: +86-15602482877

Skype: w15602482877

Website: <http://www.sky-sz.net>: www.globalsources.com/shenzhen-sky.co

Address: Building C, JunDa Industrial Park, FuYuan 2nd Road, FuYong Town, BaoAn District, Shenzhen City, Guang Dong Province, China

STAES Bart OFFICE

From: celialiu@sky-sz.net
Sent: 18 September 2013 04:54
To: COHN-BENDIT Daniel; HARMS Rebecca; EVANS Jill; CORNELISSEN Marije; EICKHOUT Bas; LUNACEK Ulrike; RIVASI Michèle; ROMEVA i RUEDA Raül; TURMES Claude; TSETSI Paraskevi; DENKINGER Joachim; LINAZASORO José Luis; ALFONSI François; AUKEN Margrete; BRANTNER Franziska Katharina; CRAMER Michael; GIEGOLD Sven; GREZE Catherine; HÄFNER Gerald; HASSI Satu; HÄUSLING Martin; JADOT Yannick; LAMBERT Jean; LICHTENBERGER Eva; LÖVIN Isabella; RUEHLE Heide; SARGENTINI Judith; STAES Bart; TAVARES Rui; TRÜPEL Helga; CORNELIUS Steven; DIMITROVS Aleksejs; silvio.falcon; INGELAERE Frank; MUIR Lachlan; UYTTERSROT Katrien; WYLIE Daniel; APOTEKER Arnaud; ARHELGER Malte; AUTH Kristian; BALTIME Nelly; BEECKMANS Paul; BELTRAME Francesca; BENTOLILA Karen; BERGAMASCHI Paolo; BROCHARD Aurélie; BURSI Camilla; CHABAUD Frédérique; CHALENCON Delphine; CUTARELLI Claudio; DEVELAY Laurent; DI FILIPPO Gerard; DRIEUX Willy; DUGNIOLLE Laurence; DULLAERT Jean-Pierre; EARLE Michael; FISERA Raphael; GAROBY Roccu; GAUDOT Edouard; GIMENEZ Marc; GRUDZIELSKI Stany; HAAS Marie Anne Sophie; HALMOS Berta; HEIDER Tobias; HERLOFSEN Veronica; HILDWEIN-SCHEELE Andrea; HORSTKOETTER Elisabeth; HUNDSDORFER Stefanie; JOSEFSSON Erik; JUNG Diana; KEMP David; KOEHLER Martin; KOELLER Tom; KRIKORIAN Gaëlle; KUPPERS Gaby; KUTTEN Jean; KWAN Claire; LEBERLE Heike; LEHTONEN Terhi; LORENZEN Hannes; LOSADA Sebastian; MEYER Sabine; MEYRL Sonja; MIGLIOLI Chiara; MORE O'FERRALL Richard; MORRISON David; MURRAY Grace; NOWAKOWSKI Andrzej; PADILLA OLIVARES Francisco Javier; PERLI Silver; PIERINI Jean-Bernard; PINZER Verena; POGLIANI Silvia; PRUMMEL Hendrik; RAQUET Michel; RECINELLA Daniela; REICHSTEIN Ruth; REINHART Simone; RIHOVSKY Hana; SCHMITT Michael; SCHOLZE Philine; SELLIER Guillaume; SGRAZZUTTI Susanne; SIDENIUS Christine; SINGHOFEN Axel; STONE Sarah; STORZ Gesa; TREPANT Ines; TSAKLANGANOS Georgia; WEIXLER Helmut; ZERROUK Isabelle; VAN BALLEGOOIJ Wouter; WALELIGN Tsiguereda; YURTTAGUL Ali; ZERGER Corinna
Cc: callyyang; tobykang
Subject: SKY E-Cigarette Starter Kits Quotation
Attachments: SKY E-Cigarette all Category Quotation Sheet-20130824.pdf

Dear Buyer,

How are you?

I'm Celia from Shenzhen SKY CORPORATION LIMITED.

We are professional manufacturer for electronic cigarette..

Our products cover mini e-cigarette rechargeable kit,disposable,atomizer,battery,CE4,CE5,510 kit,ego-c etc.

Attached is our quotation sheet for your reference.

Selling point:

- 1.Competitive price with high quality;
- 2.All our products are full inspection with reject ratio below 1%;
- 3.Short production period and delivery 3~15;
- 4.OEM/ODM is welcome

Looking forward our cooperation!

Thanks and Best regards

Celia

E-mail: celialiu@sky-sz.net

Tel : +86-755-85284033

Fax: +86-755-85284033-808

Mobile: +86-15602482877

Skype: w15602482877

Website: <http://www.sky-sz.net>: www.globalsources.com/shenzhen-sky.co

Address: Building C, JunDa Industrial Park, FuYuan 2nd Road, FuYong Town, BaoAn Distict, Shenzhen City, Guang Dong Province, China

STAES Bart OFFICE

From: Schmitt, Susanne <su.schmitt@dkfz-heidelberg.de>
Sent: 17 September 2013 10:54
To: Schmitt, Susanne
Cc: Schunk, Susanne; Pötschke-Langer, Martina
Subject: Delay of the Tobacco Products Directive - Information of the German Cancer Research Center
Attachments: Letter DKFZ to all MEP September 2013.pdf

Dear Ladies and Gentlemen of the European Parliament,

In preparation of the vote on the Tobacco Products Directive we send you a letter of Prof. Dr. med. Dr. h.c. Otmar D. Wiestler, chairman and scientific member of the management board of the German Cancer Research Center.

If you have any further queries, please do not hesitate to contact us.

Sincerely yours

Dr. Martina Pötschke-Langer

STAES Bart OFFICE

From: peter van bladel <petervanbladel@live.be>
Sent: 16 September 2013 19:37
Cc: BELET Ivo; CLAEYS Philip; DE BACKER Philippe; DEHAENE Jean-Luc; DEMESMAEKER Mark; EL KHADRAOUI Saïd; EPPINK Derkjan; NEYTS-UYTTEBROECK Annemie; STAES Bart; THYSSEN Marianne; VAN BREMPT Kathleen; VANHECKE Frank; VERHOFSTADT Guy
Subject: elektrisch-roken

Geachte,

Ik heb onlangs ergens vernomen dat het europees parlement het elektrisch roken wil gaan verbieden of het onder de medicijnenwet wil plaatsen.

Zoals je weet is bijna elke roker ooit beginnen roken net omdat het door de ouders verboden werd, alles wat je als tiener niet mocht doen deed je juist wel omdat het nu eenmaal spannender is wanneer je iets word verboden.

Nu willen al die mensen maar al te graag van hun rookverslaving afkomen en dat kan perfect met elektrisch te gaan (roken) DAMPEN, zo is het mij en heel wat vrienden al gelukt om niet meer te roken. Hierbij heb je misschien iets om toch nog maar eens over na te denken vooraleer je iets gaat verbieden

Groeten van een damper

Verzonden met Windows

STAES Bart OFFICE

From: "Campaign" <campaign@saveecigs.com>
Sent: 15 September 2013 19:50
To: STAES Bart
Subject: Request for a meeting in Brussels.

Dear Bart,

As you may be aware, a new EU-wide campaign has recently been launched campaigning on behalf of electronic cigarette users, their friends, and their families. Full details of this campaign and their letter can be found at www.saveecigs.com.

Representatives of the campaign will be in Brussels on the 1st and 2nd of October and we would very much like to take this opportunity to meet with you for no more than five minutes to set out our views and to answer any questions you may have regarding the regulation of electronic cigarettes ahead of the vote in Strasbourg on the 8th of October.

We very much hope that you will be able to spare a small amount of time to meet with us ahead of this crucial vote.

If you have any questions please do not hesitate to contact me.

Yours sincerely

Katie Knight

www.saveecigs.com

STAES Bart OFFICE

From: Martin Osinga <stannalux@ziggo.nl>
Sent: 14 September 2013 08:18
To: CLAEYS Philip; DE BACKER Philippe; DEHAENE Jean-Luc; DEMESMAEKER Mark; EL KHADRAOUI Saïd; EPPINK Derkjan; NEYTS-UYTTEBROECK Annemie; STAES Bart; THYSSEN Marianne; VAN BREMPT Kathleen; VANHECKE Frank; VERHOFSTADT Guy
Subject: Elektrisch roken

Van: Martin Osinga [mailto:stannalux@ziggo.nl]
Verzonden: zaterdag 14 september 2013 8:17
Aan: 'ivo.belet@europarl.europa.eu'
Onderwerp: Elektrisch roken

Geachte ,

Op 8 oktober wordt gestemd over de nieuwe tabaksrichtlijnen en wil graag Uw aandacht vragen voor het volgende.

E-roken (Dampen) is hetzelfde als koffie en alcohol= een genotsmiddel.

Het is geen medicijn zoals al bewezen is en als het zo slecht voor de mens zou zijn

zoals men beweert in de regering waarom zou je er dan met een goed geweten een medicijn van willen maken.

Ik ben niet ziek en heb geen "medicijn" nodig ik wil gewoon lekker dampen en genieten van al de smaakjes waar ik uit

kan kiezen.

Ik hoef er niet voor naar de winkel want alles is online te koop in goede webshops wat ik graag zo zou willen blijven zien, aangezien mijn lichamelijke beperkingen.

Het is moreel heel verkeerd als men alcohol en koffie in een winkel/online kan kopen en de e-rookwaren niet.

Daar komt nog bij en dat vind ik persoonlijk het ergste, dat de echte sigaret waar op het pakje staat dat het DODELIJK is gewoon in de winkel/online te koop is en de aanzienlijk minder schadelijke e-sigaret verboden zou worden.

Ik wil U dus vragen om TEGEN het volgende te stemmen:

1- Amendement 71 om de e-sigaret onder de geneesmiddelenwet te laten vallen.

2- Dat E-roken onder de tabaks wet gaat vallen.

Wij als Damper gemeenschap willen graag dat het blijft zoals het nu is en hoort te zijn : een genotsmiddel, wel met controle op veiligheid en kwaliteit.

Dank U voor het lezen van mijn email en ik hoop van harte dat U mijn vraag in

overweging wil nemen met het belang van de algemene volksgezondheid voor ogen,

want als de e-sigaret verboden wordt, zullen 100.000-den mensen gedwongen worden terug te grijpen naar de normale

DODELIJKE sigaret en ik kan me niet voorstellen dat iemand dat op zijn/haar geweten wil hebben.

Met vriendelijke groet,

Martin Osinga

STAES Bart OFFICE

From: missmouz@gmail.com
Sent: 14 September 2013 01:36
To: missmouz@gmail.com
Subject: Fw: Amendement 71

Geachte Europarlementarier,

Op 8 oktober wordt gestemd over de nieuwe tabaksrichtlijnen. Ik wil u graag wijzen op artikel 18, waarin ook de elektronische sigaret is opgenomen.

De ENVI-commissie stelt in Amendement 71 voor om de e-sigaret onder de geneesmiddelenwet te laten vallen.

In Nederland is al gerechtelijk bepaald dat de nicotine-houdende vloeistoffen niet als medicijn kunnen worden aangemerkt.

Ik wil u dan ook vragen om op 8 oktober te stemmen tegen amendement 71. Het is vreemd om een Europese richtlijn te hebben die er toe zou leiden dat het minder schadelijke alternatief voor roken moeilijker verkrijgbaar is dan de ongezonde sigaretten zelf. De e-sigaret is een genotmiddel, zoals ook reguliere tabaksartikelen (nicotine), koffie en thee cafeïne), en alcohol, wat overal makkelijk verkrijgbaar is.

Ik kan u uit eigen ervaring vertellen dat het daadwerkelijk een uitstekend middel is om van de rookverslaving af te komen.

Ik gebruik de e-sigaret sinds februari, en ben 2 weken na ingebruikname volledig gestopt met roken, en inmiddels damp ik nagenoeg nicotinevrij.

Mijn tweede verzoek aan u is of u er bij het stemmen aan de volgende dingen wil denken: elektronisch roken is veel minder schadelijk dan gewoon roken. Als online verkoop van elektronische sigaretten niet meer is toegestaan is het verkrijgen van het minder schadelijke alternatief voor gewoon roken in veel gevallen bijna onmogelijk. Dat kan niet de bedoeling zijn.

De meerwaarde van de elektronische sigaret wordt bovendien gehaald uit de vele smaken die verkrijgbaar zijn. Zonder deze toegevoegde smaakstoffen gaat de veelbelovende werking van de e-sigaret verloren, omdat alle overige ingrediënten smaak- en geurloos zijn. Reguliere tabaksproducten zijn tenslotte ook niet geur- en smaakloos.

Dank u voor uw aandacht,

Hoogachtend,

P. van Schaijk.

STAES Bart OFFICE

From: Sassi Emmanuel <Emmanuel.Sassi@ville-antibes.fr>
Sent: 13 September 2013 14:49
To: DELVAUX Anne; NEYTS-UYTTEBROECK Annemie; STAES Bart; EPPINK Derkjan; VANHECKE Frank; DAERDEN Frederic; RIES Frédérique; 'frieda.breepoels@europarl.europa.eu'; VERHOFSTADT Guy; DURANT Isabelle; BELET Ivo; DEHAENE Jean-Luc; VAN BREMPT Kathleen; MICHEL Louis; TARABELLA Marc; THYSSEN Marianne; KAZAK Metin; CLAEYS Philip; LAMBERTS Philippe; EL KHADRAOUI Saïd; DE KEYSER Véronique
Subject: La Cigarette électronique

La Cigarette électronique

Bonjour, fumeur depuis près de vingt ans, toutes mes précédentes tentatives pour me sauver du tabac ont échoué.

Hors, il y a quelques mois, un ami m'a fait découvrir la Ecig, qui n'a de cigarette que le nom d'ailleurs, je suis, du jour au lendemain passé d'un trentaine de cigarette par jour à la Ecig, je commence à réduire le taux de nicotine des liquides que j'utilise au fur et à mesure que les mois passent, sortir du tabac n'est pas une mince affaire, et cela prend du temps, mais j'y parvient grâce à la Ecig et a force de volonté.

Comme vous le savez certainement, la commission européenne va bientôt statuer sur le sort de la Ecig et compte pour l'heure la classer comme médicament.

Tout le succès de la Ecig provient de la diversité des modèles qui permet à chaque fumeur d'acquérir le matériel qui convient au mieux à son sevrage tabagique. Mais également de la large gamme d'arômes qui éloignent l'ancien fumeur du gout du tabac pour finir par l'en sauver totalement.

Les boutiques spécialisées fournissent le conseil essentiel à l'usage de la Ecig ,certes il en existe des sérieuses et des moins sérieuses mais l'utilisateur saura comme pour d'autres produits faire le meilleur choix, les boutiques de qualité perdureront, les moins bonnes fermeront.

Les fabricants de liquide français améliorent à chaque nouvelle génération la qualité et le sérieux de leurs produits grâce a une libre concurrence.

Pour toutes ces raisons, la Ecig ne doit pas être réglementée à outrance, c'est sa diversité et la concurrence qui pousse les fabricants à innover et à fournir les meilleurs produits possibles qui fait son succès.

La Ecig ne doit pas être le monopole d'un seul acteur, un fumeur n'ira pas dans une pharmacie, un fumeur ne veut pas être considéré comme un patient.

La Ecig sauve des vies mise en danger par le tabac, le tabac fait des millions de mort et coute énormément d'argent a la sécurité sociale.

La Ecig n'est pas anodine, mais une interdiction de vente aux mineurs ainsi qu'un contrôle régulier des produits suffisent, de nombreuses études,dont celle du Professeur Dautzenberg prouvent la toxicité infiniment moindre de la Ecig face au tabac qui lui dégage du monoxyde et du goudron, substances inexistante sur une Ecig.

Ci-joint un rapport du Docteur Farsalinos expliquant en détail l'efficacité et les avantages de la Ecig .

Merci de l'attention que vous porterez à mon courriel.

Je vous prie de croire,Monsieur le Député, en l'assurance de mes respectueuses salutations.

Mr Sassi Emmanuel

Dix bonnes raisons de NE PAS réglementer les cigarettes électroniques comme des médicaments (Dr Farsalinos)

Différentes autorités tentent de mettre en œuvre une réglementation pharmaceutique pour les cigarettes électroniques, la dernière étant MHRA au Royaume-Uni. Le bon sens est parfois le chaînon manquant dans les décisions des autorités de santé : il n'y a pas d'autre façon d'expliquer leur façon de penser.

Rappelons que toutes les tentatives dans le passé ont échoué ; toutes ont été retoquées par la justice : Pays-Bas, Allemagne, Estonie et USA. La même cause produira les mêmes effets. Il y a plusieurs raisons, juridiques et de bon sens pour cela.

1. Définition : la nicotine n'est pas un médicament. S'agissant d'un médicament, il ne serait pas possible de la considérer telle dans certains produits seulement et pas dans d'autres. Comme les cigarettes de tabac ne peuvent pas être réglementées comme des médicaments, toutes les tentatives visant à réglementer les e-liquides en fonction de la présence de nicotine échoueront.

2. Disponibilité : une réglementation pharmaceutique restreindra la disponibilité, augmentera les prix et limitera les ventes de cigarettes électroniques. Dans le même temps, les cigarettes de tabac seront disponibles partout. Ceci ne peut que favoriser la concurrence des cigarettes de tabac. On pourrait raisonnablement imaginer que le contraire devrait se produire...

3. Commodité : une réglementation pharmaceutique implique de pouvoir définir un dosage spécifique, de fixer une fourniture constante de nicotine et de spécifier des instructions précises d'utilisation. Celles-ci sont impossibles à mettre en œuvre avec les cigarettes électroniques puisque chaque consommateur a, comme avec les cigarettes de tabac, un modèle différent d'utilisation. Les substituts nicotiques ont échoué pour les mêmes raisons (entre autres). Maintenant, qui peut imaginer prescrire le vapotage avec un mode d'emploi comme "*15 bouffées de quatre secondes toutes les quatre heures*" ??? Les cigarettes électroniques sont efficaces parce qu'elles offrent du plaisir au vapoteur. Et chaque consommateur a une perception différente du plaisir. Cela interdit tout effort visant à réglementer la cigarette électronique comme un médicament.

4. Efficacité : la réglementation pharmaceutique limitera inévitablement la diversité des dispositifs et des arômes de e-liquide actuellement disponibles. Ces paramètres ont de toute évidence un rôle majeur dans le succès de l'e-cigarette comme alternative au tabagisme.

5. Technologie : la réglementation pharmaceutique freinera l'avancée technologique des cigarettes électroniques. De nouveaux appareils apparaissent chaque jour, les batteries vont évoluer tout le temps (les rendant plus petites et plus efficaces) et des circuits électroniques intelligents deviendront intégrés et augmenteront l'efficacité des dispositifs. Une réglementation pharmaceutique stoppera inévitablement toute cette innovation...

6. Philosophie : baser la réglementation pharmaceutique sur l'innocuité d'un produit de consommation est une pensée très dangereuse. Avec le même raisonnement, chaque produit de consommation devrait devenir un médicament afin d'assurer la qualité de sa production et sa sécurité. Même l'eau devraient être réglementés comme un médicament. Les autorités sanitaires empruntent un chemin très scabreux...

7. Fantasme de la sécurité : les autorités sanitaires proposent des règles pharmaceutiques avec l'alibi d'améliorer la sécurité des produits. C'est un mythe absolu. Aucune étude sur la sécurité ne sera jamais réalisée pour la réglementation proposée. Si toutes les ressources financières sont allouées aux efforts réglementaires, la recherche utile sera réduite de manière significative. Nous avons déjà l'exemple d'une société britannique qui a demandé une homologation pharmaceutique. Elle a dépensé d'énormes sommes d'argent pour cela au cours des trois dernières années et nous n'avons pas vu une seule étude fournissant des informations scientifiques utiles sur la sécurité de leurs produits. Les tests réglementaires ne fourniront aucune information significative sur ce que les vapoteurs et les communautés scientifiques attendent : des preuves sur la sécurité et la réduction du risque pour la santé. Il existe plusieurs règlements de produits de consommation courante suivant lesquels la qualité de la production peuvent déjà être assurés et inspectés.

8. Droit de choisir une alternative plus sûre : les autorités de santé publique ont-elles le droit d'interdire aux fumeurs d'utiliser une alternative plus sûre ? Ont-elles le droit de réglementer les cigarettes électroniques de manière stricte quand nous en avons besoin comme concurrence aux cigarettes de tabac librement disponibles ? Qui va supporter les conséquences éthiques et juridiques d'une telle décision, qui aura un effet négatif sur la santé des fumeurs?

9. Bannir une appellation : la plupart des autorités n'aiment tout simplement pas le terme 'cigarette électronique'. Et elles n'aiment pas qu'elle contienne de la nicotine, que vapoter imite le tabagisme et procure du plaisir à l'utilisateur. Cependant, ce sont les principales raisons de son succès, et ces caractéristiques ne sont pas présentes dans aucun autre produit de sevrage tabagique homologué comme médicament : ceci est précisément la raison pour laquelle tous ces produits ont échoué...

10. Ouverture d'esprit : une caractéristique majeure de la science, c'est que vous devez aborder un problème avec un esprit ouvert. Les autorités ont affiché exactement le contraire : elle rejettent un produit en raison d'une idéologie. Les effets de cette façon de faire seront immensément dommageables pour la santé publique.

Dr K. FARSALINOS



Hôtel de Ville d'Antibes Juan - les - Pins
Cours Masséna - BP 2205
06600 ANTIBES Cedex

Tel. 04 92 90 50 00 - Fax 04 92 90 50 01 - www.antibes-juanlespins.com - mairie@ville-antibes.fr - n° Vert 0 800 10 20 00



La Ville d'Antibes Juan-les-Pins protège l'environnement, n'imprimez ce mail que si c'est nécessaire !

STAES Bart OFFICE

From: francoise.clairottet@club-internet.fr
Sent: 11 September 2013 15:53
To: STAES Bart
Subject: The electronic cigarette is not a medicine

Sir Deputy,

I am anxious to bring my testimony concerning the "personal spray", I smoked cigarettes of tobacco for more than 40 years (approximately 1 and a half package a day). I tried to stop repeatedly without any success (patches, gums, acupuncture, hypnosis, zyban and so on...)

Last year I really needed not to smoke any more and I took information on the "e.cigarette", I ordered it and from reception, that was a real revelation, my consumption passed in third party of what I smoked and 4 months later, no more cigarette tobacco.

It has been more than 9 months since I switched on a cigarette and as for me it is a real miracle because that it is made without any suffering, just another way of indulging itself.

The electronic cigarette or the personal spray is an alternative in the tobacco without its 4000 dangerous substances. Profits it are very fast felt: I do not cough any more, I found the breath, the flavors, my skin is not any more grey, I do not smell any more bad, my blood tests are perfected, etc..

If you decide to regulate it sale only in pharmacy, you go to discourage the smokers who wish to escape the misdeeds of the tobacco which will continue to die by one hundred every day in France.

I do not think whether it is the purpose of your approach and that it is not the financial interests which drive you, so thank you for analyzing well this revolutionary method which can save lives before making a decision which could become a real sanitary scandal.

It is good to remind that the AIDUCE association collected this day 35000 signatures within 6 months for its petition - [www.aiduce.fr / petition/](http://www.aiduce.fr/petition/) (French association)

I thank you in advance for your attention,

Receive, my respectful greetings.

Françoise CLAIROTTET

13700 MARIIGNANE/FRANCE

STAES Bart OFFICE

From: Anca Toma <anca.toma@ersnet.org>
Sent: 05 September 2013 15:22
To: Florence Berteletti
Cc: Anca Toma
Subject: Smoke Free Partnership press release - Tobacco Products Directive delay
Attachments: SFP statement on delay of the TPD vote_5_sept.pdf



PRESS RELEASE

The Smoke Free Partnership condemns efforts to weaken and delay the Tobacco Products Directive in the European Parliament

Brussels, 5 September 2013 – The Smoke Free Partnership (SFP) expresses deep concern over the decision taken by the heads of political groups in the European Parliament today to postpone the debate and vote on the Tobacco Products Directive. The vote had been scheduled for the European Parliament’s (EP) September plenary session, but has now been delayed to 8 October.

Florence Berteletti, Director of SFP, said: *“This is outrageous. Ever since John Dalli ceased to be Health Commissioner last year, we have repeatedly expressed concern over the delay tactics of the tobacco industry and what a delay of the Directive would mean for public health in Europe. We suspect that tobacco industry interference is now once again at play – this time by overturning a longstanding commitment of the European Parliament to secure a swift resolution of this Directive.”*

In July 2013, the EP’s Committee on the Environment, Public Health and Food Safety (ENVI) adopted a strong position on the Tobacco Products Directive including large, mandatory pictorial health warnings on tobacco products covering 75% of the front and the back of tobacco packs; a ban on all characterising flavours of tobacco products (detectable flavours of tobacco smoke such as menthol, vanilla, strawberry); a ban on slim cigarettes and slim cigarette packs; strong measures against counterfeiting and illicit trade of tobacco products with independent supervision; and provisions safeguarding the Member States’ right to adopt stronger measures than those in the Directive.

The plenary vote was scheduled on 10 September and was a necessary step to kick-start the European Parliament’s negotiations with the Council of the EU so as to allow the adoption of the Directive before next year’s European elections. A month-long delay in the plenary vote significantly reduces the time for negotiations and endangers the possibility of a successful agreement before the Health Council on 10 December and the last EP plenary session in April 2014.

Since 2011, the European Parliament has expressed concerns over the timeline of the Directive and has called on the Commission to speed up the preparatory process. Despite this track record, and despite the ambitious calendar set and so far respected for the parliamentary debates, the delay of the vote calls into question the European Parliament’s commitment to adopt the Tobacco Products Directive.

According to media reports, supporters of the delay argued that “there was not enough time to discuss” the ENVI report. However, these claims are contradicted by the large number of plenary amendments tabled (almost 70 amendments as of 5 September noon). Most of the amendments tabled aim to weaken the provisions of the proposal by reducing the size of health warnings to 50% of pack surface, extending exemptions from the ban on characterising flavours and eliminating the ban on slim cigarettes.

Florence Berteletti added: *“EU citizens support tobacco control. The measures adopted in the ENVI Committee are effective in helping prevent children and young people from taking up smoking. Before the European elections citizens need to feel that the institutions represent their interests and not those of one single industry. A delay,*

coupled with subversive efforts to weaken the legislation, only serves the tobacco industry. This does no favours to popular perception of the European Union.

It was also widely reported that another reason for the delay of the TPD vote is that German MEPs need to focus on the German general elections. Do we expect the EU institutions to stop working every time Germany or any other member state for that matter holds a general election? And why only the Tobacco Products Directive? Why are the other important issues on the September plenary agenda not being postponed?"

/ends

Anca Toma Friedlaender
Senior Policy Advisor
Smoke Free Partnership

49/51 Rue de Trèves, 1040 Brussels, Belgium

T: +32 (0) 22 38 53 65

F: +32 (0) 22 38 53 61

anca.toma@ersnet.org

www.smokefreepartnership.eu



The Smoke Free Partnership is a strategic, independent and flexible partnership between the European Respiratory Society (www.ersnet.org), Cancer Research UK (www.cancerresearchuk.org), the European Heart Network (www.ehnheart.org) and Action on Smoking and Health UK (www.ash.org.uk). We aim to promote tobacco control advocacy and policy research at EU and national levels in collaboration with other EU health organisations and EU tobacco control networks.

Please don't print this e-mail unless you really need to.

STAES Bart OFFICE

From: Annie Van Praet <ADB@vbo-feb.be> on behalf of Olivier Joris <OJ@vbo-feb.be>
Sent: 05 September 2013 10:00
To: BELET Ivo; DAERDEN Frederic; DE BACKER Philippe; DEHAENE Jean-Luc; DE KEYSER Véronique; DELVAUX Anne; DEMESMAEKER Mark; DURANT Isabelle; EL KHADRAOUI Saïd; EPPINK Derkjan; GROSCHE Mathieu; LAMBERTS Philippe; MICHEL Louis; NEYTS-UYTTEBROECK Annemie; RIES Frédérique; STAES Bart; TARABELLA Marc; THYSSEN Marianne; VAN BREMPT Kathleen; VERHOFSTADT Guy
Cc: BELET Ivo; VALKENBORGS Ellen; VANDEVELDE Annelies; GONZALEZ Javier; JANQUIN Denis; LEGER Anne; LEONE Alexandra Ioana; eline.joukes@europarl.europa.eu; MINTIENS Emely; VAN DE VENNE Ghanima; MEYFROODT Tine; ROBIJNS Marie-Claire; LAURIJSSSEN Tanya; MARTINEZ ALARCON Waldo; BOISDEQUIN Delphine; BOLDRINI Sandra; DELVAUX Anne OFFICE; MOULIN Yves; PATHO Wouter; UYTTERSROOT Katrien; VAN STEENBERGEN Laurijn; DURANT Isabelle OFFICE; LEMAIRE Dimitri; MONAMI Eric; OPDEBEECK Reza; VALETTE Bruno; BORDON Francis; MAURISSEN Lies; Mail_Europa; BILLIET Stijn; GEUDENS Tessa; WASSENBERG Toon; JANDA Erik; VANDEPUTTE Martine; VANDERHAEGEN Gaetan; MOENS Jan; EL KHADRAOUI Saïd OFFICE; EPPINK Derkjan OFFICE; DEHAEMERS Christine; KANSOUZIDIS Andrea; SOLOVIEVA Anna; FRANCOIS Josephine; PETRUC Cezara; RAMJOIE Christophe; DENIS Gaspard; DERRUINE Olivier; LAMBERTS Philippe OFFICE; MARECHAL Aurelie; LAMBERTS Philippe OFFICE; FRANCKEN Matthias; PAQUE Luc Albert; SOUDANT Daniel; VAN DEN BERG Bénédicte; BUEDS Paul; NEYTS-UYTTEBROECK Annemie OFFICE; DUBOIS Pascal; STRUYS Gerda; AUDIBERT Patrice; MUTAMBA Musumba; SCHOONBROODT Oriane; REDANT Barbara; VAN SCHAREN Hans; VANDEKERCKHOVE Angelique; CENTIONI Alessia; FOULON Emmanuel; LEONE Alexandra Ioana; POLIS Aurelie; DE BACKER Raf; HEREMANS Tinne; VANMAERCKE Luk
Subject: Debat over de herziening van de richtlijn voor tabaksproducten - Débat sur la révision de la directive sur les produits du tabac
Attachments: Olivier Joris.vcf
Importance: High

Aan de Belgische leden van het Europees Parlement

Mevrouw de Volksvertegenwoordiger,
Mijnheer de Volksvertegenwoordiger,

Tijdens de plenaire zitting van september zal het Europees Parlement debatteren en stemmen over het rapport met betrekking tot het voorstel voor een herziening van de richtlijn betreffende de productie, de presentatie en de verkoop van tabaks- en aanverwante producten.

De tekst die momenteel op tafel ligt baart het VBO wat zorgen. In de aanloop naar het debat willen we dan ook graag onze drie belangrijkste bekommernissen over dit voorstel met u meedelen.

1. Bescherming van intellectuele eigendomsrechten:

Het verslag vereist een uitbreiding tot minimum 75% gezondheidswaarschuwingen op de verpakkingen van tabaksproducten. Het grootste gevolg van een verdere uitbreiding van de oppervlakte van de gezondheidswaarschuwing zou dus zijn dat de fabrikanten de mogelijkheid ontnomen wordt om elementen te gebruiken die de merkidentiteit en de kenmerken uitmaken. Fabrikanten de mogelijkheid ontnemen om logo's, merknamen, kleuren en andere grafische elementen te gebruiken die de merkidentiteit uitmaken, vormt een inbreuk op nationale, Europese en internationale wetgeving op de intellectuele eigendom.

2. Gevaarlijk precedent:

De invalshoek van waaruit de ontwerprichtlijn werd opgesteld berust op het concept van 'aantrekkelijkheid'. Ondernemingen het recht ontzeggen om hun producten op een onderscheidende wijze aantrekkelijk te

maken voor potentiële consumenten, dit ongeacht de industrie of sector, ervaren we als een ongepaste en onredelijke regelgeving, die overigens een gevaarlijk precedent zou scheppen voor de toekomst, omdat het risico bestaat dat dit uitgebreid wordt naar andere producten.

3. Namaak:

Ten slotte willen we u erop wijzen dat een meer gestandaardiseerde verpakking het risico op namaak doet stijgen. In het algemeen, en dus niet enkel voor tabaksproducten, wordt door een gestandaardiseerde verpakking, zonder onderscheidende logo's of andere kenmerken, het namaken vergemakkelijkt.

Het VBO vraagt dus dat de nieuwe wetgeving de intellectuele eigendomsrechten ten volle respecteert en de nodige aandacht besteedt aan de strijd tegen namaakproducten. We hopen dat u bovenvermelde bekommernissen ter harte zult willen nemen tijdens het debat over dit verslag.

Hoogachtend,

Olivier Joris



Aux membres belges du Parlement européen

Madame la Députée européenne,
Monsieur le Député européen,

Durant la session plénière de septembre, le Parlement européen débattera et votera sur le rapport relatif à la proposition visant à revoir la directive qui régit la fabrication, la présentation et la vente des produits du tabac.

Préalablement au débat, nous voudrions vous faire part de nos trois principales préoccupations au sujet du texte actuel.

1. Protection des droits de propriété intellectuelle:

Le rapport exige de porter à minimum 75% les avertissements sanitaires sur les emballages de produits du tabac. La principale conséquence d'une nouvelle extension de la taille des avertissements sanitaires serait de priver les fabricants de la possibilité d'utiliser des éléments constituant l'identité de la marque et ses caractéristiques. Le fait d'empêcher les fabricants d'utiliser des logos, noms de marque, couleurs et autres éléments graphiques constituant l'identité de leur marque représente une atteinte à la législation nationale, européenne et internationale en matière de propriété intellectuelle.

2. Précédent dangereux:

La perspective dans laquelle est rédigée la proposition de directive repose sur le concept d'attrait'. Priver les entreprises du droit de rendre leurs produits attrayants d'une manière distinctive pour les consommateurs potentiels, et ce quel que soit l'industrie ou le secteur concerné, est pour nous une réglementation inadéquate et injustifiée, qui pourrait de plus créer un précédent dangereux pour l'avenir, vu le risque que cela soit appliqué à d'autres produits.

3. Contrefaçon:

Enfin, nous tenons à faire remarquer qu'un conditionnement plus standardisé accroît le risque de contrefaçon. De manière générale, et donc pas uniquement pour les produits du tabac, un conditionnement standardisé, sans logos ou autres éléments distinctifs, facilite la contrefaçon.

La FEB demande dès lors que la nouvelle directive respecte pleinement les droits de propriété intellectuelle et accorde l'attention nécessaire à la lutte contre les produits contrefaits. Nous espérons que vous voudrez bien prendre en compte ces préoccupations lors du débat sur ce rapport.

Nous vous prions de croire, Madame la Députée, Monsieur le Député, en l'expression de nos sentiments distingués.

Olivier Joris



 Rue Ravensteinstraat 4
1000 BRUXELLES/BRUSSEL
T + 32 2 515 08 11
www.vbo-feb.be

Olivier Joris
Responsable Département Européen
Hoofd Europees Departement

oj@vbo-feb.be
T + 32 (0)2 515 08 34
GSM + 32 (0)477 55 64 08



 **REINVENT**
YOUR BUSINESS

VBO FORUM FEB
17/09/2013 THE EGG/BXL
WWW.REINVENTYOURBUSINESS.BE

 **VBO FEB**
Verband van Belgische Ondernemingen | Fédération des Entreprises de Belgique

STAES Bart OFFICE

From: Stimson, Gerry V <g.stimson@imperial.ac.uk>
Sent: 05 September 2013 09:44
To: 'alfredo.pallone@europarl.europa.eu'; 'vladkotodorov.panayotov@europarl.europa.eu';
'monika.panayotova@europarl.europa.eu'; 'pierantonio.panzeri@europarl.europa.eu';
'antigoni.papadopoulou@europarl.europa.eu';
'georgios.papanikolaou@europarl.europa.eu';
'georgios.papastamkos@europarl.europa.eu'; 'gilles.pargneaux@europarl.europa.eu';
'antonyia.parvanova@europarl.europa.eu'; 'ioanmircea.pascu@europarl.europa.eu';
'jaroslav.paska@europarl.europa.eu'; 'mariadoceu.patraoneves@europarl.europa.eu';
'aldo.patriciello@europarl.europa.eu'; 'marit.paulsen@europarl.europa.eu';
'andres.perellorodriguez@europarl.europa.eu'; 'alozj.peterle@europarl.europa.eu';
'sandra.petrovicjakovina@europarl.europa.eu'; 'tonino.picula@europarl.europa.eu';
'markus.pieper@europarl.europa.eu'; 'sirpa.pietikainen@europarl.europa.eu';
'mirosław.piotrowski@europarl.europa.eu'; 'mario.pirillo@europarl.europa.eu';
'hubert.pirker@europarl.europa.eu'; 'andreas.pitsillides@europarl.europa.eu';
'gianni.pittella@europarl.europa.eu'; 'andrej.plenkovic@europarl.europa.eu';
'pavel.poc@europarl.europa.eu'; 'anni.podimata@europarl.europa.eu';
'maurice.ponga@europarl.europa.eu'; 'tomasz.poreba@europarl.europa.eu';
'mail@bernd-posselt.de'; 'hans-gertrud.potterting@europarl.europa.eu';
'konstantinos.poupakis@europarl.europa.eu'; 'cristiandan.preda@europarl.europa.eu';
'phil.prendergast@europarl.europa.eu'; 'vittorio.prodi@europarl.europa.eu';
'jacek.protasiewicz@europarl.europa.eu'; 'franck.proust@europarl.europa.eu';
'fiorello.provera@europarl.europa.eu'; 'godelieve.quisthoudt-rowohl@europarl.europa.eu';
'paulo.rangel@europarl.europa.eu'; 'miloslav.ransdorf@europarl.europa.eu';
'bernhard.rapkay@europarl.europa.eu'; 'sylvana.rapti@europarl.europa.eu';
'evelyn.regner@europarl.europa.eu'; 'britta.reimers@europarl.europa.eu';
'vladimir.remek@europarl.europa.eu'; 'mitro.repo@europarl.europa.eu';
'herbert.reul@europarl.europa.eu'; 'teresa.rieramadurell@europarl.europa.eu';
'frederique.ries@europarl.europa.eu'; 'niccolo.rinaldi@europarl.europa.eu';
'dominique.riquet@europarl.europa.eu'; 'michele.rivasi@europarl.europa.eu';
'crescenzo.rivellini@europarl.europa.eu'; 'jean.roatta@europarl.europa.eu';
'robert.rochefort@europarl.europa.eu'; 'ulrike.rodust@europarl.europa.eu';
'jens.rohde@europarl.europa.eu'; 'zuzana.roithova@europarl.europa.eu';
'carmen.romerolopez@europarl.europa.eu'; 'raul.romevairueda@europarl.europa.eu';
'licia.ronzulli@europarl.europa.eu'; 'anna.rosbach@europarl.europa.eu';
'oreste.rossi@europarl.europa.eu'; 'dagmar.roth-behrendt@europarl.europa.eu';
'libor.roucek@europarl.europa.eu'; 'paul.ruebig@europarl.europa.eu';
'alfreds.rubiks@europarl.europa.eu'; 'heide.ruehle@europarl.europa.eu';
'karlis.sadurskis@europarl.europa.eu'; 'tokia.saifi@europarl.europa.eu';
'josegnacio.salafranca@europarl.europa.eu'; 'potito.salatto@europarl.europa.eu';
'nikolaos.salavrakos@europarl.europa.eu'; 'matteo.salvini@europarl.europa.eu';
'antolin.sanchezpresedo@europarl.europa.eu'; 'marie-therese.sanchez-
schmid@europarl.europa.eu'; 'dacianaoctavia.sarbu@europarl.europa.eu';
'judith.sargentini@europarl.europa.eu'; 'amalia.sartori@europarl.europa.eu';
'petri.sarvamaa@europarl.europa.eu'; 'jacek.saryusz-wolski@europarl.europa.eu';
'david.sassoli@europarl.europa.eu'; 'algirdas.saudargas@europarl.europa.eu';
'vilja.savisaar-toomast@europarl.europa.eu'; 'marietje.schaake@europarl.europa.eu';
'christel.schaldemose@europarl.europa.eu'; 'carl.schlyter@europarl.europa.eu';
'olle.schmidt@europarl.europa.eu'; 'horst.schnellhardt@europarl.europa.eu';
'birgit.schnieber-jastram@europarl.europa.eu'; 'helmut.scholz@europarl.europa.eu';
'gyorgy.schopflin@europarl.europa.eu'; 'elizabeth.schroedter@europarl.europa.eu';
'martin.schulz@europarl.europa.eu'; 'werner.schulz@europarl.europa.eu';
'andreas.schwab@europarl.europa.eu'; 'giancarlo.scotta@europarl.europa.eu';
'marco.scurria@europarl.europa.eu'; 'salvador.sedo@europarl.europa.eu';
'richard.seeber@europarl.europa.eu'; 'olga.sehnalova@europarl.europa.eu';
'joanna.senyszyn@europarl.europa.eu'; 'adrian.severin@europarl.europa.eu';
'czeslaw.siekierski@europarl.europa.eu'; 'sergio.silvestris@europarl.europa.eu';
'peter.simon@europarl.europa.eu'; 'brian.simpson@europarl.europa.eu';
'nikki.sinclair@europarl.europa.eu'; 'birgit.sippel@europarl.europa.eu';
'marek.siwiec@europarl.europa.eu'; 'peter.skinner@europarl.europa.eu';
'joanna.skrzydowska@europarl.europa.eu'; 'theodoros.skyllakakis@europarl.europa.eu';
'alyn.smith@europarl.europa.eu'; 'monika.smolkova@europarl.europa.eu';
'csaba.sogor@europarl.europa.eu'; 'renate.sommer@europarl.europa.eu';
'sorenbo.sondergaard@europarl.europa.eu'; 'boguslaw.sonik@europarl.europa.eu';
'sophocles.sophocleous@europarl.europa.eu';

To: 'francisco.sosawagner@europarl.europa.eu'; 'alda.sousa@europarl.europa.eu';
'francescoenrico.speroni@europarl.europa.eu'; 'ewald.stadler@europarl.europa.eu';
'bart.staes@europarl.europa.eu'; 'laurence.stassen@europarl.europa.eu';
'peter.stastny@europarl.europa.eu'; 'georgios.stavrakakis@europarl.europa.eu';
'jutta.steinruck@europarl.europa.eu'; 'struan.stevenson@europarl.europa.eu';
'davor.stier@europarl.europa.eu'; 'catherine.stihler@europarl.europa.eu';
'daniel.vanderstoep@europarl.europa.eu'; 'theodordumitru.stolojan@europarl.europa.eu';
'dimitar.stoyanov@europarl.europa.eu'; 'ivo.strejcek@europarl.europa.eu';
'michele.striffler@europarl.europa.eu'; 'robert.sturdy@europarl.europa.eu';
'dubravka.suica@europarl.europa.eu'; 'laszlo.surjan@europarl.europa.eu';
'alf.svensson@europarl.europa.eu'; 'kay.swinburne@europarl.europa.eu';
'hannes.swoboda@europarl.europa.eu'; 'jozsef.szajer@europarl.europa.eu';
'csanad.szegedi@europarl.europa.eu'

Subject: For immediate attention: Tobacco Products Directive

Please see letter below to the Conference of Presidents, which is meeting this morning, regarding the need to postpone the vote on the Tobacco Products Directive.

From: Gerry Stimson [<mailto:gerry@kachange.eu>] On Behalf Of Stimson, Gerry V

Sent: 04 September 2013 21:18

To: 'martin.schulz@europarl.europa.eu'; 'joseph.daul@europarl.europa.eu'; 'hannes.swoboda@europarl.europa.eu';
'guy.verhofstadt@europarl.europa.eu'; 'rebecca.harms@europarl.europa.eu'; 'daniel.cohn-
bendit@europarl.europa.eu'; 'nigel.farage@europarl.europa.eu'; 'martin.callanan@europarl.europa.eu';
'francescoenrico.speroni@europarl.europa.eu'; 'gabriele.zimmer@europarl.europa.eu'

Subject: For immediate attention: Tobacco Products Directive

Martin Schulz
Joseph Daul
Hannes Swoboda
Guy Verhofstadt
Rebecca Harms
Daniel Cohn-Bendit
Nigel Farage
Martin Callanan
Francescoenrico Speroni
Gabriele Zimmer

Dear Members of the Conference of Presidents,

As public health experts, we urge you to delay the debate and vote on the Tobacco Products Directive and hold it in October. We applaud members of the EPP, ALDE and ECR groups for already having declared their intention of doing so and hope that the Conference of Presidents will see fit to do the same.

The Directive is complex and far reaching, but is likely in its current form to obstruct the progress of an important new class of products, e-cigarettes, by misclassifying them as medicines. Goldman Sachs describes e-cigarettes as one of eight globally disruptive technologies. Some analysts see e-cigarettes overtaking cigarettes with a decade. The impact of that on public health will vastly overshadow all other measures in the directive, and it is critical that we get the regulatory regime right - thousands of lives are at stake. Taking an extra few weeks to do this properly is a sound investment in the lives of millions of Europeans.

The likely effect of the directive in its current form is to take the vast majority of the products off the market, to cause users to revert to smoking, to close hundreds of sound small businesses and to provide regulatory protection to pharmaceutical and tobacco companies. It is clear from debates and public statements that Members still have little awareness of what medicines regulation would mean for the e-cigarette market. Further concerns arise from dissent in the opinion committees - for example Legal Affairs found no acceptable legal base for this regulation. Further afield, there are four cases in which medicines regulation has been struck down by the courts in member states. The Commission has failed to consult properly on its proposal and the Impact Assessment is far from an adequate account of the impacts. For all these reasons we urge you to give Members more time to understand this critical technology and the regulatory options.

It has been widely reported that it is the major tobacco firms that want a delay. We have no brief for them or any interest in their objectives. But many public health experts, consumers and small businesses also want a delay so the directive can be scrutinised and revised carefully. A legislature should conduct its business with great care and transparency, and it should not matter whether tobacco companies agree or disagree with its chosen timetable.

We think it is essential that Members have adequate time to understand and scrutinise these proposals thoroughly, and we therefore urge you to support holding the debate and vote on this important directive in October.

Yours sincerely

Professor Gerry Stimson

Emeritus Chair at Imperial College London and Visiting Professor at the London School of Hygiene and Tropical Medicine.

Clive Bates

Former Director of Action on Smoking and Health (1997-2003) and former senior civil servant (2003-12). *Director Counterfactual Consulting and Advocacy*

Konstantinos Farsalinos, M.D.

Researcher, Onassis Cardiac Surgery Center, Athens Greece; Researcher, University Hospital Gathuisberg, Leuven, Belgium

Jacques Le Houezec

Consultant in Public Health and Tobacco dependence. He is a special Lecturer at the Department of Epidemiology & Public Health of the University of Nottingham in the UK. He was an expert of the European Commission's Scientific Committee on Emerging and Newly Identified Health Risks (SCHENIR): working group on smokeless tobacco products (2006-2008).

Prof Gerry Stimson

Mob 44 (0) 7872 600 908

www.kachange.eu

STAES Bart OFFICE

From: Charles Hamshaw-Thomas <Charles@e-lites.co.uk>
Sent: 05 September 2013 09:41
To: Charles Hamshaw-Thomas
Subject: 100 Words On E-Cigarettes: Why The Tobacco Companies Will Love Linda McAvan

The oldest trick in the book? Create a Directive which most MEPs agree on and then hide in it something less attractive. Most MEPs want tougher regulation on tobacco packaging. But many are very unhappy Linda is bouncing them into imposing crushing regulation on e-cigarettes. That suits tobacco companies – because e-cigarettes are reducing their sales - but horrifies public health experts. Linda has produced no evidence that e-cigarettes are unsafe. She has no explanation for why e-cigarettes should be regulated more toughly than tobacco. 12 million Europeans use e-cigarettes. Their lives will be damaged if the TPD is rushed through.

Charles Hamshaw-Thomas, Legal & Corporate Affairs Director for E-Lites

1. Wells Fargo, January 2013: “within 10 years there could be more e-cigarette users than cigarette smokers”
2. The Guardian, July 2013: reported the downgrading of shares of British American Tobacco and Imperial Tobacco because of the growth of e-cigarettes
3. Professor Gerry Stimson, Clive Bates, Konstantinos Farsalinos MD and Jacques Le Houezec, September 2013: “the impact of e-cigarettes on public health will vastly overshadow all other measures in the TPD”
4. Drexel University, August 2013: “chemicals in e-cigarettes pose no health concern for users or bystanders” August 2013,
5. Professor Robert West, University College London: “the risk is negligible, and compared with smoking there is no contest”
6. E-cigarette users stop smoking tobacco: Polosa, June 2013
<http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0066317#s4>
7. E-Lites is the main brand of Zandera Ltd, the UK’s largest e-cigarette company
8. E-Lites believes tight regulation of product quality and safety is important



E-Lites

Charles Hamshaw-Thomas | Director of Legal & Corporate Affairs
+ 44 (0) 7715 091 254 | + 44 (0) 1527 573 492 | www.E-Lites.co.uk
Zandera Ltd, 18 Buntsford Park Road, Bromsgrove, Worcestershire B60 3DX

This email and any attachments to it may be confidential and are intended solely for the use of the individual to whom it is addressed. Any views or opinions expressed are solely those of the author and do not necessarily represent those of Zandera Ltd/E-Lites. If you are not the intended recipient of this email, you must neither take any action based upon its contents, nor copy or show it to anyone. Please contact the sender if you believe you have received this email in error.



[Check out our latest advert on YouTube!](#)

This email has been scanned by the Symantec Email Security.cloud service.
Provided by ATG-IT - www.atg-it.co.uk

STAES Bart OFFICE

From: AIDUCE <contact@aiduce.fr>
Sent: 04 September 2013 23:04
To: STAES Bart
Subject: AIDUCE - Don't turn vapers back to tobacco !
Attachments: The future of Vaping in the European Union.docx

Dear Member of the European Parliament,

As President of the French independent association of electronic cigarette users (AIDUCE), I am writing to ask you to refuse the de facto ban on electronic cigarettes contained in the draft Directive on tobacco products.

As pointed out by many experts and specialist organizations and as confirmed by the vast majority of the members of user forums, the proposal to classify electronic cigarettes as medicines will effectively eliminate from the market the major part of what makes them attractive to smokers.

As a result, hundreds of thousands of European vapers would return to tobacco and tens of millions of smokers would be discouraged from discovering in the electronic cigarette an alternative that, according to the French Office against Tobacco Addiction (OFT), is far less dangerous.

Faced with this threat, in recent months many petitions have been launched across Europe; the one initiated by our Association having collected more than 33,000 signatures from French speakers:
<http://www.aiduce.fr/petition/>

We are also aware of the illegal nature of this proposal, highlighted by the opinion of the JURI Committee and by many legal experts such as Sir Francis Jacobs QC, the former Advocate General at the Court of Justice of the EU.

Should this proposal be approved by the full Parliament and by the EU Council, the ensuing legislation would be therefore both liberticidal and contrary to the interest of public health. AIDUCE has the means to challenge it in national and European Courts.

To help fully inform you about electronic cigarettes and about the nature of the debate surrounding them, please find enclosed a report based on our own research and on the experience and testimony of tens of thousands of vapers.

We will be attending the European Parliament in Strasbourg on the 9th September where we would be delighted to supply any further information you may require.

Yours sincerely

Brice LEPOUTRE
AIDUCE President
Association Indépendante Des Utilisateurs de Cigarette Electronique
<http://www.aiduce.fr>

STAES Bart OFFICE

From: Charles Hamshaw-Thomas <Charles@e-lites.co.uk>
Sent: 04 September 2013 08:11
To: Charles Hamshaw-Thomas
Subject: E-Cigarettes: 3 Key Issues Where Karl-Heinz Florenz Has No Answer

Dear MEP,

You may have seen that Karl Heinz Florenz has been criticised by Fabrizio Bartot (<http://www.clivebates.com/?p=1486#more-1486>) over his support for medicinal regulation of e-cigarettes. Here are 3 issues which you may want to raise with Mr Florenz:

1. The Safety of E-Cigarettes

Karl-Heinz Florenz does not quote a single academic study to support his view that safety issues justify medicinal regulation of e-cigarettes. You might ask him to give his thoughts on the following:

- *Drexel University, August 2013*: “the study released today confirms that chemicals in e-cigarettes pose no health concern for users or bystanders”
- *Hajek, Lancet, July 2013*: “the chemicals that make cigarettes dangerous are either absent or present only in trace concentrations”
- *Inhalation Toxicology, October, 2012*: “the study indicates no apparent risk to human health from e-cigarette emissions”
- *Professor Robert West of University College London*: “the risk is negligible, and compared with smoking there is no contest”
- *Professor John Britton of the Royal College of Physicians*: “if all the smokers in Britain stopped smoking cigarettes and started smoking e-cigarettes we would save 5 million deaths”

2. Equal Treatment for E-Cigarettes

Karl-Heinz Florenz calls for “a level playing field” between e-cigarettes and the nicotine replacement therapy (NRT) products like the gum and patches produced by pharmaceutical companies. But the “playing field” e-cigarettes compete on is against tobacco cigarettes. And financial experts say e-cigarettes are winning:

- *EU Sales in 2012*: e-cigarettes replaced the equivalent of over 2.5 billion tobacco cigarettes across the EU (based on the Commission’s figures)
- *Wells Fargo, January 2013*: within 10 years there could be more e-cigarette users than tobacco smokers
- *The Guardian Newspaper, 9 July 2013*: shares in British American Tobacco and Imperial Tobacco are downgraded because e-cigarettes are reducing cigarette sales
- *Goldman Sachs, August 2013*: e-cigarettes are a key disruptive technology undermining tobacco companies’ business model

There is no evidence that NRT products, introduced 30 years ago, have reduced cigarette sales. One of the reasons e-cigarettes have been so successful is because their regulation has been light enough to allow innovation. By contrast medicinal regulation has been so expensive for pharmaceutical companies that it has stopped them from innovating their nicotine products: “NRT products represent a classic example of the stifling effect of medicinal regulation. There have been no major improvements since they were introduced” *Hajek, Lancet, July 2013*.

3. Legal Certainty

Karl-Heinz Florenz says that medicinal regulation of e-cigarettes would provide legal certainty. Yet the classification of e-cigarettes as medicines has already been rejected by four courts in the EU. In addition, a former Advocate-General to the European Court of Justice, Sir Francis Jacobs, said in July 2013 that medicinal regulation is “a very extreme and intrusive form of regulation” that is likely to be annulled.

Let me be transparent. I work for the UK e-cigarette company Zandera Ltd which supports the creation of a regulatory framework for product quality & safety across the EU. Has Karl Heinz Florenz been transparent with you?

Kind regards,

Charles Hamshaw-Thomas



E-Lites

Charles Hamshaw-Thomas | Director of Legal & Corporate Affairs
+ 44 (0) 7715 091 254 | + 44 (0) 1527 573 492 | www.E-Lites.co.uk
Zandera Ltd, 18 Buntsford Park Road, Bromsgrove, Worcestershire B60 3DX

This email and any attachments to it may be confidential and are intended solely for the use of the individual to whom it is addressed. Any views or opinions expressed are solely those of the author and do not necessarily represent those of Zandera Ltd/E-Lites. If you are not the intended recipient of this email, you must neither take any action based upon its contents, nor copy or show it to anyone. Please contact the sender if you believe you have received this email in error.



[Check out our latest advert on YouTube!](#)

This email has been scanned by the Symantec Email Security.cloud service.
Provided by ATG-IT - www.atg-it.co.uk

STAES Bart OFFICE

From: Charles Hamshaw-Thomas <Charles@e-lites.co.uk>
Sent: 04 September 2013 07:38
To: Charles Hamshaw-Thomas
Subject: 100 Words on E-Cigarettes: The TPD's e-cigarette regulation – a consolation prize for the tobacco industry?

Why are MEP's mailboxes full of angry messages from e-cigarette users? It's because MEPs are about to do huge damage to an industry whose products help millions of Europeans to switch from smoking. They find it incomprehensible that MEPs who are motivated by their desire to undermine the tobacco industry are instead allowing Linda McAvan to bounce them into rushing through regulation of e-cigarettes. All the evidence shows e-cigarettes are safer than cigarettes and reduce tobacco sales. So defer the TPD. Or amend it. But don't allow it to go through with the folly of medicinal regulation of e-cigarettes inside.

Charles Hamshaw-Thomas, Legal & Corporate Affairs Director for E-Lites

1. Wells Fargo, January 2013: "within 10 years there could be more e-cigarette users than cigarette smokers"
2. The Guardian, July 2013: reported the downgrading of shares of British American Tobacco and Imperial Tobacco because of the growth of e-cigarettes
3. Goldman Sachs, August 2013: e-cigarettes are one of the world's top "disruptive technologies"
4. Canaccord Genuity, July 2013: e-cigarettes are "the most significant development in the history of the organised tobacco industry"
5. Drexel University, August 2013: "chemicals in e-cigarettes pose no health concern for users or bystanders" August 2013,
6. Professor Robert West, University College London: "the risk is negligible, and compared with smoking there is no contest"
7. E-cigarette users stop smoking tobacco: Polosa, June 2013
<http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0066317#s4>
8. The effectiveness of 'harm reduction': <http://www.clivebates.com/?p=1205>
9. E-Lites is the main brand of Zandera Ltd, the UK's largest e-cigarette company
10. E-Lites believes tight regulation of product quality and safety is important



E-Lites

Charles Hamshaw-Thomas | Director of Legal & Corporate Affairs
+ 44 (0) 7715 091 254 | + 44 (0) 1527 573 492 | www.E-Lites.co.uk
Zandera Ltd, 18 Buntsford Park Road, Bromsgrove, Worcestershire B60 3DX

This email and any attachments to it may be confidential and are intended solely for the use of the individual to whom it is addressed. Any views or opinions expressed are solely those of the author and do not necessarily represent those of Zandera Ltd/E-Lites. If you are not the intended recipient of this email, you must neither take any action based upon its contents, nor copy or show it to anyone. Please contact the sender if you believe you have received this email in error.



[Check out our latest advert on YouTube!](#)

This email has been scanned by the Symantec Email Security.cloud service.
Provided by ATG-IT - www.atg-it.co.uk

STAES Bart OFFICE

From: Charles Hamshaw-Thomas <Charles@e-lites.co.uk>
Sent: 03 September 2013 14:54
To: Charles Hamshaw-Thomas
Subject: 100 Words On E-Cigarettes: The TPD Plenary Vote – The Wisdom of Waiting

MEPs may think the ENVI Committee is trying to rush them into voting on the TPD. The Committee has given MEPs just three working days between making available its report and the deadline for amendments. MEPs looking for a reason behind the rush may suspect it's an attempt to hide the proposed medicinal regulation of e-cigarettes. That would wreck the e-cigarette sector which is having more success in reducing tobacco sales than pharmaceutical industry alternatives have managed over the last 30 years. The e-cigarette industry asks MEPs to defer the vote to consider how to wisely regulate this new sector.

Charles Hamshaw-Thomas, Legal & Corporate Affairs Director for E-Lites

1. Wells Fargo, January 2013: within 10 years there could be “more e-cigarette users than cigarette smokers”
2. The Guardian, July 2013: reported the downgrading of shares of British American Tobacco and Imperial Tobacco because of the growth of e-cigarettes
3. Goldman Sachs, August 2013: e-cigarettes are one of the world's top “disruptive technologies”
4. Drexel University, August 2013: “chemicals in e-cigarettes pose no health concern for users or bystanders”
5. Professor Robert West, University College London: “the risk is negligible, and compared with smoking there is no contest”
6. E-Lites is the main brand of Zandera Ltd, the UK's largest e-cigarette company
7. E-Lites believes tight regulation of product quality and safety is important



E-Lites

Charles Hamshaw-Thomas | Director of Legal & Corporate Affairs
+ 44 (0) 7715 091 254 | + 44 (0) 1527 573 492 | www.E-Lites.co.uk
Zandera Ltd, 18 Buntsford Park Road, Bromsgrove, Worcestershire B60 3DX

This email and any attachments to it may be confidential and are intended solely for the use of the individual to whom it is addressed. Any views or opinions expressed are solely those of the author and do not necessarily represent those of Zandera Ltd/E-Lites. If you are not the intended recipient of this email, you must neither take any action based upon its contents, nor copy or show it to anyone. Please contact the sender if you believe you have received this email in error.



[Check out our latest advert on YouTube!](#)

This email has been scanned by the Symantec Email Security.cloud service.
Provided by ATG-IT - www.atg-it.co.uk

STAES Bart OFFICE

From: Zoltan Massay-Kosubek <zoltan@epha.org>
Sent: 02 September 2013 22:24
To: STAES Bart
Subject: Re: Call from the public health community: Do not postpone the plenary vote on the Tobacco Products Directive, 10 September

Dear MEP Bart Staes,

Thank you very much for your support, which is very important for the public health community. All of our joint efforts are needed to succeed in this very relevant vote.

Kind regards,

Zoltán

On 2 September 2013 22:17, STAES Bart <bart.staes@europarl.europa.eu> wrote:
Dear all,

You can count on me.

Kind regards,

Bart Staes, MEP

Op 2 sep. 2013 om 18:00 heeft "Zoltan Massay-Kosubek" <zoltan@epha.org> het volgende geschreven:

Dear Members and Substitute Members of the ENVI Committee,

Ahead of the Wednesday 10 July vote on the draft report on the Tobacco Products Directive (TPD), the European Public Health Alliance (EPHA) - a leading European NGO advocating for better health - contacts you on behalf of the European public health community.

The Public Health Community is **extremely concerned about the possible delay of the vote on the TPD which would not serve population's health in Europe**. We trust that you, as a representative of the ENVI Committee, will advocate **the timely vote on 10 September** and forward-looking measures in the ENVI Report within your political group and within your national delegation.

May we kindly remind you that with the 10th July vote, the ENVI Committee listened to the **concerns of the health and tobacco control community** and adopted a strong report on the Tobacco Products Directive. As you know, the key measures in the report include:

- Large, **mandatory pictorial health warnings** on tobacco products covering 75% of the front and the back of tobacco packs
- **Ban on all characterizing flavours** of tobacco products (detectable flavours of tobacco smoke such as menthol, vanilla, strawberry etc)
- **A ban on slim cigarettes** and slim cigarette packs
- Strong measures **against counterfeiting and illicit trade** of tobacco products with independent supervision
- Protecting the **Member States' right to adopt stronger measures** than those in the Directive.

The European tobacco control community welcomed the outcome of the ENVI Committee debate. Despite the fierce lobbying against them by hundreds of tobacco industry representatives and their third party allies, the measures adopted in July put public health ahead of tobacco industry interests. Tobacco is responsible for several deadly diseases, among others **for the Chronic Obstructive Pulmonary Disease (COPD)** which is a long term, irreversible lung and airways disease that affects up to **10% of Europeans[1]**; it is today the fifth cause of death worldwide and expected to be the third leading cause of death by 2030.

The plenary vote on 10 September is crucial to the future of tobacco control policies in Europe and will have effects for decades from today. The directive has the potential to stop young people from taking up the deadly habit of smoking, with its devastating effects that we witness in our everyday work. The health of millions of European children will benefit from your vote and from your support.

The public health community in your country and in the whole of Europe counts on your support and look forward to your vote for a Tobacco Products Directive that places the health of European citizens first.

Yours sincerely,

European Public Health Alliance (EPHA)

PS: It has come to our attention that a number of arguments against the tobacco products are not backed up by the evidence. To that end we have put the link to a [leaflet](#) that distinguishes between facts and fiction.

[1] EU Public Health Information System (Halbert et al., 2003, Interpreting COPD prevalence estimates: what is the true burden of disease? Chest, 2003; 123(5): 1684-92. Estimate – there is not enough epidemiological information on the matter

--

Mr. Zoltán MASSAY-KOSUBEK

Policy Coordinator for Policy Coherence (@EU_ZMK)
European Public Health Alliance (EPHA) | Rue de Trèves, 49-51, 1040 Brussels
Tel: +32 2 233 3872 | Skype: massay.zoltan | Fax: [+32 2 233 3880](tel:+3222333880)
zoltan@epha.org | www.epha.org
Follow EPHA on *Twitter* @EPHA_EU & *Facebook* www.facebook.com/epha.eu

EPHA is the European Platform bringing together public health organisations representing health professionals, patients groups, health promotion and disease specific NGOs, academic groupings and other health associations.

This email arises from the European Public Health Alliance which has received funding from the European Union, in the framework of the Health Programme. Sole responsibility for this email lies with EPHA and the Executive Agency is not responsible for any use that may be made of the information contained therein.

--

Mr. Zoltán MASSAY-KOSUBEK

Policy Coordinator for Policy Coherence (@EU_ZMK)
European Public Health Alliance (EPHA) | Rue de Trèves, 49-51, 1040 Brussels
Tel: +32 2 233 3872 | Skype: massay.zoltan | Fax: +32 2 233 3880
zoltan@epha.org | www.epha.org
Follow EPHA on *Twitter* @EPHA_EU & *Facebook* www.facebook.com/epha.eu

EPHA is the European Platform bringing together public health organisations representing health professionals, patients groups, health promotion and disease specific NGOs, academic groupings and other health associations.

This email arises from the European Public Health Alliance which has received funding from the European Union, in the framework of the Health Programme. Sole responsibility for this email lies with EPHA and the Executive Agency is not responsible for any use that may be made of the information contained therein.

STAES Bart OFFICE

From: Zoltan Massay-Kosubek <zoltan@epha.org>
Sent: 02 September 2013 18:00
To: Zoltan Massay-Kosubek
Subject: Call from the public health community: Do not postpone the plenary vote on the Tobacco Products Directive, 10 September

Dear Members and Substitute Members of the ENVI Committee,

Ahead of the Wednesday 10 July vote on the draft report on the Tobacco Products Directive (TPD), the European Public Health Alliance (EPHA) - a leading European NGO advocating for better health - contacts you on behalf of the European public health community.

The Public Health Community is **extremely concerned about the possible delay of the vote on the TPD which would not serve population's health in Europe**. We trust that you, as a representative of the ENVI Committee, will advocate **the timely vote on 10 September** and forward-looking measures in the ENVI Report within your political group and within your national delegation.

May we kindly remind you that with the 10th July vote, the ENVI Committee listened to the **concerns of the health and tobacco control community** and adopted a strong report on the Tobacco Products Directive. As you know, the key measures in the report include:

- Large, **mandatory pictorial health warnings** on tobacco products covering 75% of the front and the back of tobacco packs
- **Ban on all characterizing flavours** of tobacco products (detectable flavours of tobacco smoke such as menthol, vanilla, strawberry etc)
- **A ban on slim cigarettes** and slim cigarette packs
- Strong measures **against counterfeiting and illicit trade** of tobacco products with independent supervision
- Protecting the **Member States' right to adopt stronger measures** than those in the Directive.

The European tobacco control community welcomed the outcome of the ENVI Committee debate. Despite the fierce lobbying against them by hundreds of tobacco industry representatives and their third party allies, the measures adopted in July put public health ahead of tobacco industry interests. Tobacco is responsible for several deadly diseases, among others **for the Chronic Obstructive Pulmonary Disease (COPD)** which is a long term, irreversible lung and airways disease that affects up to **10% of Europeans^[1]**; it is today the fifth cause of death worldwide and expected to be the third leading cause of death by 2030.

The plenary vote on 10 September is crucial to the future of tobacco control policies in Europe and will have effects for decades from today. The directive has the potential to stop young people from taking up the

deadly habit of smoking, with its devastating effects that we witness in our everyday work. The health of millions of European children will benefit from your vote and from your support.

The public health community in your country and in the whole of Europe counts on your support and look forward to your vote for a Tobacco Products Directive that places the health of European citizens first.

Yours sincerely,

European Public Health Alliance (EPHA)

PS: It has come to our attention that a number of arguments against the tobacco products are not backed up by the evidence. To that end we have put the link to a [leaflet](#) that distinguishes between facts and fiction.

[1] EU Public Health Information System (Halbert et al., 2003, Interpreting COPD prevalence estimates: what is the true burden of disease? Chest, 2003; 123(5): 1684-92. Estimate – there is not enough epidemiological information on the matter

--

Mr. Zoltán MASSAY-KOSUBEK

Policy Coordinator for Policy Coherence (@EU_ZMK)

European Public Health Alliance (EPHA) | Rue de Trèves, 49-51, 1040 Brussels

Tel: +32 2 233 3872 | Skype: massay.zoltan | Fax: +32 2 233 3880

zoltan@epha.org | www.epha.org

Follow EPHA on *Twitter* @EPHA_EU & *Facebook* www.facebook.com/epha.eu

EPHA is the European Platform bringing together public health organisations representing health professionals, patients groups, health promotion and disease specific NGOs, academic groupings and other health associations.

This email arises from the European Public Health Alliance which has received funding from the European Union, in the framework of the Health Programme. Sole responsibility for this email lies with EPHA and the Executive Agency is not responsible for any use that may be made of the information contained therein.

STAES Bart OFFICE

From: Roberta Savli <roberta.savli@efanet.org>
Sent: 02 September 2013 14:09
To: STAES Bart
Cc: VANDEKERCKHOVE Angelique
Subject: RE: EFA - Request for a meeting on TPD

Dear Mr. Staes,

First of all, thank you very much for your e-mail. We are glad that you are sharing our concerns about tobacco use, its marketing in Europe and the proven negative effects it has on citizens' health.

Please, let us know in case we can help you to support the forward-looking measures voted in the ENVI report in July within your political group and especially your national delegation. We would be happy to do it as much as possible.

Yours sincerely,

Roberta Savli
EU Policy Officer

EFA European Federation of Allergy and Airways Diseases Patients' Associations – www.efanet.org
35 Rue du Congrès, 1000 Brussels, Belgium – Tel.: +32 (0)2 227 2720 – Fax: +32 (0)2 218 3141 – E-mail:
roberta.savli@efanet.org – Skype: robertasavli.efa
Transparency Register Identification Number: 28473847513-94
VISIT OUR [WEBSITE](#) and **FOLLOW US on [FACEBOOK](#) and [TWITTER](#)**

PLEASE [SIGN](#) OUR CALL TO ACTION on RESPIRATORY ALLERGIES in EUROPE & Help to raise awareness & relieve the burden

From: STAES Bart [mailto:bart.staes@europarl.europa.eu]
Sent: 02 September 2013 12:22
To: Roberta Savli
Cc: VANDEKERCKHOVE Angelique
Subject: Re: EFA - Request for a meeting on TPD

Dear mrs. Savli,

I fully support the ENVI-report and I share your arguments. I think a meeting is unnecessary. I think it would be much more useful on those colleagues who do not share your conviction.

I am on your side.

Kind regards,

Bart Staes

Op 30 aug. 2013 om 16:15 heeft "Roberta Savli" <roberta.savli@efanet.org> het volgende geschreven:

Dear Honourable Member of the European Parliament,

Ahead of the plenary vote on the ENVI report on the Tobacco Products Directive on the 10th of September, I am contacting you as a representative of patients with allergy and respiratory diseases in Europe.

Tobacco kills 1 in 2 of its users. It is highly addictive and extremely harmful to human health. We are very much concerned about tobacco use and its marketing in Europe, and especially about the proven negative effects it has on citizens' health. Ahead of the vote, I would thus like to request a meeting with you or someone from your staff in the following days (either in Brussels next week or in Strasbourg the week of the vote) to present our position and discuss the main points of interest for patients and public health in the report.

As tobacco is a major source of nuisance and exacerbation for people with allergy and respiratory diseases, we hope that you will side with public health interests and advocate for the forward-looking measures voted in the ENVI report in July within your political group and national delegation.

For all references and additional information, please check EFA's position paper available on our website at: <http://www.efanet.org/wp-content/uploads/2013/06/EFA-position-on-TPD.pdf>.

I stay at your disposal for any kind of question you may have. I thank you in advance for your cooperation and I hope to receive a positive reply from you.

Yours sincerely,

Roberta Savli

EU Policy Officer

EFA European Federation of Allergy and Airways Diseases Patients' Associations – www.efanet.org
35 Rue du Congrès, 1000 Brussels, Belgium – Tel.: +32 (0)2 227 2720 – Fax: +32 (0)2 218 3141 – E-mail: roberta.savli@efanet.org – Skype: robertasavli.efa

Transparency Register Identification Number: 28473847513-94

VISIT OUR [WEBSITE](http://www.efanet.org) and FOLLOW US on [FACEBOOK](#) and [TWITTER](#)

PLEASE [SIGN](#) OUR CALL TO ACTION on RESPIRATORY ALLERGIES in EUROPE & Help to raise awareness & relieve the burden

STAES Bart OFFICE

From: Marleen Kestens <mkestens@ehnheart.org>
Sent: 02 September 2013 12:30
To: STAES Bart
Subject: RE: Plenary vote on the Tobacco Products Directive, 10 September

Doen we zeker. Bedankt voor alle hulp!

Groeten

Marleen Kestens
Network Coordinator

European Heart Network (EHN)

Rue Montoyer 31 - 1000 Brussels - Belgium

Tel: +32 2 502 15 41 - Fax: +32 2 503 35 25

mkestens@ehnheart.org – www.ehnheart.org

From: STAES Bart [mailto:bart.staes@europarl.europa.eu]
Sent: Monday, September 02, 2013 12:29 PM
To: Marleen Kestens
Cc: VANDEKERCKHOVE Angelique
Subject: Re: Plenary vote on the Tobacco Products Directive, 10 September

Beste Marleen,

Het hoeft waarschijnlijk niet herhaald: u kan voor de volle 100 procent rekenen op mezelf en op de groene fractie in het EP!!!

Hartelijke groet,

Bart Staes

Op 30 aug. 2013 om 14:26 heeft "Marleen Kestens" <mkestens@ehnheart.org> het volgende geschreven:

Dear Member of the Committee on the Environment, Public Health and Food Safety

We are writing to you ahead of the Tuesday 10 September vote on the ENVI report on the Tobacco Products Directive (TPD). The **European Heart Network (EHN)**, working with our members across Europe to curb unnecessary death and suffering from heart disease and stroke, is adamant that the TPD has the potential to reduce smoking in Europe. Tobacco use is a very significant risk factor for heart disease and stroke.

Firstly, we would, therefore, like to express our **gratitude for the outcome of the vote in the ENVI Committee on the TPD** on the 10th of July. With that vote, the ENVI Committee laid the groundwork for an effective measure to reach our objective of reducing smoking.

The ENVI Committee's strong report on the TPD includes key measures:

- Large, mandatory pictorial and text health warnings on tobacco products covering 75% of the front and the back of tobacco packs
- A ban on all characterising flavours of tobacco products (detectable flavours of tobacco smoke such as menthol, vanilla, strawberry)
- A ban on slim cigarettes and slim cigarette packs
- Strong measures against counterfeiting and illicit trade of tobacco products with independent supervision
- Protecting the Member States' right to adopt stronger measures.

We are aware that the tobacco industry representatives and allied industries have strong aversions to the Report and that they are undertaking extensive lobbying to weaken it in Plenary. But, the Report that you adopted in the ENVI Committee is the correct measure and there is substantial evidence to support it. **We trust that you, as a member of the ENVI Committee, will advocate for the evidence-based measures included in your Committee's Report within your political group.**

The plenary vote on 10 September is crucial to reducing tobacco use in Europe and will have effects for decades from today. The directive has the potential to stop young people from taking up the deadly habit of smoking, with its devastating effects that we witness in our everyday work.

EHN counts on your support and looks forward to your vote for a Tobacco Products Directive that will improve the health of European citizens.

Yours sincerely,

Marleen Kestens
Network Coordinator

<image001.png>

<image002.jpg>

European Heart Network (EHN)

Rue Montoyer 31 - 1000 Brussels - Belgium

Tel: +32 2 502 15 41 - Fax: +32 2 503 35 25

mkestens@ehnheart.org – www.ehnheart.org

The European Heart Network plays a leading role in the prevention and reduction of cardiovascular diseases, in particular heart disease and stroke, through advocacy, networking, education and patient support, so that they are no longer a major cause of premature death and disability throughout Europe.

STAES Bart OFFICE

From: Roberta Savli <roberta.savli@efanet.org>
Sent: 30 August 2013 16:09
Subject: EFA - Request for a meeting on TPD

Importance: High

Dear Honourable Member of the European Parliament,

Ahead of the plenary vote on the ENVI report on the Tobacco Products Directive on the 10th of September, I am contacting you as a representative of patients with allergy and respiratory diseases in Europe.

Tobacco kills 1 in 2 of its users. It is highly addictive and extremely harmful to human health. We are very much concerned about tobacco use and its marketing in Europe, and especially about the proven negative effects it has on citizens' health. Ahead of the vote, I would thus like to request a meeting with you or someone from your staff in the following days (either in Brussels next week or in Strasbourg the week of the vote) to present our position and discuss the main points of interest for patients and public health in the report.

As tobacco is a major source of nuisance and exacerbation for people with allergy and respiratory diseases, we hope that you will side with public health interests and advocate for the forward-looking measures voted in the ENVI report in July within your political group and national delegation.

For all references and additional information, please check EFA's position paper available on our website at: <http://www.efanet.org/wp-content/uploads/2013/06/EFA-position-on-TPD.pdf>.

I stay at your disposal for any kind of question you may have. I thank you in advance for your cooperation and I hope to receive a positive reply from you.

Yours sincerely,

Roberta Savli
EU Policy Officer

EFA European Federation of Allergy and Airways Diseases Patients' Associations – www.efanet.org
35 Rue du Congrès, 1000 Brussels, Belgium – Tel.: +32 (0)2 227 2720 – Fax: +32 (0)2 218 3141 – E-mail:
roberta.savli@efanet.org – Skype: robertasavli.efa

Transparency Register Identification Number: 28473847513-94

VISIT OUR [WEBSITE](#) and FOLLOW US on [FACEBOOK](#) and [TWITTER](#)

PLEASE [SIGN](#) OUR CALL TO ACTION on RESPIRATORY ALLERGIES in EUROPE & Help to raise awareness & relieve the burden

STAES Bart OFFICE

From: Marleen Kestens <mkestens@ehnheart.org>
Sent: 30 August 2013 14:27
To: Marleen Kestens
Subject: Plenary vote on the Tobacco Products Directive, 10 September

Dear Member of the Committee on the Environment, Public Health and Food Safety

We are writing to you ahead of the Tuesday 10 September vote on the ENVI report on the Tobacco Products Directive (TPD). The **European Heart Network** (EHN), working with our members across Europe to curb unnecessary death and suffering from heart disease and stroke, is adamant that the TPD has the potential to reduce smoking in Europe. Tobacco use is a very significant risk factor for heart disease and stroke.

Firstly, we would, therefore, like to express our **gratitude for the outcome of the vote in the ENVI Committee on the TPD** on the 10th of July. With that vote, the ENVI Committee laid the groundwork for an effective measure to reach our objective of reducing smoking.

The ENVI Committee's strong report on the TPD includes key measures:

- Large, mandatory pictorial and text health warnings on tobacco products covering 75% of the front and the back of tobacco packs
- A ban on all characterising flavours of tobacco products (detectable flavours of tobacco smoke such as menthol, vanilla, strawberry)
- A ban on slim cigarettes and slim cigarette packs
- Strong measures against counterfeiting and illicit trade of tobacco products with independent supervision
- Protecting the Member States' right to adopt stronger measures.

We are aware that the tobacco industry representatives and allied industries have strong aversions to the Report and that they are undertaking extensive lobbying to weaken it in Plenary. But, the Report that you adopted in the ENVI Committee is the correct measure and there is substantial evidence to support it. **We trust that you, as a member of the ENVI Committee, will advocate for the evidence-based measures included in your Committee's Report within your political group.**

The plenary vote on 10 September is crucial to reducing tobacco use in Europe and will have effects for decades from today. The directive has the potential to stop young people from taking up the deadly habit of smoking, with its devastating effects that we witness in our everyday work.

EHN counts on your support and looks forward to your vote for a Tobacco Products Directive that will improve the health of European citizens.

Yours sincerely,

Marleen Kestens
Network Coordinator



fighting heart disease
and stroke
european heart network



European Heart Network (EHN)

Rue Montoyer 31 - 1000 Brussels - Belgium

Tel: +32 2 502 15 41 - Fax: +32 2 503 35 25

mkestens@ehnheart.org – www.ehnheart.org

The European Heart Network plays a leading role in the prevention and reduction of cardiovascular diseases, in particular heart disease and stroke, through advocacy, networking, education and patient support, so that they are no longer a major cause of premature death and disability throughout Europe.

STAES Bart OFFICE

From: Charles Hamshaw-Thomas <Charles@e-lites.co.uk>
Sent: 28 August 2013 17:59
To: Charles Hamshaw-Thomas
Subject: 100 Words On E-Cigarettes: Will the TPD Double The Price Of E-Cigarettes?

Europe's e-cigarette market is unlike big tobacco. There are thousands of small e-cigarette companies competing intensely to offer smokers the best tobacco replacement products at the lowest possible price. But then the TPD. It would wipe out the market by imposing a medicines regulation 'tax'. First year costs could exceed €1m on every product. Only the tobacco companies can afford that. Do you think they would want to keep the price of their main competitor low? If MEPs think this is scaremongering then they should commission proper economic impact assessments into the TPD's impact on e-cigarettes. Otherwise they're legislating blind.

Charles Hamshaw-Thomas, Legal & Corporate Affairs Director for E-Lites

Notes:

1. Medicinal regulation: The Lancet: [http://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(13\)70124-3/fulltext](http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(13)70124-3/fulltext)
2. E-cigarettes lead to stopping smoking: Polosa, June 2013
<http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0066317#s4>
3. The effectiveness of 'harm reduction' <http://www.clivebates.com/?p=1205>
4. E-Lites is the main brand of Zandera Ltd, the UK's largest e-cigarette company
5. E-Lites believes tight regulation of product quality and safety is important



E-Lites

Charles Hamshaw-Thomas | Director of Legal & Corporate Affairs
+ 44 (0) 7715 091 254 | + 44 (0) 1527 573 492 | www.E-Lites.co.uk
Zandera Ltd, 18 Buntsford Park Road, Bromsgrove, Worcestershire B60 3DX

This email and any attachments to it may be confidential and are intended solely for the use of the individual to whom it is addressed. Any views or opinions expressed are solely those of the author and do not necessarily represent those of Zandera Ltd/E-Lites. If you are not the intended recipient of this email, you must neither take any action based upon its contents, nor copy or show it to anyone. Please contact the sender if you believe you have received this email in error.



[Check out our latest advert on YouTube!](#)

This email has been scanned by the Symantec Email Security.cloud service.
Provided by ATG-IT - www.atg-it.co.uk

STAES Bart OFFICE

From: Charles Hamshaw-Thomas <Charles@e-lites.co.uk>
Sent: 19 August 2013 13:17
To: Charles Hamshaw-Thomas
Subject: 100 Words On E-Cigarettes: Legislate In Haste, Repent At Leisure

The determination of MEPs to pass the Tobacco Products Directive is energised by their desire to free Europe's smokers from tobacco. Yet buried within the TPD is a measure that will condemn millions of smokers to remaining hooked on the deadly weed. It's the medicinal regulation of e-cigarettes which is so immensely expensive that it will kill off innovation - just as it has with nicotine replacement therapies. Medicinal regulators want to build up their empires. Smokers want cheap e-cigarette products. On beating up big tobacco – let MEPs decide. But on how to reduce their tobacco dependency, let smokers decide.

Charles Hamshaw-Thomas, Legal & Corporate Affairs Director for E-Lites

Notes:

- NRTs represent classic example of stifling effect of medicinal regulation: The Lancet: [http://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(13\)70124-3/fulltext](http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(13)70124-3/fulltext)
- The effectiveness of 'harm reduction' <http://www.clivebates.com/?p=1205>
- E-Lites is the main brand of Zandera Ltd, the UK's largest e-cigarette company
- E-Lites believes tight regulation of product quality and safety is important



E-Lites

Charles Hamshaw-Thomas | Director of Legal & Corporate Affairs
+ 44 (0) 7715 091 254 | + 44 (0) 1527 573 492 | www.E-Lites.co.uk
Zandera Ltd, 18 Buntsford Park Road, Bromsgrove, Worcestershire B60 3DX

This email and any attachments to it may be confidential and are intended solely for the use of the individual to whom it is addressed. Any views or opinions expressed are solely those of the author and do not necessarily represent those of Zandera Ltd/E-Lites. If you are not the intended recipient of this email, you must neither take any action based upon its contents, nor copy or show it to anyone. Please contact the sender if you believe you have received this email in error.



[Check out our latest advert on YouTube!](#)

This email has been scanned by the Symantec Email Security.cloud service.
Provided by ATG-IT - www.atg-it.co.uk

STAES Bart OFFICE

From: Luk Van Daele <lukvandaele@gmail.com> on behalf of Luc Van Daele <lvd@sound-silence.com>
Sent: 31 July 2013 18:26
To: DELVAUX Anne; BELET Ivo; DEHAENE Jean-Luc; THYSSEN Marianne; GROSCHE Mathieu; DURANT Isabelle; LAMBERTS Philippe; STAES Bart; EPPINK Derkjan; MICHEL Louis; RIES Frédérique; DEMESMAEKER Mark; VANHECKE Frank; DE BACKER Philippe; NEYTS-UYTTEBROECK Annemie; VERHOFSTADT Guy; DAERDEN Frederic; DE KEYSER Véronique; TARABELLA Marc; EL KHADRAOUI Saïd; VAN BREMPT Kathleen; CLAEYS Philip
Subject: Electric cigarette vote on 9/9
Attachments: AIDUCE_ENVI_EN.pdf

Dear Madam/Sir MEP,

I am a long time smoker and already undertook several attempts to quit, but always relapsed after six months to a year because of the craving for tobacco. I undertook another attempt to give up smoking tobacco in 2007, using the electronic cigarette. I did have to fight the addiction for the real thing, probably caused by the additives used by the tobacco industry to make their product even more addictive, I also had to get used to the taste without smell, but after some incidents I can say I am smoke free and it seems to be working wonders as a tobacco smoking replacement product.

I did not intend to fight the nicotine addiction at that time, and didn't prepare for it either. Diminishing the nicotine levels in the liquid just came natural over the years. Now I've heard that the European Council wants to impose a de facto ban on the liquids for the electronic cigarette by imposing medicinal requirements the product obviously can not meet. I do not understand why harmless PG with added nicotine could be considered more dangerous than cigarette smoke with the same amount of nicotine, which is available in the shops everywhere. Cigarette smoke contains about 1600 hazardous products while PG is the one of the most inert products on earth. I do understand that the best thing is to quit completely, but with my experience on relapsing, I rather go for the next best thing of sucking clean vapour into my lounges instead of being forced by the government to suck cancerous fumes into them again.

Could you as an MEP find out why such draconian measures were taken and this without any prior notice to the people depending on the product? Since my life is depending on this, I would like to make a plea to leave the sale of this product free until it is proven that inhaling vapour (breathing air basically, which consists mostly of vapour) is more dangerous than smoking tobacco. I would rather die peacefully of old age sucking on a little steam engine, than being forced into a premature death from cancer.

The authorities undertook enormous efforts over the last decades in campaigning against smoke and the hazardous effects on the smoker as well as on the passive smoker. A smoking ban was introduced for that reason. The government should be embracing the product instead of banning it or making its access more difficult. I admit there is a health issue with the nicotine, but this is exactly the same with tobacco and other related drugs like the caffeine in coffee and tea, not to speak of the far more dangerous alcohol. At least the electronic cigarette does not cause cancer, and does not kill, which is undeniably the greatest health risk of all.

Since the introduction of the electric cigarette governments all over Europe have been trying to ban the product, mostly by falsely classifying it as a medicine. All governments but one (Belgium) have been revoked their decisions in court. My Belgian friends who did quit smoking have to smuggle their liquids through customs or buy it on the black market; and now the proposed article 17 is a carbon copy of that Belgian de facto ban on liquids, so it is a no-brainer to figure out what the European Council's real intentions are. This was also mentioned by the spokesperson of commissioner Borg in

the ENVI-workshop when asked where this article 17 originated from: “we took the most severe we could find in the member states”, meaning the effective de facto ban in Belgian, which is preventing people to quit smoking and to save their lives. The former Irish president of the European Council also confirmed this in his last press conference as president: “the biggest nightmare we could face is a world where everybody stopped smoking and converted to electric cigarettes”.

Could this be a tax issue? It was always told that the monster tax on tobacco was to make the guilty party (the smokers – guilty as charged) pay for the increased cost in the healthcare, and that even with the actual amount of taxation this was not even close to pay for the full cost of cancer treatments of smokers and passive smokers. There are even rumours that in the future doctors could refuse cancer treatment to smokers for that reason. So for every smoker that quits smoking tobacco the government loses on taxation, but gains far more in reduced health care costs, even if that smoker keeps on inhaling vaper with nicotine. I do understand the EU governments are in need of money now during the crisis and not in 10 or 20 years, but only the European parliament is capable to stop the European Council in their intention to kill millions for money. This is why I’m putting my pea to you. Could you inform me what your stands is on this?

Awaiting your reply, sincerely yours

Luk Van Daele
lvd@sound-silence.com

PS: I enclosed a text that states my opinions much better and more professionally as I would be able to put it.

STAES Bart OFFICE

From: Debbie Millward <debbie.millward@ash.org.uk>
Sent: 18 July 2013 11:50
To: STAES Bart
Subject: Tobacco Products Directive - ENVI committee amendment on e-cigarettes

Dear Mr STAES

On Wednesday 10th July the European Parliament Committee responsible for the Tobacco Products Directive dossier (ENVI Committee) passed an amendment requiring medicines regulation for all e-cigarettes.

If the TPD comes into force with this amendment in place it will mean that from 2016 onwards all e-cigarettes and other nicotine containing products will have to gain market authorisation under the medicines directive.

The RCP and ASH are writing to you to explain why we support this proposal which is in line with the UK government and UK medicines regulator the [MHRA's decision](#) about how these products should be regulated.

To summarise we believe that e-cigarettes have significant potential to help smokers who aren't otherwise ready or able to quit smoking by providing them with much safer alternatives to smoked tobacco, and indeed that e-cigarettes and similar products are a potential major benefit to public health. It is therefore important that regulation does not stifle the development and growth of this market. However, we also believe that some safeguards are required to ensure that these products are effective, reliable, as safe as is reasonably possible, and are not marketed to non-smokers, including children. We believe that the medicines regulation proposed by the MHRA will achieve this.

The reasons we are in favour of e-cigarettes, and comparable products currently in development, are:

1. Currently there are nearly [10 million](#) addicted smokers in the UK, with around [100,000](#) dying from their addiction each year. To quote Professor Mike Russell a pioneer in the treatment of nicotine addiction from the Institute of Psychiatry in the 1970s, *"people smoke for the nicotine but they die from the tar."* While the Stop Smoking Services in the UK are highly cost-effective and can quadruple smokers' chances of quitting, it is still very difficult to quit and only a small proportion of smokers take up the Services available.
2. Smokers like e-cigarettes because of their similarity to cigarettes and because substituting one behaviour for another similar one is easier than stopping the behaviour altogether. [Research by ASH](#) and others shows that e-cigarettes are being used by smokers primarily for the same purposes as medicinal Nicotine Replacement Therapy (NRT) – to quit, to cut down, as an alternative to smoking and to use where they can't smoke – all purposes that NRT is licensed for in the UK and can be elsewhere. The e-cigarette industry has to say they're for recreational purposes because otherwise they get caught by medicines regulation, but smokers themselves freely admit they're using them to help them quit smoking.
3. The [MHRA concluded](#) that the products currently on the market do not meet appropriate standards of safety, quality and efficacy: *"Testing data confirm that nicotine levels can vary considerably from the labelled content and the amount of nicotine per product can differ from batch to batch. In terms of how well NCPs work, there can be widely differing amounts of nicotine from the same format with one form delivering what could be an effective therapeutic dose,*

another a 'placebo' dose. With regards to safety, toxic elements may be included at unexpectedly high doses which could produce adverse effects, particularly in vulnerable patient groups."

4. Some e-cigarette companies say medicines regulation would be too expensive and too difficult, but this is a potentially large and very profitable market. Licensed nicotine products are also taxed at the lowest level of VAT, which is 5%, and licensed products will also be able to be prescribed through the NHS. The costs of meeting minimum regulatory standards will be minor in this context. A recent report by Wells Fargo, a US investment analyst, came to the conclusion that:

- *Within a decade e-cig sales in the US could overtake cigarettes.*
- *While the big 3 tobacco brands in the US are likely to be key players independents will continue to have significant market share.*
- *Margins are growing on e-cigarettes as the market grows and evolves: by 2017 margins could be higher than current conventional cigarette margins of around 40%*
- *The Wells Fargo model doesn't consider new entrants amongst non-smokers – all of the e-cig volume consumption in the model is driven by existing conventional cigarette users*
- *Regulation is not considered likely to undermine the long-term growth of the e-cigarette market. it is however considered likely to entrench existing e-cigarette players as it increases barriers to entry.*

5. E-cigarettes are still a relatively young and rapidly evolving product and consolidation is inevitable. Already the small companies are being swallowed up, largely by the tobacco industry, and this process will continue whether medicines regulation is imposed or not. We need a strong regulatory framework in place to help shape how the market develops, particularly because of the move into the market of the tobacco industry. The UK model can and should set the standard for how these products should be regulated in other Member States (MS) too.

6. There is an understandable concern amongst users that, while in the UK e-cigarettes will continue to be available on general sale not only everywhere cigarettes are available but also in pharmacies, in some parts of Europe this might not be the case. However, most MS already have forms of NRT available as non-prescription medicines and most MS already have a category of medicines which can be sold outside pharmacies. And all Member States can (and we think should) allow e-cigarettes to be on general sale in the transposing of the TPD to their domestic law.

7. Even if they do not do so, if e-cigarettes are licensed they will be on sale in pharmacies throughout the EU. While in some jurisdictions they may not be as freely available as cigarettes, smokers will still be able to get hold of them, just as consumers can get hold of the medicines they need.

8. We therefore need to encourage other MS to adopt the same abridged licensing processes as the MHRA already has in place. The [MHRA's](#) abridged licensing process does not require expensive clinical trials, but will require e-cigarette manufacturers to prove the quality, safety and efficacy of their product.

9. Lastly it has also been suggested that the use of these products may make it difficult to enforce smokefree legislation and the French government is considering a public places ban on their use. We do not believe this is appropriate, nor does the Chartered Institute of Environmental Health, the professional body for officials responsible for enforcing smokefree legislation in the UK. Smoked tobacco is immediately recognisable from the smell and easily distinguishable from e-cigarettes. Use of e-cigarettes is far safer than smoking, both for the user and those around them.

Do let us know if you have any questions.

Deborah Arnott, MBA FRCP(Hon), chief executive, ASH

deborah.arnott@ash.org.uk

Professor John Britton CBE, Chair of the Royal College of Physicians Tobacco Advisory Group.

j.britton@virgin.net

STAES Bart OFFICE

From: Luk Van Daele <lukvandaele@gmail.com> on behalf of Luc Van Daele <lvd@sound-silence.com>
Sent: 16 July 2013 15:52
To: ROITHOVA Zuzana; BIELAN Adam; GIEREK Adam; KÓSA Ádám; V LEAN Adina Ioana; SEVERIN Adrian; HANKISS Ágnes; LE BRUN Agnès; DÍAZ DE MERA GARCÍA-CONSUEGRA Agustín; CADEC Alain; LAMASSOURE Alain; MÉSZÁROS Alajos; DESS Albert; SOUSA Alda; PATRICIELLO Aldo; CERCAS Alejandro; VIDAL-QUADRAS Alejo; ALVARO Alexander; MIRSKY Alexander; LAMBSDORFF Alexander Graf; THEIN Alexandra; SVENSSON Alf; ANTONIOZZI Alfredo; PALLONE Alfredo; RUBIKS Alfreds; SAUDARGAS Algirdas; PETERLE Alojz; SMITH Alyn; SARTORI Amalia; ANDERSDOTTER Amelia; GOMES Ana Maria; GYURK Andras; EŠKOVÁ Andrea; COZZOLINO Andrea; ZANONI Andrea; MÖLZER Andreas; PITSILLIDES Andreas; SCHWAB Andreas; PLENKOVI Andrej; PERELLO RODRIGUEZ Andres; BRONS Andrew Henry Wiliam; DUFF Andrew; KOVATCHEV Andrey; GRZYB Andrzej; NIEBLER Angelika; WERTHMANN Angelika; WEISGERBER Anja; HEDH Anna; IBRISAGIC Anna; ROSBACH Anna; ZABORSKA Anna; CORAZZA BILDT Anna Maria; DELVAUX Anne; JENSEN Anne E.; JÄÄTTEENMÄKI Anneli; NEYTS-UYTTEBROECK Annemie; PODIMATA Anni; MCINTYRE Anthea; PAPADOPOULOU Antigoni; SÁNCHEZ PRESEDO Antolín; ANTINORO Antonello; CORREIA DE CAMPOS António Fernando; CANCIAN Antonio; LÓPEZ ISTÚRIZ Antonio; MASIP HIDALGO Antonio; PARVANOVA Antonya; BRATKOWSKI Arkadiusz Tomasz; MCCARTHY Arlene; DANJEAN Arnaud; ZASADA Artur; WESTLUND Asa; FOX Ashley; LULLING Astrid; ZIJLSTRA Auke; VOSS Axel; LOCHBIHLER Barbara; MATERA Barbara; WEILER Barbara; STAES Bart; EICKHOUT Bas; BELDER Bastiaan; GLATTFELDER Béla; KOVÁCS Béla; BENDTSEN Bendt; VERGNAUD Bernadette; LANGE Bernd; RAPKAY Bernhard; BORZAN Biljana; NEWTON DUNN Bill; COLLIN-LANGEN Birgit; SCHNIEBER-JASTRAM Birgit; SIPPEL Birgit; biuro@pawelkowl.pl; MARCINKIEWICZ Bogdan Kazimierz; LIBERADZKI Bogusław; SONIK Boguslaw; ZALA Boris; SIMPSON Brian; briancrowleymep@eircom.net; HORTEFEUX Brice; REIMERS Britta; THOMSEN Britta; GOLLNISCH Bruno; BALZ Burkhard; SCHLYTER Carl; CASINI Carlo; FIDANZA Carlo; COELHO Carlos; ITURGAIZ ANGULO Carlos; FRAGA ESTÉVEZ Carmen; ROMERO LÓPEZ Carmen; IVAN C t lin-Sorin; BEARDER Catherine; GREZE Catherine; STIHLER Catherine; TRAUTMANN Catherine; WIKSTRÖM Cecilia; ANGOURAKIS Charalampos; GOERENS Charles; TANNOCK Charles; chris@chrisdaviesmep.org.uk; KLASS Christa; SCHALDEMOSE Christel; EHLER Christian; ENGSTRÖM Christian; DE VEYRAC Christine; FJELLNER Christofer; PALIADELI Chrysoula; MORAES Claude; TURMES Claude; ABELA BALDACCHINO Claudette; MORGANTI Claudio; T N SESCU Claudiu Ciprian; MASTELLA Clemente; LE GRIP Constance; WORTMANN-KOOL Corien; CRETU Corina; LEPAGE Corinne; ERNST Cornelia; RIVELLINI Crescenzo; MUSCARDINI Cristiana; PREDĂ Cristian Dan; GUTIERREZ-CORTINES Cristina; ORY Csaba; SÓGOR Csaba; TABAJDI Csaba; SZEGEDI Csanád; SIEKIERSKI Czeslaw; SARBU Daciana Octavia; ROTH-BEHRENDT Dagmar; JØRGENSEN Dan; ZAMFIRESCU Dan Dumitru; CASPARY Daniel; COHN-BENDIT Daniel; HANNAN Daniel; VAN DER STOEP Daniel; HUEBNER Danuta Maria; JAZŁOWIECKA Danuta; CAMPBELL BANNERMAN David; CASA David; MARTIN David; SASSOLI David-Maria; STIER Davor Ivo; DE JONG Dennis; VAUGHAN Derek; CLARK Derek Roland; EPPINK Derkjan; DODDS Diane; KOCH Dieter-Lebrecht; STOYANOV Dimitar; DROUTSAS Dimitrios; FEIO Diogo; GARCÍA-HIERRO ÇARABALLO Dolores; RIQUET Dominique; VLASTO Dominique; PACK Doris Gisela; ŠUIÇA Dubravka; BAUER Edit; HERCZOG Edit; ESTRELA Edite; KUKAN Eduard; KOŽUŠNÍK Edvard; MCMILLAN-SCOTT Edward; GARDIAZÁBAL RUBIAL Eider; KORHOLA Eija-Riitta; B SESCOU Elena; THEOCHAROUS Eleni; FERREIRA Elisa; JEGGLE Elisabeth; KÖSTINGER Elisabeth; MORIN-CHARTIER Elisabeth; SCHROEDTER Elisabeth; GARDINI Elisabetta; BROK Elmar; ŁUKACIJEWSKA El bieta Katarzyna; COSTELLO Emer; TURUNEN Emilie; MENENDEZ DEL VALLE Emilio; BOZKURT Emine; MCCLARKIN Emma; GUERRERO SALOM Enrique; ANDRIEU Eric; BÁNKI Erik; MAZZONI Erminia; DE LANGE Esther; HERRANZ GARCIA Esther; JOLY Gro Eva; LICHTENBERGER Eva; ORTIZ VILELLA Eva; REGNER Evelyn; GEBHARDT Evelyne; KIRILOV Evgeni; TOŠENOVSKÝ Evžen; STADLER Ewald; BERTOT Fabrizio; KACZMAREK Filip; HYUSMENOVA Filiz Hakaeva; HALL Fiona; PROVERA Fiorello; BALZANI Francesca; BARRACCIU Francesca; DE ANGELIS Francesco; SPERONI Francesco Enrico; MILLÁN MON Francisco; SOSA WAGNER Francisco; PROUST Franck; BONANINI Franco; FRIGO Franco; ALFONSI François; CASTEX Françoise; GROSSETETE Françoise; ENGEL Frank; VANHECKE Frank; OBERMAYR Franz; BRANTNER Franziska Katharina; KELLER Franziska; DAERDEN Frederic; RIES Frédérique; MATO Gabriel; ZIMMER Gabriele; FRANCO

To: Gaston; MITCHELL Gay; VAN ORDEN Geoffrey; LYON George; BACH Georges; CUTA George Sabin; KOUMOUTSAKOS Georgios; PAPANIKOLAOU Georgios; PAPASTAMKOS Georgios; STAVRAKAKIS Georgios; TOUSSAS Georgios; HÄFNER Gerald; BATTEN Gerard; GERBRANDY Gerben-Jan; MEISSNER Gesine; SCOTTA' Giancarlo; PITTELLA Gianni; VATTIMO Gianni; CHICHESTER Giles; PARGNEAUX Gilles; TREMATERRA Gino; UGGIAS Giommaria; LA VIA Giovanni; GARGANI Giuseppe; WILLMOTT Glenis; QUISTHOUDT-ROWOHL Godelieve; BLOOM Godfrey; FÄRM Göran; WATSON Graham; MILANA Guido; HÖKMARK Gunnar; VERHOFSTADT Guy; SCHÖPFLIN György; SWOBODA Hannes; TAKKULA Hannu; VAN BAALEN Johannes Cornelis; POETTERING Hans-Gert; MARTIN Hans-Peter; MAYER Hans-Peter; DESIR Harlem; RUEHLE Heide; BECKER Heinz K.; FLAUTRE Hélène; TRÜPEL Helga; SCHOLZ Helmut; WEBER Henri; DORFMANN Herbert; REUL Herbert; WINKLER Hermann; KRAHMER Holger; SCHNELLHARDT Horst; PIRKER Hubert; FAJMON Hynek; HUDGHTON Ian; GÁLL-PELCZ Ildikó; IOTOVA Iliana Malinova; TARAND Indrek; AYALA SENDER Inés; ZUBER Inês; VAIDERE Inese; GRAESSLE Ingeborg; ENCIU Ioan; PASCU Ioan Mircea; TSOUKALAS Ioannis A.; MATULA Iosif; GARCÍA-PEREZ Iratxe; LÖVIN Isabella; DURANT Isabelle; THOMAS Isabelle; ERTUG Ismail; WINKLER Iuliu; ZANICCHI Iva; KALFIN Ivailo; MALETI Ivana; PADAR Ivari; GODMANIS Ivars; BELET Ivo; STREJCEK Ivo; VAJGL Ivo; BILBAO BARANDICA Izaskun; KURSKI Jacek; PROTASIEWICZ Jacek; SARYUSZ-WOLSKI Jacek; WŁOSOWICZ Jacek Władysław; HENIN Jacky; FOSTER Jacqueline; MAYOR OREJA Jaime; ELLES James; NICHOLSON James; ALBRECHT Jan Philipp; BREZINA Jan; KOZŁOWSKI Jan; MULDER Jan; OLBRYCHT Jan; ZHRADIL Jan; WOJCIECHOWSKI Janusz; ZEMKE Janusz; KOHLICEK Jaromír; PAŠKA Jaroslav; KALINOWSKI Jarosław; WAŁ SA Jarosław; LAMBERT Jean; ROATTA Jean; BICEP Jean-Jacob; COTTIGNY Jean-Louis; BENNAHMIA Jean-Luc; DEHAENE Jean-Luc; MÉLÉNCHON Jean-Luc; CAVADA Jean-Marie; LE PEN Jean-Marie; BESSET Jean-Paul; GAUZÉS Jean-Paul; AUDY Jean-Pierre; KACIN Jelko; GEIER Jens; NILSSON Jens; ROHDE Jens; BUZEK Jerzy; EVANS Jill; HIGGINS Jim; MASTALKA Jiri; LEINEN Jo; ZELLER Joachim; SENYSZYN Joanna; SKRZYDLEWSKA Joanna Katarzyna; FERREIRA João; LEICHTFRIED Jörg; ATTARD-MONTALTO John; BUFTON John; AGNEW John Stuart; HIBNER Jolanta Emilia; CHATZIMARKAKIS Jorgo; BOVÉ José; WEIDENHOLZER Josef; ANDRES BAREA Josefa; SALAFRANCA José Ignacio; FERNANDES José Manuel; CUSCHIERI Joseph; DAUL Joseph; SZAJER Jozsef; NARANJO ESCOBAR Juan; LÓPEZ AGUILAR Juan Fernando; MERKIES Judith A.; SARGENTINI Judith; KLUTE Jürgen; GIRLING Julie; IMBRASAS Juozas; CREUTZMANN Jürgen; PALECKIS Justas Vincas; VITKAUSKAITE BERNARD Justina; HAUG Jutta; STEINRUCK Jutta; ZERIBI Karim; DELLI Karima; KADENBACH Karin; FLORENZ Karl-Heinz; ŠADURSKIS K rliis; LIOTARD Kartika Tamara; NEVE ALOVÁ Katarína; VAN BREMPT Kathleen; SWINBURNE Jacqueline Kay; TAYLOR Keith; JOHANSSON Kent; WESTPHAL Kerstin; GÁL Kinga; GÖNCZ Kinga; LEHNE Klaus-Heiner; FLECKENSTEIN Knut; SZYMANSKI Konrad; POUPAKIS Konstantinos; KARI Š Krišj nis; OJULAND Kristiina; MORVAI Krisztina; ARSENIS Kriton; LISEK Krzysztof; TRIANTAPHYLLOIDES Kyriacos; ANDRIKIENE Laima Liucija; BOKROS Lajos; VAN NISTELROOIJ Lambert; COMI Lara; SURJAN Laszlo; T KÉS László; STASSEN Laurence; KOLARSKA-BOBI SKA Lena; DOMENICI Leonardo; DONSKIS Leonidas; AYLWARD Liam; ROUCEK Libor; RONZULLI Licia; GERINGER DE OEDENBERG Lidia Joanna; HOANG NGOC Liem; JAAKONSAARI Liisa; MCAVAN Linda; JÁRÓKA Livia; FONTANA Lorenzo; BISKY Lothar; MICHEL Louis; HARTONG Lucas; BERLINGUER Luigi; DE MITA Luigi Ciriaco; DE GRANDES PASCUAL Luis; YAÑEZ-BARNUEVO GARCÍA Luis; CAPOULAS SANTOS Luis Manuel; ALVES Luís Paulo; ALLAM Magdi Cristiano; mail@bernd-posselt.de; McGUINNESS Mairead; HARBOUR Malcolm; HANDZLIK Malgorzata; BENARAB-ATTOU Malika; WEBER Manfred; BIZZOTTO Mara; TARABELLA Marc; SCURRIA Marco; SIWIEC Marek; MIGALSKI Marek Henryk; GRÓBARCZYK Marek Józef; AUKEN Margrete; BADIA i CUTCHET Maria; IRIGOYEN PÉREZ María; MUÑIZ DE URQUIZA María; CORREA ZAMORA María Auxiliadora; CARVALHO Maria Da Graça; PATRÃO NEVES Maria do Céu; KOPPA Maria Eleni; HARKIN Marian; MARINESCU Marian-Jean; THYSSEN Marianne; VERGIAT Marie-Christine; DE SARNEZ Marielle; GALLO Marielle; SANCHEZ-SCHMID Marie-Thérèse; SCHAAKE Marietje; GIANNAKOU Marietta; CORNELISSEN Marije; YANNAKOUDAKIS Marina; LE PEN Marine; BALDINI Marino; BORGHEZIO Mario; DAVID Mário; PIRILLO Mario; MATIAS Marisa; PAULSEN Marit; ULVSKOG Marita; GABRIEL Mariya; DEMESMAEKER Mark; FERBER Markus; PIEPER Markus; MIZZI Marlene; ANDREASEN Marta; CALLANAN Martin; EHRENHAUSER Martin; HÄUSLING Martin; KASTLER Martin; SCHULZ Martin, President; ANDERSON Martina; LYUBCHEVA Marusya; HONEYBALL Mary; GROSCHE Mathieu; SALVINI Matteo; GROOTE Matthias; PONGA Maurice; KAZAK Metin; CASHMAN Michael; CRAMER Michael; GAHLER Michael; THEURER Michael; NATTRASS Michael Henry; KAMI SKI Michał Tomasz; DANTIN Michel; RIVASI Michèle; STRIFFLER Michele; MARTINEZ

To: Miguel Angel; GUSTAFSSON Mikael; CABRNOCH Milan; ZVER Milan; RANS DORF Miloslav; CLIVETI Minodora; MIKOLAŠIK Miroslav; OUZKY Miroslav; PIOTROWSKI Miroslaw; REPO Mitro; KLEVA KEKUŠ Mojca; MACOVEI Monica Luisa; FLAŠÍKOVÁ BE OVÁ Monika; HOHLMEIER Monika; PANAYOTOVA Monika; SMOLKOVÁ Monika; LØKKEGAARD Morten; MESSERSCHMIDT Morten; NEYNSKY Nadezhda; HIRSCH Nadja; GRIESBECK Nathalie; CHILDERS Nessa; RINALDI Niccolò; GRIFFIN Nick; KIIL-NIELSEN Nicole; FARAGE Nigel; TZAVELA Niki; SINCLAIRE Nikki; VULJANI Nikola; CHOUNTIS Nikolaos; SALAVRAKOS Nikolaos; CHRYSOGELOS Nikos; TORVALDS Nils; DEVA Nirj; BERRA Nora; GLANTE Norbert; NEUSER Norbert; NICOLAI Norica; MELO Nuno; TEIXEIRA Nuno; ANTONESCU Elena Oana; VLASAK Oldrich; CHRISTENSEN Ole; VALJALO Oleg; SEHNALOVÁ Olga; LUDVIGSSON Olle; SCHMIDT Olle; ROSSI Oreste; KARAS Othmar; ARIAS ECHEVERRIA Pablo; ZALBA BIDE GAIN Pablo; BARTOLOZZI Paolo; DE CASTRO Paolo; TIROLIEN Patrice; VAN DER KAMMEN Patricia; LE HYARIC Patrick; TOIA Patrizia; GALLAGHER Pat the Cope; MURPHY Paul; NUTTALL Paul; RUBIG Paul; RANGEL Paulo; POC Pavel; ZALEWSKI Paweł; BERES Pervenche; JAHR Peter; LIESE Peter; SIMON Peter; SKINNER Peter; STASTNY Peter; VAN DALEN Peter; KAMMEREVERT Petra; SARVAMAA Petri; LUHAN Petru Constantin; BENNION Phil; PRENDERGAST Phil; BRADBOURN Philip; CLAEYS Philip; BOULLAND Philippe; DE BACKER Philippe; DE VILLIERS Philippe; JUVIN Philippe; LAMBERTS Philippe; PANZERI Pier Antonio; AYUSO Pilar; DEL CASTILLO Pilar; ARLACCHI Pino; BORYS Piotr; SALATTO Potito; BORISSOV Preslav; DATI Rachida; MORK NAIT - MIKUL NIEN Radvil ; TRZASKOWSKI Rafał; BALDASSARRE Raffaele; OBIOLS I GERMA Raimon; WIELAND Rainer; TREMOSA i BALCELLS Ramon; M NESCU Ramona Nicole; NICULESCU Rare -Lucian; ROMEVA i RUEDA Raül; HARMS Rebecca; TAYLOR Rebecca; BASTOS Regina; BOEGE Reimer; BÜTIKOFER Reinhard Hans; SOMMER Renate; WEBER Renate; OOMEN-RUIJTEN Ria; CORTÉS LASTRA Ricardo; ASHWORTH Richard; FALBR Richard; HOWITT Richard; SEEGER Richard; PAKARINEN Riikka; BORSELLINO Rita; ATKINS Robert; DUŠEK Robert; GOEBBELS Robert; ROCHEFORT Robert; ANGELILLI Roberta; METSOLA Roberta; GUALTIERI Roberto; ZILE Roberts; KRATSA-TSAGAROPOULOU Rodi; HELMER Roger; PAKSAS Rolandas; JORDAN Romana; ESTARAS FERRAGUT Rosa; THUN UND HOHENSTEIN Ró a Maria Gräfin von; TAVARES Rui; TOMAŠI Ruža; rwsturdy@btconnect.com; CZARNECKI Ryszard; LEGUTKO Ryszard Antoni; LÖSING Sabine; VERHEYEN Sabine; WILS Sabine; EL KHADRAOUI Saïd; KARIM Sajjad; GARRIGA POLLEDO Salvador; SEDÓ I ALABART Salvador; CARONNA Salvatore; IACOLINO Salvatore; TATARELLA Salvatore; TERHO Sampo; KALNIETE Sandra; PETROVI JAKOVINA Sandra; BÉLIER Sandrine; FISAS AXXELA Santiago; LUDFORD Sarah; ESSAYAH Sari; HASSI Satu; KELLY Seán; BODU Sebastian Valentin; KOZLIK Sergej; BERLATO Sergio; COFFERATI Sergio Gaetano; GUTIÉRREZ PRIETO Sergio; SILVESTRIS Sergio Paolo Francesco; BOWLES Sharon; J DRZEJEWSKA Sidonia El bieta; OVIIR Siiri; KOCH-MEHRIN Silvana; COSTA Silvia; IC U Silvia Adriana; PIETIKÄINEN Sirpa; BINEV Slavi; NITRAS Sławomir; ALFANO Sonia; AUCONIE Sophie; IN'T VELD Sophie; SOPHOCLEOUS Sophocles; SØNDERGAARD Søren Bo; DANELLIS Spyros; ILCHEV Stanimir; HUGHES Stephen; STEVENSON Struan; DE MARTINI Susy; GIEGOLD Sven; MALINOV Svetoslav Hristov; KAMALL Syed; RAPTI Sylvana; GOULARD Sylvie; GUILLAUME Sylvie; CYMA SKI Tadeusz; ZWIEFKA Tadeusz; HADJIGEORGIOU Takis; DEUTSCH Tamás; FAJON Tanja; CRONBERG Tarja; ZDANOKA Tatjana; JIMENEZ-BECERRIL BARRIO Teresa; RIERA MADURELL Teresa; STOLOJAN Theodor Dumitru; SKYLAKAKIS Theodoros; BERMAN Thijs; HÄNDEL Thomas; MANN Thomas; ULMER Thomas; KIRKHOPE Timothy; MOTTI Tiziano; MANDERS Toine; SAĪFI Tokia; POREBA Tomasz Piotr; PICULA Tonino; UNGUREANU Traian; COLMAN Trevor; VADIM Tudor Corneliu; KELAM Tunne; BULLMANN Udo; LUNACEK Ulrike; RODUST Ulrike; TOMAŠEVSKI Valdemar; D NCIL Vasilica Viorica; LOPE FONTAGNÉ Veronica; DE KEYSER Véronique; MATHIEU HOUILLON Véronique; GARCÉS RAMÓN Vicente; FORD Victoria Grace; BO TINARU Victor; BLINKEVI I T Vilija; SAVISAAR-TOOMAST Vilja; IOVINE Vincenzo; MOREIRA Vital; BONSIGNORE Vito; PRODI Vittorio; MANKA Vladimir; REMEK Vladimir; URUTCHEV Vladimir Andreev; PANAYOTOV Vladko Todorov; MYNÁ Vojt ch; LANDSBERGIS Vytautas; KUHN Werner; LANGEN Werner; SCHULZ Werner; DARTMOUTH William; MEYER Willy; VAN DE CAMP Wim; OLEJNICZAK Wojciech Michał; KLINZ Wolf; KREISSL-DORFLER Wolfgang; JADOT Yannick; OMARJEE Younous; COCHET Yves; ZIOBRO Zbigniew; BUŠI Zdravka; BAL YTIS Zigmantas; GURMAI Zita; MAZEJ KUKOVI Zofija; BAGÓ Zoltán; BRZOBOHATÁ Zuzana

Subject: Emailing: e-cigarette-info



STAES Bart OFFICE

From: Fleur van Bladeren <FBladeren@kwfkankerbestrijding.nl>
Sent: 15 July 2013 12:42
To: STAES Bart
Subject: Dank voor uw steun tbv Tabaksrichtlijn

Geachte heer Staes,

Graag willen we u vanuit KWF Kankerbestrijding heel hartelijk bedanken voor uw inzet op de Tabaksproductenrichtlijn en de prettige samenwerking met u. We vinden het goed nieuws dat een aantal voor ons zeer relevante punten, zoals de 75% voor fotowaarschuwingen op de sigarettenpakjes en het verbieden van menthol sigaretten, zijn aangenomen tijdens de stemming over de richtlijn afgelopen woensdag.

Helaas zijn de voorstellen over plain packaging en het verminderen van het aantal verkooppunten, waar wij als KWF en u als Europarlementariër, voor pleiten niet aangenomen. Graag vernemen wij van u of u of uw fractie van plan bent om na de zomer nog een aantal amendementen hierover in te dienen voor de plenaire stemming. Graag hoor ik van u of wij u nog ergens bij kunnen ondersteunen. Maar eerst een heel goede zomer gewenst!

Hartelijke groet,
Fleur van Bladeren



Fleur van Bladeren
Senior Beleidsmedewerker

KWF Kankerbestrijding
Delflandlaan 17 | Postbus 75508 | 1070 AM Amsterdam
T 0205700519 | **M** 0650613553 | **E** FBladeren@kwfkankerbestrijding.nl
W www.kwfkankerbestrijding.nl



From: Blandine Cassou-Mounat <blandine.cassou-mounat@aim-mutual.org>
Sent: 12 July 2013 18:20
To: Blandine Cassou-Mounat
Subject: AIM welcomes the vote of ENVI MEPs for stricter regulation on tobacco products
Attachments: AIM Press Release on Adoption of ENVI Report on Tobacco Products Directive.pdf

➤ *Press Release*

Brussels, 12 July 2013

AIM welcomes the vote of ENVI MEPs for stricter regulation on tobacco products

Close to 700,000 people in Europe are killed every year by tobacco in Europe and millions more suffer from diseases caused by smoking, such as cancers, cardiovascular and respiratory diseases. This is why health mutuals and health insurance funds support a stricter regulation of tobacco products.

The European Parliament's Committee for Environment and Health (ENVI) has adopted a report on 10 July drafted by MEP Linda Mc Avan (S&D, UK) which validates the most important points of the Commission proposal including bigger warnings on tobacco packaging, the ban of flavourings, better ingredients regulation, tighter measures against illicit trade as well as the prohibition of cross-border sales.

AIM welcomes the obligation for tobacco packages to display at least 75% of health warnings

AIM members support big health warnings on the package because studies show clearly that pack colours, shapes and openings are especially attractive to young people. In that respect insisting on health warnings informs on the harmful effects of tobacco and curbs the increase of smokers in the younger generations. With 70% of smokers starting before the age of 18, tackling the reasons that could encourage young people to smoke such as attractive packaging is the priority.

AIM endorses the prohibition of cross-border sales

Cross-border distance sales of tobacco facilitate access to tobacco products of young people. They also present a risk to undermine compliance with the requirements provided for by tobacco control legislation. AIM members therefore approve the prohibition of cross-border sales to prevent children and adolescents from having access to tobacco.

AIM welcomes the ban on flavourings and stricter measures against illicit trade

On flavourings and illicit trade, AIM members welcome the common position of the Parliament as banning flavourings will make tobacco less attractive.

Regarding Illicit trade, the use of an identifier will help to fight against illegal trade which facilitates the consumption of tobacco in Europe.

This strong line to protect consumers' health should be maintained as well in the vote of the Plenary. AIM calls all MEPs to support the adopted report.

About AIM

The Association Internationale de la Mutualité (AIM) is a grouping of autonomous health insurance and social protection bodies operating according to the principles of solidarity and non-profit-making orientation. Currently, AIM's membership consists of 50 national federations representing 28 countries. In Europe, they provide social coverage against sickness and other risks to more than 160 million people. AIM strives via its network to make an active contribution to the preservation and improvement of access to health care for everyone.

More info: <http://www.aim-mutual.org/>

Contact: blandine.cassou-mounat@aim-mutual.org



Blandine CASSOU-MOUNAT

Junior Project Manager

Rue d'Arlon 50 | B-1000 Brussels
Tel. +32 2 234 57 05 | Fax +32 2 234 57 08
blandine.cassou-mounat@aim-mutual.org
www.aim-mutual.org | [Join us on Twitter](#)

STAES Bart OFFICE

From: AkriggNeil <neil.akrigg@pendle.gov.uk>
Sent: 11 July 2013 16:18
To: MCAVAN Linda
Cc: ANDERSON Martina; ANTONESCU Elena Oana; ARIAS ECHEVERRIA Pablo; ARSENIS Kriton; AUCONIE Sophie; AUKEN Margrete; AYALA SENDER Inés; AYUSO Pilar; BÁNKI Erik; BARTOLOZZI Paolo; BÉLIER Sandrine; BERLATO Sergio; BLOOM Godfrey; BOKROS Lajos; BONANINI Franco; BORSELLINO Rita; BUSOI Cristian Silviu; CABRNOCH Milan; CALLANAN Martin; CHILDERS Nessa; CHRYSOGELOS Nikos; CLIVETI Minodora; COCHET Yves; CYMA SKI Tadeusz; VAN DALEN Peter; DELVAUX Anne; DEMESMAEKER Mark; DE VEYRAC Christine; EICKHOUT Bas; ESTRELA Edite; EVANS Jill; FERNANDES José Manuel; FERREIRA João; FJELLNER Christofer; FLORENZ Karl-Heinz; FORD Victoria Grace; FOSTER Jacqueline; FRANCO Gaston; GARCÍA-HIERRO CARABALLO Dolores; GARDINI Elisabetta; GERBRANDY Gerben-Jan; GIREEK Adam; GIRLING Julie; GROOTE Matthias; GROSSETETE Françoise; GUTIERREZ-CORTINES Cristina; HARMS Rebecca; HASSI Satu; HAUG Jutta; HERRANZ GARCIA Esther; HIBNER Jolanta Emilia; IVAN C t lin-Sorin; JORDAN Romana; JØRGENSEN Dan; JUVIN Philippe; KACZMAREK Filip; KADENBACH Karin; KALINOWSKI Jarosław; KLASS Christa; KORHOLA Eija-Riitta; KOUMOUTSAKOS Georgios; KOZLIK Sergej; KRAHMER Holger; DE LANGE Esther; LEINEN Jo; LEPAGE Corinne; LIESE Peter; LIOTARD Kartika Tamara; LYUBCHEVA Marusya; MCAVAN Linda; McGUINNESS Mairead; MANDERS Toine; MASTALKA Jiri; MAZEJ KUKOVI Zofija; MERKIES Judith A.; MIKOLASIK Miroslav; MIZZI Marlene; MORK NAIT - MIKUL NIEN Radvil ; NICHOLSON James; NUTTALL Paul; ORTIZ VILELLA Eva; OUZKY Miroslav; PAKARINEN Riikka; PALECKIS Justas Vincas; PANAYOTOV Vladko Todorov; PARGNEAUX Gilles; PAULSEN Marit; PERELLO RODRIGUEZ Andres; PETERLE Alojz; PIRILLO Mario; POC Pavel; PRODI Vittorio; REIMERS Britta; RIES Frédérique; RIVASI Michèle; RIVELLINI Crescenzo; ROSBACH Anna; ROSSI Oreste; ROTH-BEHRENDT Dagmar; ŠADURSKIS K rlis; SARBU Daciana Octavia; SCHALDEMOSE Christel; SCHLYTER Carl; SCHNELLHARDT Horst; SCHNIEBER-JASTRAM Birgit; SCOTTA' Giancarlo; SEEBER Richard; SKYLAKAKIS Theodoros; SOMMER Renate; SONIK Boguslaw; SOPHOCLEOUS Sophocles; SOUSA Alda; STADLER Ewald; STAES Bart; STEVENSON Struan; TABAJDI Csaba; T N SESCO Claudiu Ciprian; TATARELLA Salvatore; TAYLOR Rebecca; THEOCHAROUS Eleni; THYSSEN Marianne; ULMER Thomas; ULVSKOG Marita; URUTCHEV Vladimir Andreev; VAN BREMPT Kathleen; DE VILLIERS Philippe; WEISGERBER Anja; WESTLUND Asa; WILLMOTT Glenis; WILS Sabine; YANNAKOUDAKIS Marina; ZABORSKA Anna; ZANONI Andrea; BORZAN Biljana; PARVANNOVA Antonyia
Subject: NCP regulation

Dear Linda McAvan and MEP's,

I do hope that you will take time to both read and reply to this e-mail.

For the past 30 year I have been a smoker, of twenty to thirty a day, and some 6 months ago thought I would try an electronic cigarette and see if it would help me cut down the number of real cigarettes I was smoking. I can't tell you how glad I am at making that choice. For the past five months I have not touched a tobacco cig. In the past I have tried **ALL** the NRT's on the market as well as prescription medicines. Not one of them has worked and Champix had the worst effect nearly driving me to suicide. Over the past five months I have dropped the nic content of my e-cig from 1.8% (18mg) to 1.1% (11mg) in a steady attempt to come off the nicotine completely.

With all that in mind I come to the crux of this e-mail.

Yesterdays vote in the E.U. witch will regulate and put tighter restrictions on the sale and marketing of e-cigs (NCP).

If current e-cigs where restricted to 0.4% (4mg) nicotine then they **WOULD NOT** have help me stop as a 20-30 cig a day smoker, and yet again I would be confined to a slow painful death as a smoker.

If current e-cigs where restricted to just tobacco flavour (which I Hate)they would not have aided i me giving up. The socially unaccepted smell and taste is something i wanted to get away from.

It seems to me that a rash ill thought out choice has been made that only benefits two parties and is anything but the right way to go. To some extent I could have accepted a Tax being placed on e-cigs, because of the loss of revenue to the public purse through less people smoking, or an enforceable legal age limit. In my eyes the only people to benefit will be:-

A) THE TOBACCO INDUSTRY

They will benefit from more people returning to smoking normal cigarettes. And they will be the only people with the financial clout to afford all the red tape introduced by this legislation and produce their own e-cigs.

B) THE DRUG COMPANIES

Who will get revenue from upholding the legislation. As well as ensuring sales of cancer drugs through continued use of tobacco cigs.

I would like you to answer the following:-

- why was more research not done first?
- has lobbying taken place to impose these strict regulations?
- why the nicotine content has been set at such a low limit 18mg would be ideal?
- In a time of austerity why would the council want to put so many people in this industry out of work?

In the past I SERVED as a Labour Party Councillor for my local authority for 8 years and from turning 18 I have never failed to vote, but in light of the recent events I am going to find it hard to vote in the E.U. elections knowing that the people I am voting for are more concerned with the profits of multinational companies than they are for the lives, health and wellbeing of the people they represent. For if this is passed at council I will have no alternative but to return to smoking tobacco with the prospect of an early death.

I look forward to your reply



Saving 20% of the energy you use not only reduces your bills; it will also help in combating climate change. Click the link to see what YOU can do to help.

<http://www.energysavingtrust.org.uk/Take-action/Money-saving-tips>

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this email in error please notify the system manager.

This footnote also confirms that this email message has been swept by Mimecast for the presence of computer viruses.

Pendle Borough Council
<http://www.pendle.gov.uk>

STAES Bart OFFICE

From: AkriggNeil <neil.akrigg@pendle.gov.uk>
Sent: 10 July 2013 12:58
To: ANDERSON Martina; ANTONESCU Elena Oana; ARIAS ECHEVERRIA Pablo; ARSENIS Kriton; AUCONIE Sophie; AUKEN Margrete; AYALA SENDER Inés; AYUSO Pilar; BĀNKI Erik; BARTOLOZZI Paolo; BÉLIER Sandrine; BERLATO Sergio; BLOOM Godfrey; BOKROS Lajos; BONANINI Franco; BORSELLINO Rita; BUSOI Cristian Silviu; CABRNOCH Milan; CALLANAN Martin; CHILDERS Nessa; CHRYSOGELOS Nikos; CLIVETI Minodora; COCHET Yves; CYMA SKI Tadeusz; VAN DALEN Peter; DELVAUX Anne; DEMESMAEKER Mark; DE VEYRAC Christine; EICKHOUT Bas; ESTRELA Edite; EVANS Jill; FERNANDES José Manuel; FERREIRA João; FJELLNER Christofer; FLORENZ Karl-Heinz; FORD Victoria Grace; FOSTER Jacqueline; FRANCO Gaston; GARCÍA-HIERRO CARABALLO Dolores; GARDINI Elisabetta; GERBRANDY Gerben-Jan; GIREEK Adam; GIRLING Julie; GROOTE Matthias; GROSSETETE Françoise; GUTIERREZ-CORTINES Cristina; HARMS Rebecca; HASSI Satu; HAUG Jutta; HERRANZ GARCIA Esther; HIBNER Jolanta Emilia; IVAN C t lin-Sorin; JORDAN Romana; JØRGENSEN Dan; JUVIN Philippe; KACZMAREK Filip; KADENBACH Karin; KALINOWSKI Jarosław; KLASS Christa; KORHOLA Eija-Riitta; KOUMOUTSAKOS Georgios; KOZLIK Sergej; KRAHMER Holger; DE LANGE Esther; LEINEN Jo; LEPAGE Corinne; LIESE Peter; LIOTARD Kartika Tamara; LYUBCHEVA Marusya; MCAVAN Linda; McGUINNESS Mairead; MANDERS Toine; MASTALKA Jiri; MAZEJ KUKOVI Zofija; MERKIES Judith A.; MIKOLASIK Miroslav; MIZZI Marlene; MORK NAIT - MIKUL NIEN Radvil ; NICHOLSON James; NUTTALL Paul; ORTIZ VILELLA Eva; OUZKY Miroslav; PAKARINEN Riikka; PALECKIS Justas Vincas; PANAYOTOV Vladko Todorov; PARGNEAUX Gilles; PAULSEN Marit; PERELLO RODRIGUEZ Andres; PETERLE Alojz; PIRILLO Mario; POC Pavel; PRODI Vittorio; REIMERS Britta; RIES Frédérique; RIVASI Michèle; RIVELLINI Crescenzo; ROSBACH Anna; ROSSI Oreste; ROTH-BEHRENDT Dagmar; ŠADURSKIS K rlis; SARBU Daciana Octavia; SCHALDEMOSE Christel; SCHLYTER Carl; SCHNELLHARDT Horst; SCHNIEBER-JASTRAM Birgit; SCOTTA' Giancarlo; SEEBER Richard; SKYLAKAKIS Theodoros; SOMMER Renate; SONIK Boguslaw; SOPHOCLEOUS Sophocles; SOUSA Alda; STADLER Ewald; STAES Bart; STEVENSON Struan; TABAJDI Csaba; T N SESCO Claudiu Ciprian; TATARELLA Salvatore; TAYLOR Rebecca; THEOCHAROUS Eleni; THYSSEN Marianne; ULMER Thomas; ULVSKOG Marita; URUTCHEV Vladimir Andreev; VAN BREMPT Kathleen; DE VILLIERS Philippe; WEISGERBER Anja; WESTLUND Asa; WILLMOTT Glenis; WILS Sabine; YANNAKOUDAKIS Marina; ZABORSKA Anna; ZANONI Andrea; BORZAN Biljana; PARVANOVVA Antonyia

Dear all

Please remember that the elections are on next June. Please vote for amendment 58 and protect our right to vape and not kill ourselves on real tobacco cigs.

Thanks
Neil Akrigg



**INVESTORS
IN PEOPLE**



Beacon Authority
2010-2014
Creative and resilient communities



LIBERATA



Saving 20% of the energy you use not only reduces your bills; it will also help in combating climate change. Click the link to see what YOU can do to help.

<http://www.energysavingtrust.org.uk/Take-action/Money-saving-tips>

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they

are addressed. If you have received this email in error please notify the system manager.

This footnote also confirms that this email message has been swept by Mimecast for the presence of computer viruses.

Pendle Borough Council
<http://www.pendle.gov.uk>

STAES Bart OFFICE

From: katesmith760@gmail.com on behalf of Kate Smith <kate@kate-smith.co.uk>
Sent: 10 July 2013 13:31
To: ORTIZ VILELLA Eva; OUZKY Miroslav; PAKARINEN Riikka; PALECKIS Justas Vincas; PANAYOTOV Vladko Todorov; PARGNEAUX Gilles; PAULSEN Marit; PERELLO RODRIGUEZ Andres; PETERLE Alojz; PIRILLO Mario; POC Pavel; PRODI Vittorio; REIMERS Britta; RIES Frédérique; RIVASI Michèle; RIVELLINI Crescenzo; ROSBACH Anna; ROSSI Oreste; ROTH-BEHRENDT Dagmar; ŠADURSKIS K rlis; SARBU Daciana Octavia; SCHALDEMOSE Christel; SCHLYTER Carl; SCHNELLHARDT Horst; SCHNIEBER-JASTRAM Birgit; SCOTTA' Giancarlo; SEEGER Richard; SKYLAKAKIS Theodoros; SOMMER Renate; SONIK Boguslaw; SOPHOCLEOUS Sophocles; SOUSA Alda; STADLER Ewald; STAES Bart; STEVENSON Struan; TABAJDI Csaba; T N Sescu Claudiu Ciprian; TATARELLA Salvatore; TAYLOR Rebecca; THEOCHAROUS Eleni; THYSSEN Marianne; ULMER Thomas; ULVSKOG Marita; URUTCHEV Vladimir Andreev; VAN BREMPT Kathleen; DE VILLIERS Philippe; WEISGERBER Anja; WESTLUND Asa; WILLMOTT Glenis; WILS Sabine; YANNAKOUDAKIS Marina; ZABORSKA Anna; ZANONI Andrea; BORZAN Biljana; PARVANOVA Antonyia
Subject: Fwd: Amendment 58

Kate Smith

www.kate-smith.co.uk



Latest post: Only on for another week... Back Story...The Mark

Like · Comment · Share

Kate Smith Visual Artist page on Facebook



Get this email app!

Get a signature like this. [CLICK HERE.](#)

----- Forwarded message -----

From: **Kate Smith** <kate@kate-smith.co.uk>

Date: Wed, Jul 10, 2013 at 12:29 PM

Subject: Amendment 58

To: martina.anderson@europarl.europa.eu, oana.antonescu@europarl.europa.eu, pablo.ariasecheverria@europarl.europa.eu, kriton.arsenis@europarl.europa.eu, sophie.auconie@europarl.europa.eu, margrete.auken@europarl.europa.eu, ines.ayalasender@europarl.europa.eu, pilar.ayuso@europarl.europa.eu, erik.banki@europarl.europa.eu, paolo.bartolozzi@europarl.europa.eu, sandrine.belier@europarl.europa.eu, sergio.berlato@europarl.europa.eu, godfrey.bloom@europarl.europa.eu, lajos.bokros@europarl.europa.eu, franco.bonanini@europarl.europa.eu, rita.borsellino@europarl.europa.eu, cristiansilviu.busoi@europarl.europa.eu, milan.cabrmoch@europarl.europa.eu, martin.callanan@europarl.europa.eu, nessa.childers@europarl.europa.eu, nikos.chrysoyelos@europarl.europa.eu, minodora.cliveti@europarl.europa.eu, yves.cochet@europarl.europa.eu, tadeusz.cymanski@europarl.europa.eu, peter.vandalen@europarl.europa.eu, anne.delvaux@europarl.europa.eu, mark.demesmaecker@europarl.europa.eu, christine.deveyrac@europarl.europa.eu, bas.eickhout@europarl.europa.eu, edite.estrela@europarl.europa.eu, Jill.evans@europarl.europa.eu,

josemanuel.fernandes@europarl.europa.eu, joao.ferreira@europarl.europa.eu,
christofer.fjellner@europarl.europa.eu, karl-heinz.florenz@europarl.europa.eu,
vicky.ford@europarl.europa.eu, jacqueline.foster@europarl.europa.eu, gaston.franco@europarl.europa.eu,
dolores.garcia-hierrocaraballo@europarl.europa.eu, elisabetta.gardini@europarl.europa.eu, [gerben-
jan.gerbrandy@europarl.europa.eu](mailto:gerben-
jan.gerbrandy@europarl.europa.eu), adam.gierek@europarl.europa.eu, julie.girling@europarl.europa.eu,
matthias.groote@europarl.europa.eu, francoise.grossetete@europarl.europa.eu, [cris
tina.gutierrez-
cortines@europarl.europa.eu](mailto:cris
tina.gutierrez-
cortines@europarl.europa.eu), rebecca.harms@europarl.europa.eu, satu.hassi@europarl.europa.eu,
jutta.haug@europarl.europa.eu, esther.herranzgarcia@europarl.europa.eu,
jolantaemilia.hibner@europarl.europa.eu, catalin-sorin.ivan@europarl.europa.eu,
romana.jordan@europarl.europa.eu, dan.jorgensen@europarl.europa.eu, philippe.juvin@europarl.europa.eu,
filip.kaczmarek@europarl.europa.eu, karin.kadenbach@europarl.europa.eu,
jaroslaw.kalinowski@europarl.europa.eu, christa.klass@europarl.europa.eu, [eija-
riitta.korhola@europarl.europa.eu](mailto:eija-
riitta.korhola@europarl.europa.eu), georgios.koumoutsakos@europarl.europa.eu,
sergej.kozlik@europarl.europa.eu, holger.krahmer@europarl.europa.eu,
esther.delange@europarl.europa.eu, jo.leinen@europarl.europa.eu, corinne.lepage@europarl.europa.eu,
peter.liese@europarl.europa.eu, kartikatamara.liotard@europarl.europa.eu,
marusya.lyubcheva@europarl.europa.eu, linda.mcavan@europarl.europa.eu,
mairead.mcguinness@europarl.europa.eu, toine.manders@europarl.europa.eu,
jiri.mastalka@europarl.europa.eu, zofija.mazejkukovic@europarl.europa.eu,
judith.merkies@europarl.europa.eu, miroslav.mikolasik@europarl.europa.eu,
marlene.mizzi@europarl.europa.eu, radvile.morkunaite-mikuleniene@europarl.europa.eu,
james.nicholson@europarl.europa.eu, paul.nuttall@europarl.europa.eu

Please vote for amendment 58 today. I have been a tobacco smoker for 38 years and will return to them if ecigs are made difficult to access at the relevant nicotine level. Ecigs should not be harder to access than tobacco cigarettes, Bst Wishes, kate

Kate Smith

www.kate-smith.co.uk



Latest post: Only on for another week... Back Story...The Mark

Like · Comment · Share

Kate Smith Visual Artist page on Facebook



Get this email app!

Get a signature like this. [CLICK HERE.](#)

From: Secretariat CPME <Secretariat@cpme.eu>
Sent: 10 July 2013 13:18
To: Secretariat CPME
Subject: Standing Committee of European Doctors - Voting on the Tobacco Products Directive
Attachments: CPME_AD_EC_18032013_015_Final_EN.PDF



In the Standing Committee of European Doctors (CPME), representing National Medical Associations across Europe, doctors unite in an appeal to you to put the health of your citizens at the heart of your vote. Please support Compromise Amendments 33, 39, 46 and 51

Smoking is harmful to health – unconditionally. The morbidity and mortality caused by tobacco consumption and exposure to its emissions poses an immense social and economic burden on Europe; all the more deplorable because this harm could be prevented.

- Maintain the proposed scope of the draft **Directive to cover all tobacco and related products**, including herbal products for smoking, novel tobacco products, tobacco for oral use, and nicotine-containing products.
- Prohibit the inclusion of **additives** which make tobacco products more palatable and attractive, in order to disincentivise up-take and consumption in particular by young people. Similarly, the proposed **ban** of tobacco products with a **characterising flavour, including menthol**, should be supported.
- **Prohibit** forms of presentation or appearance of tobacco products which imply a reduced level of harm to consumers, in particular the so-called **'slim' cigarettes**.
- Safeguard that the packaging and labelling of tobacco and related products clearly and accurately communicates the risks associated with the consumption of the product to consumers and supports smoking cessation and the **health warnings cover 75%** of the packet surface. For unit packets of cigarettes we propose **'standardised packaging'**.
- Regulate **nicotine-containing products** in the scope of the Directive and ensuring that any classification and approval of nicotine-replacement therapies is based on independent scientific research.
- Ensure that the sale of and access to tobacco and related products contribute to the best possible protection of public health. **Cross-border distance selling, sales**

through postal services or vending machines as well as **point-of-sale display** are not compatible with this objective and should be **prohibited**.

The evidence base for action is clear and compelling. The European Union and its Member States have the opportunity to prove their political commitment to protecting the health of their citizens and become a role model for action against tobacco-related harm.

For more information, please contact:

Birgit BEGER

CPME Secretary General

Tel.: +32 2 732 72 02

Fax: +32 2 732 73 44

e-mail: secretariat@cpme.eu

For more information about CPME, consult our website: <http://www.cpme.eu>

The Standing Committee of European Doctors (CPME) represents national medical associations across Europe. We are committed to contributing the medical profession's point of view to EU and European policy-making through pro-active cooperation on a wide range of health and healthcare related issues.

STAES Bart OFFICE

From: julie p.o <juliegardner27@mypostoffice.co.uk>
Sent: 10 July 2013 13:09
To: STADLER Ewald; STAES Bart; STEVENSON Struan; TABAJDI Csaba; T N SESCOU Claudiu Ciprian; TATARELLA Salvatore; TAYLOR Rebecca; THEOCHAROUS Eleni; THYSSEN Marianne; ULMER Thomas; ULVSKOG Marita
Subject: E-cigs

Hello to all MEP's

I will keep this email simple. I am a vaper, I use an electronic cigarette. I switched to vaping from smoking traditional tobacco cigarettes just over 2 years ago. I never had any intention of switching to vaping, but tried e-cigs because a friend recommended them to me, I never did go back to traditional cigarettes. I feel better, I smell better, my house smells better, and my children will no doubt have their mum around for longer. Smoking traditional cigarettes would have no doubt shortened my lifespan, and I would have died from some horrible smoking related illness!

Please do not force me back to smoking traditional cigarettes, I don't want to go back. I don't want to die early! But that is exactly what will happen if e-cigs become medicinal products. I don't want to wean myself off nicotine, I tried on many occasions and failed. I enjoy my nicotine, like I enjoy my coffee during the day, and my vodka and coke at the weekends!

Could I ask you all that you please vote for amendment 58. Why make e-cigs impossible for me to purchase and use, and yet leave tobacco cigarettes untouched and so easy to purchase.

Please don't sign my death warrant, vote for amendment 58.

Thankyou and yours sincerely
Julie Gardner

STAES Bart OFFICE

From: George Yiangou <G.Yiangou@AESGP.eu>
Sent: 10 July 2013 13:00
Subject: WHO issues statement on electronic cigarettes

Dear Member of the Committee on the Environment, Public Health and Food Safety,

Further to our earlier communication on the need to ensure a consistent regulatory framework for nicotine containing products, we would like to bring to your attention a statement on e-cigarettes (ENDS) issued yesterday by the World Health Organisation, in which it is noted that the safety and efficacy of ENDS has *not* been scientifically demonstrated, concluding that:

"Until such time as a given ENDS is deemed safe and effective and of acceptable quality by a competent national regulatory body, consumers should be strongly advised not to use any of these products, including electronic cigarettes."

http://www.who.int/tobacco/communications/statements/electronic_cigarettes/en/index.html

In light of the ENVI vote on the TPD taking place today, the WHO statement highlights the need to regulate these products as medicines, as proposed with CAM 57.

Sincerely,
George Yiangou



Dr George Yiangou

AESGP - Association of the European Self-Medication Industry

7 avenue de Tervuren, B-1040 Brussels | Tel: +3227355130 | Fax: +3227355222

E-mail: g.yiangou@aesgp.eu URL: <http://www.aesgp.eu>

From: George Yiangou
Sent: mardi 9 juillet 2013 17:32
Subject: Tobacco Products Directive - Regulation of non-tobacco nicotine products

Dear Member of the Committee on the Environment, Public Health and Food Safety

RE: ENVI vote on the Tobacco products Directive on 10 July

Ahead of the Wednesday 10 July vote on the draft report on the Tobacco Products Directive, I am contacting you on behalf of the Association of the European Self-Medication Industry (AESGP) which represents the manufacturers of non-prescription medicines, food supplements and self-care medical devices in Europe, including companies manufacturing and marketing Nicotine Replacement Therapy products.

We are requesting your support for a single regulatory framework for all nicotine-containing products classifying them as medicines in line with the objective set by the European Commission's proposal that: "The proposal removes current legislative divergence between Member States and the differential treatment between Nicotine Replacement Therapies and Nicotine Containing Products".

Regulating all nicotine containing products as medicines is not only about appropriately managing quality and safety risks, it is also about realising a healthcare opportunity and effectively advancing public health across the European Union.

Article 18 – Nicotine containing products

AESGP supports CAM 57 and rejects CAM 58 on public health grounds and in order to most effectively protect smokers in the EU as they seek to quit tobacco or to reduce the harm of tobacco to themselves and those around them.

Support for CAM 57

- Nicotine containing products should be regulated as medicinal products in order to protect consumers by ensuring an appropriate and consistent level of safety, efficacy and quality and to ensure that all non-tobacco nicotine products are marketed in a way that advances public health.
- Products that reduce the harmful effects of tobacco to smokers and to those around them should be welcomed on public health grounds but the potential benefits can only be achieved effectively if they are subjected to an appropriate regulatory framework. In the absence of appropriate regulatory frameworks for nicotine containing products, including e-cigarettes, or studies into their effects, the WHO and some EU Member State competent authorities have expressed strong concerns around possible health harms and misuse.
- There is a legal basis upon which to regulate all nicotine containing products as medicinal by function based upon the physiological effect they have on the body.
- It is important to note that medicinal regulation will not lead to products being unnecessarily removed from the market as has been suggested by some organizations. Only where it is inherently not possible for a product or a manufacturer is unwilling to demonstrate appropriate standards are met for safety, efficacy and quality would a product risk being removed from the market. On average in the EU marketing authorisation evaluation procedures take between 12 to 18 months (except in case of major unforeseen element).

Rejection of CAM 58

- CAM 58 creates loopholes in the regulation of a product that remains a medicine despite being less harmful than smoking. General product safety regulation is not an appropriate legal framework for these products as they satisfy the statutory definition of a 'medicine' by function and thus should be regulated as such in order to protect consumers and to advance public health. Medicines regulation akin to what the MHRA has announced will protect consumers and advance public health while avoiding reinforcing consumer misperceptions about the role and effects of nicotine.

Sincerely,
George Yiangou



Dr George Yiangou

AESGP - Association of the European Self-Medication Industry

7 avenue de Tervuren, B-1040 Brussels | Tel: +3227355130 | Fax: +3227355222

E-mail: g.yiangou@aesgp.eu URL: <http://www.aesgp.eu>

STAES Bart OFFICE

From: Clive Bates <clivedbates@gmail.com>
Sent: 10 July 2013 08:24
To: MCAVAN Linda; FLORENZ Karl-Heinz; RIES Frédérique; SCHLYTER Carl; CALLANAN Martin; ANDERSON Martina; ROSSI Oreste
Cc: AYALA SENDER Inés; BLOOM Godfrey; BORSELLINO Rita; BUSOI Cristian Silviu; CHRYSOGELOS Nikos; VAN DALEN Peter; DE VEYRAC Christine; FERNANDES José Manuel; FOSTER Jacqueline; FRANCO Gaston; GARCÍA-HIERRO CARABALLO Dolores; GIEREK Adam; GIRLING Julie; HARMS Rebecca; HAUG Jutta; HERRANZ GARCIA Esther; JORDAN Romana; JUVIN Philippe; KACZMAREK Filip; KALINOWSKI Jarosław; KOUMOUTSAKOS Georgios; KOZLIK Sergej; MANDERS Toine; MASTALKA Jiri; MERKIES Judith A.; MIKOLASIK Miroslav; McGUINNESS Mairead; NICHOLSON James; ORTIZ VILELLA Eva; PALECKIS Justas Vincas; PAULSEN Marit; PETERLE Alojz; PRODI Vittorio; REIMERS Britta; RIVASI Michèle; RIVELLINI Crescenzo; SCHALDEMOSE Christel; SCHNIEBER-JASTRAM Birgit; SCOTTA' Giancarlo; SOMMER Renate; STADLER Ewald; STEVENSON Struan; TABAJDI Csaba; TAYLOR Rebecca; THEOCHAROUS Eleni; ULVSKOG Marita; URUTCHEV Vladimir Andreev; VAN BREMPT Kathleen; DE VILLIERS Philippe; ZANONI Andrea; ZABORSKA Anna; BÁNKI Erik; CLIVETI Minodora; DEMESMAEKER Mark; FERREIRA João; FJELLNER Christofer; FORD Victoria Grace; IVAN C t lin-Sorin; MIZZI Marlene; PAKARINEN Riikka; SOPHOCLEOUS Sophocles; SOUSA Alda; STAES Bart; elenaona.antonescu@europarl.europa.eu; ARSENIS Kriton; AUCONIE Sophie; AYUSO Pilar; BARTOLOZZI Paolo; BERLATO Sergio; BOKROS Lajos; BÉLIER Sandrine; CHILDERS Nessa; COCHET Yves; CYMA SKI Tadeusz; DAVIES Chris; DELVAUX Anne; EICKHOUT Bas; EVANS Jill; GARDINI Elisabetta; GERBRANDY Gerben-Jan; GRIFFIN Nick; GROOTE Matthias; GROSSETETE Francoise; GUTIERREZ-CORTINES Cristina; HASSI Satu; HIBNER Jolanta Emilia; JØRGENSEN Dan; KADENBACH Karin; KLASS Christa; KORHOLA Eija-Riitta; KRAHMER Holger; DE LANGE Esther; LEINEN Jo; LEPAGE Corinne; LIESE Peter; LIOTARD Kartika Tamara; MAZEJ KUKOVI Zofija; radvile.morkunaite@europarl.europa.eu; NUTTALL Paul; OUZKY Miroslav; PANAYOTOV Vladko Todorov; PARGNEAUX Gilles; PARVANOV Antonia; PERELLO RODRIGUEZ Andres; PIRILLO Mario; POC Pavel; ROSBACH Anna; ROTH-BEHRENDT Dagmar; SCHNELLHARDT Horst; SEEBER Richard; SONIK Boguslaw; SARBU Daciana Octavia; TATARELLA Salvatore; T N Sescu Claudiu Ciprian; ULMER Thomas; WEISGERBER Anja; WESTLUND Asa; WILLMOTT Glenis; WILS Sabine; YANNAKOUDAKIS Marina; ŠADURSKIS K rlis
Subject: E-cigarettes and medicines regulation

Today the ENVI committee will vote on the regulatory approach to electronic cigarettes. This is by far the biggest issue in the tobacco products directive, and probably I public health. Some analysts believe these products could dramatically erode the cigarette market and surpass cigarette consumption in 10 years - an amazing pro-health disruptive technology. No other measures under consideration come remotely close to this potential.

Given the importance of getting the regulatory framework right, if you are voting I would be grateful if you could consider the following two articles before you vote:

The case for regulating e-cigarettes as medicines
<http://t.co/pgpN8VfFTY>

10 reasons not to regulate e-cigarettes as medicines
<http://t.co/4PpKcihOy9>

Please consider the arguments carefully - this really matters. If you are voting, please support amendment 58 - robust application and enforcement of consumer protection legislation, with a follow up review. This will give the the right balance of consumer protection while allowing the e-cigarette to compete successfully with cigarettes - which is where the real public health gains will be made. There is no crisis justifying extremely intrusive regulation - just many thousands of happy users. If more specific regulation is needed

(and that is far from clear), it can be introduced later, designed properly, subject to consultation, given a credible legal base and scrutinised by the parliament - this is how regulation of cosmetics has proceeded, for example. Defining e-cigarettes as medicines when they are not medicines and with no consultation would instead create a crisis, add costs and red tape, throttle innovation, aid the cigarette industry and eventually fail in the European Court of Justice.

Clive Bates

Former Director Action on Smoking and Health UK (1997-2003) and former senior civil servant (2003-2012)

Disclaimer: I speak strictly for myself - former employers may not necessarily support the views herein

Disclosure: I have no competing interests - my only interest is in the public health outcome

STAES Bart OFFICE

From: john sanger <jhn_sanger@yahoo.co.uk>
Sent: 10 July 2013 02:13
To: SCHLYTER Carl; SCHNELLHARDT Horst; SCHNIEBER-JASTRAM Birgit; SCOTTA' Giancarlo; SEEER Richard; SKYLAKAKIS Theodoros; SOMMER Renate; SONIK Boguslaw; SOPHOCLEOUS Sophocles; SOUSA Alda; STADLER Ewald; STAES Bart; STEVENSON Struan; TABAJDI Csaba; T N Sescu Claudiu Ciprian; TATARELLA Salvatore; TAYLOR Rebecca; THEOCHAROUS Eleni; THYSSEN Marianne; ULMER Thomas; ULVSKOG Marita; URUTCHEV Vladimir Andreev; VAN BREMPT Kathleen; DE VILLIERS Philippe; WEISGERBER Anja; WESTLUND Asa; WILLMOTT Glenis; WILS Sabine; YANNAKOUDAKIS Marina; ZABORSKA Anna; ZANONI Andrea; BORZAN Biljana; PARVANOVA Antonia
Subject: REGARDING PUBLIC HEALTH / E CIGARETTES AND SPENDING!

It has come to my attention there is going to be a vote for electronic cigarettes by MEPs who sit in the European Parliaments Environment and Public Health Committee. They will have three electronic cigarettes choices before them to vote upon.

It came as such a shock that my electronic cigarette which I use could be treated like a tobacco product which it is not. Such thinking would be very unbeneficial to people thinking of giving up smoking tobacco or wanting to cut down there consumption or giving up tobacco all together. In my view electronic cigarettes should not be treated as such and voting for amendment 57* would be a grave mistake on public health. Electronic cigarettes are not solely medicinal in any way and to make them so would severely restrict the appeal and benefits they hold for the smoker of tobacco products in which they are aimed for!

Voting for the compromising option Amendment 58* I feel would be a more common sense approach: simply complying with general product safety requirements, (I know this has the support of the Conservatives.)

I know I have sent the same letter to all my MEPs, I do apologise though I have little time to react to this matter.

I wouldn't have given up smoking tobacco successfully with out the use of electronic cigarettes on the market today and the appeal they offered to lure myself away from smoking tobacco. I have felt much improvement to my health and feel surrounding family and friends have also benefitted. I really don't think the NHS would be able to offer a viable and enjoyable alternative to this; and why should the taxpayer pay for people to use electronic cigarettes? This could become a reality if you vote for amendment 57*. There is already a private viable infrastructure for people to purchase there own electronic cigarettes as a personal aid or choice not a medicinal necessity! What incentive would there be to completely refrain from all smoking and vaping if the NHS are funding this rather than the individual choosing to budget for it?

I hope by writing this letter, it will assist in making a good decision!

Yours sincerely,
Jon Sanger.

STAES Bart OFFICE

From: Zoltan Massay-Kosubek <zoltan@epha.org>
Sent: 09 July 2013 17:30
To: Zoltan Massay-Kosubek
Subject: EPHA public health voting recommendations - ENVI vote on the Tobacco Products Directive (TPD) on 10 July (Wednesday)
Attachments: EPHA - TPD Voting Recommendations - ENVI.pdf

Dear Members and Substitute Members of the ENVI Committee,

Ahead of the Wednesday 10 July vote on the draft report on the Tobacco Products Directive (TPD), the European Public Health Alliance (EPHA) - a leading European NGO advocating for better health - contacts you on behalf of the European public health community.

We are extremely concerned about the opinions that have emanated from other European Parliament Committees. We are aware that your colleagues in most of these Committees do not have people's health as their first priority. **But as a member of the ENVI Committee, your priority is the health of all citizens of the EU.**

We are calling on your support for a strong Tobacco Products Directive.

In particular, we call on two crucial votes from you:

- Please **vote in favour of compromise amendment 39** which maintains the size of **75% of the front and the back of the pack.**
- Please **vote against compromise amendment 38** which reduces the size of warnings to **65% of the front and the back of the pack.**

Why?

- 70% of smokers start before the age of 18 and 94% before the age of 25 years.
- Pictorial warnings of 75% or more are not just proven to be more **effective in reducing the attractiveness of tobacco products to children and young people**; they are also in force in several countries around the world where significant reductions in youth smoking were registered after their introduction.
- Pictorial warnings covering 75% of the front and the back of the pack **have NOT been legally challenged anywhere in the world.**
- **75% of all European citizens are in favour** of this measure

The Tobacco Products Directive is one of the **last major pieces of EU regulation that will be adopted before next year's elections** to the European Parliament. The directive has the potential to stop young people from taking up the deadly habit of smoking, with its devastating effects that we witness in our

everyday work. That is why **your vote on this crucial piece of legislation will be your legacy to Europe's young people** and your contribution to reducing death and disease from chronic diseases such as cancer, heart attacks, respiratory illness and diabetes.

We also urge you to make sure that **flavours that make cigarettes more attractive and palatable are not allowed** and that the so-called **“slim” cigarettes are no-longer on the market** to seduce young girls, in particular.

Also, we call on you to vote for amendments that **include standard packs and the strengthening of traceability and security features for combating illicit trade.**

The attached document provides a more comprehensive list of the amendments and compromise amendments which we consider as the most important.

The European public health community counts on your support and look forward to your vote for a Tobacco Products Directive that places the health of European citizens above the interests of the tobacco industry.

Yours sincerely,

European Public Health Alliance (EPHA)

PS: It has come to our attention that a number of arguments against the tobacco products are not backed up by the evidence. To that end we have put the link to a [leaflet](#) that distinguishes between facts and fiction.

--

[Mr. Zoltán MASSAY-KOSUBEK](#)

Policy Coordinator for Policy Coherence (@EU_zmk)

European Public Health Alliance (EPHA) | Rue de Trèves, 49-51, 1040 Brussels

Tel: +32 2 233 3872 | Skype: massay.zoltan | Fax: +32 2 233 3880

zoltan@epha.org | www.epha.org

Follow EPHA on Twitter @EPHA_EU & Facebook www.facebook.com/epha.eu

Join our **European Citizens' Initiative (ECI)**! Every signature counts!

WATER and SANITATION is a human right! **SIGN NOW!** <http://www.right2water.eu/>

EPHA is the European Platform bringing together public health organisations representing health professionals, patients groups, health promotion and disease specific NGOs, academic groupings and other health associations.

This email arises from the European Public Health Alliance which has received funding from the European Union, in the framework of the Health Programme. Sole responsibility for this email lies with EPHA and the Executive Agency is not responsible for any use that may be made of the information contained therein.

STAES Bart OFFICE

From: Marleen Kestens <mkestens@ehnheart.org>
Sent: 09 July 2013 16:27
To: Marleen Kestens
Subject: Tobacco products directive : voting recommendations European Heart Network
Attachments: ENVI Voting Recommendations_EHN_final final.docx

Dear Member of the Committee on the Environment, Public Health and Food Safety,

We are writing to you ahead of the vote on Wednesday 10 July on the draft report on the Tobacco Products Directive. In the meantime, we have seen the compromise amendments and with this email we are sending you our voting recommendations.

Specifically, we need the health warnings to be prominent. Our first call on you is to:

- Please **vote in favour of compromise amendment 39** which maintains the size of **75% of the front and the back of the pack**
- Please **vote against compromise amendment 38** which reduces the size of warnings to **65% of the front and the back of the pack**

Why?

- 70% of smokers start before the age of 18 and 94% before the age of 25 years.
- Pictorial warnings of 75% or more are not just proven to be more **effective in reducing the attractiveness of tobacco products to children and young people**; they are also in force in several countries around the world where significant reductions in youth smoking were registered after their introduction.
- Pictorial warnings covering 75% of the front and the back of the pack **have NOT been legally challenged anywhere in the world.**
- **75% of all European citizens are in favour** of this measure

We have more recommendations. They are set out in the attached document.

If you have any questions to our recommendations, please do not hesitate to contact us. We count on your support and we thank you in advance.

Yours sincerely,

Susanne Løgstrup
Director, European Heart Network



European Heart Network (EHN)

Rue Montoyer 31 - 1000 Brussels - Belgium
Tel: +32 2 502 15 41 - Fax: +32 2 503 35 25

mkestens@ehnheart.org – **www.ehnheart.org**

The European Heart Network plays a leading role in the prevention and reduction of cardiovascular diseases, in particular heart disease and stroke, through advocacy, networking, education and patient support, so that they are no longer a major cause of premature death and disability throughout Europe.

STAES Bart OFFICE

From: Juha Arffman <bendekooy@pp.inet.fi>
Sent: 09 July 2013 13:19
To: STAES Bart
Subject: TPD voting tomorrow 10.7

Honorable Member of European Parliament's ENVI committee,

You have tomorrow 10.7.2013 a critical voting about the revision of the Tobacco Directive. There is one thing which goes over the others considering the magnitude of impact to smoked tobacco's prevalence in Europe. It is the question about nicotine containing e-cigarettes. It is proposed that they should be regulated as pharmaceutical products. It would be a huge mistake. Please, don't vote for that option. It is estimated that there is about 7 - 10 million e-cigarette users in Europe at this moment. According to studies almost everyone of them are tobacco smokers or ex-smokers. It is pretty obvious that all of them had improved their health essentially by switching burned tobacco cigarettes to non-combustible e-cigarettes. *Nobody of them is curing themselves* from some "disease" called nicotine dependency. They simply use the product to satisfy their need of nicotine and smoking habits by healthier way than smoking tobacco. *Nobody sell e-cigarettes as medicine* because they are not medicine. Nicotine doesn't cure anything. E-cigarettes are recreational products which offer way out from smoking burned tobacco by substituting it. Restricting heavily availability of smoked tobacco's substitute with pharmaceutical regulation will slow down the decreasing trend of smoking in Europe and puts millions of european's life in danger.

Success of nicotine containing e-cigarettes is devastating to sales of smoked tobacco. E-cigarettes are dangerous enemy to tobacco industry, not some evil plot developed by it. Naturally e-cigarettes are enemy of pharmaceutical companies too, which have developed medicines to "cure" tobacco dependency. There has been lot of speculation about tobacco industry lobbying concerning TPD. Lobbying e-cigarettes is not in tobacco industry's agenda. It's originating from independent e-cigarette industry and EU-citizens like me, which have happily switched tens of years smoking to e-cigarettes. This kind e-cigarette lobbying is a child's play compared to pharmaceutical industry's lobbying in this case of e-cigarette. Now you can see results of pharma lobbying with your own eyes. Pharma funded organisations like e.g. European Respiratory Society and Smokefree Partnership have loudest voice in this issue and what they, not surprisingly, are demanding. They are shouting that e-cigarette industry should be monopolized to pharmaceutical industry. Is that really an option? Making a medicine about the product which is not sold as medicine, and doesn't cure anything, and is used only as recreational way to use nicotine, and is decreasing smoking rates in Europe. That is madness.

I live now much more healthier life thanks to nicotine containing e-cigarettes. I have used them over three years and I have no intention to stop using them, because there has not been negative impact to my health and I enjoy using them. So, what if they were medicines. It is obvious that their price would be ridiculous. Let's make little comparison. Smoking a pack of cigarettes a day costs here in Finland about 2000 euros a year. Using e-cigarettes costs me about 600 euros a year. How about if e-cigarettes was classified as medicine? We don't know how much using "pharmaceutical e-cigarette" would cost, but we can estimate it e.g. by looking bubblegum's price. One ordinary bubblegum pillow costs about 2 - 5 cents, pharmaceutical nicotine bubblegum costs about 20 -25 cents per pillow (to factories medical nicotine is almost free, by the way). So if I someday in future had to use pharmaceutical e-cigarettes it could cost to me about 2400 - 3000 per year, maybe even more (estimated by using bubblegum price factor). Naturally the popularity of e-cigarette would collapse among smokers, which are in terrible risk to get some smoking related disease and die prematurely. This simply is not acceptable. There should not be any kind of pharmaceutical option to e-cigarette regulation, *not heavy or not light touch pharmaceutical regulating*. "Light touch" pharmaceutical regulation is presented to you as some kind of compromise option, but it is not. "Light touch" leads to same insane pricing like "normal" pharmaceutical regulating. It would be devastating to life of millions of european e-cigarette users and to over 100 000 000 european tobacco

addicts. Many of ex-smokers saved by e-cigarettes would be forced to go back smoking because of insane pricing and smokers won't switch to them anymore. *We already have appropriate safety regulations to consumer products applicable to e-cigarettes and there is no need to stricter regulation.* There is not even one relevant science based argument that would justify pharmaceutical regulation in this case. Actually I don't see *any* relevant argument behalf of pharmaceutical regulation. Only huge amount of speculation which doesn't base anything, not in science or not in empiric observations from real life.

I see only one reasonable limitation to sales of nicotine containing e-cigarettes, and it could be prohibition of selling e-cigarettes to minors. Actually that is common practise among e-cigarette sellers at this moment. Grown up european citizens don't need some nanny to tell him how much nicotine he has right to use and how to use it. That is ludicrous. According to experts nicotine is a pretty harmless recreational product. It doesn't cause cancer or any diseases overall. They compare nicotine's "dangers" to caffeine's dangers. Regulating that kind of product like dangerous drug is over-regulating and huge mistake. It would kill millions of europeans to tobacco related diseases by restricting nicotine's availability only in smoked tobacco and over-priced "medicines".

Sincerely Yours
Citizen of EU, Juha Arffman

STAES Bart OFFICE

From: Pötschke-Langer, Martina <m.poetschke-langer@dkfz-heidelberg.de>
Sent: 09 July 2013 11:50
To: WEISGERBER Anja; WESTLUND Asa; WILLMOTT Glenis; WILS Sabine; YANNAKOUDAKIS Marina; ARIAS ECHEVERRIA Pablo; AUKEN Margrete; AYALA SENDER Inés; BÁNKI Erik; BLOOM Godfrey; BORSELLINO Rita; BUSOI Cristian Silviu; CHRYSOGELOS Nikos; CLIVETI Minodora; DE VEYRAC Christine; DE VILLIERS Philippe; DEMESMAEKER Mark; FERNANDES José Manuel; FERREIRA João; FJELLNER Christofer; FORD Victoria Grace; FOSTER Jacqueline; FRANCO Gaston; GARCÍA-HIERRO CARABALLO Dolores; GIEREK Adam; GIRLING Julie; HARMS Rebecca; HAUG Jutta; HERRANZ GARCIA Esther; IVAN C t lin-Sorin; JORDAN Romana; JUVIN Philippe; KACZMAREK Filip; KALINOWSKI Jarosław; KOUMOUTSAKOS Georgios; KOZLIK Sergej; MANDERS Toine; PAKARINEN Riikka; MASTALKA Jiri; McGUINNESS Mairead; MERKIES Judith A.; MIKOLASIK Miroslav; NICHOLSON James; ORTIZ VILELLA Eva; PALECKIS Justas Vincas; PAULSEN Marit; PETERLE Alojz; PRODI Vittorio; REIMERS Britta; RIVASI Michèle; RIVELLINI Crescenzo; SCHALDEMOSE Christel; SCHNIEBER-JASTRAM Birgit; SCOTTA' Giancarlo; SOMMER Renate; SOPHOCLEOUS Sophocles; SOUSA Alda; STADLER Ewald; STAES Bart; STEVENSON Struan; TABAJDI Csaba; TAYLOR Rebecca; THEOCHAROUS Eleni; THYSSEN Marianne; ULVSKOG Marita; URUTCHEV Vladimir Andreev; VAN BREMPT Kathleen; VAN DALEN Peter; VIGENIN Kristian; ZABORSKA Anna; ZANONI Andrea
Cc: Pötschke-Langer, Martina
Subject: TPD - new information: Why menthol as a tobacco additive should be banned
Attachments: DKFZ Position Paper Menthol July 2013.pdf

Dear Members of the ENVI Committee,

In these days, you are overloaded by emails of tobacco and e-cigarette lobbyists on your vote of tomorrow. There are many misleading, errors and false data among these lobby attempts so that we want to remind you on the scientific findings of independent, public funded organizations such as the German Cancer Research Center:

1. You know that the German Cancer Research Center is providing the evidence for effectiveness of pictorial health warnings:

http://www.dkfz.de/de/tabakkontrolle/download/Publikationen/AdWfP/AdWfP_Pictorial_Health_Warnings.pdf

Please, vote for 75% size of the combined (picture+text) health warnings on cigarette packs.

2. You know that the German Cancer Research Center is supporting the proposal for regulation of e-cigarettes as medicinal products;

http://www.dkfz.de/de/tabakkontrolle/download/Publikationen/RoteReihe/Band_19_e-cigarettes_an_overview.pdf

Please, vote for the regulation of e-cigarettes as medicinal products – for consumer safety reasons.

3. You know that the German Cancer Research Center is supporting the ban on slim cigarettes because these cigarettes are made for girls and women, the most vulnerable groups in our countries. We observe a sharp increase of smoking related lung cancer deaths among women in the last decade.

Please, vote for a ban on slim cigarettes – and stop the further increase on lung cancer in women.

4. You know that the German Cancer Research Center is supporting a ban on menthol (and other ingredients) as tobacco additive. Because there are misleading lobby papers, we just summarized the scientific evidence on this subject and send you today a new position paper attached.

Please, vote for a ban of menthol and other ingredients as tobacco additives.

We wish you wise decisions for the votes tomorrow and ask you to consider the health aspects and to resist the tobacco and e-cigarette lobbyists.

Best regards

Dr Martina Pötschke-Langer MD, M. A.

Head of Executive Office Cancer Prevention and
Head of WHO Collaborating Centre for Tobacco Control
German Cancer Research Center - Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
69120 Heidelberg
Germany

Tel: +49 (0)6221 42 3014

Fax: +49 (0)6221 42 3020

E-Mail: m.poetschke-langer@dkfz.de

Web: www.dkfz.de / www.tabakkontrolle.de

dkfz. DEUTSCHES
KREBSFORSCHUNGSZENTRUM

STAES Bart OFFICE

From: Maria Lilia Andrade <m.lilia.andrade@hotmail.com>
Sent: 09 July 2013 03:07
To: KACZMAREK Filip; 'karin.kadenbach@europarl.europa.eu'; KALINOWSKI Jarosław; KORHOLA Eija-Riitta; KOUMOUTSAKOS Georgios; KOZLIK Sergej; LEINEN Jo; KRAHMER Holger; LEPAGE Corinne; LIESE Peter; LIOTARD Kartika Tamara; LYUBCHEVA Marusya; MANDERS Toine; MASTALKA Jiri; MAZEJ KUKOVI Zofija; MCAVAN Linda; McGUINNESS Mairead; MERKIES Judith A.; MIKOLASIK Miroslav; MIZZI Marlene; MORK NAIT -MIKUL NIEN Radvil; NICHOLSON James; NUTTALL Paul; 'eva.ortizvilella@europarl.europa.eu'; OUZKY Miroslav; rikka.pakarinen@europarl.europa.eu; PALECKIS Justas Vincas; PANAYOTOV Vladko Todorov; PARGNEAUX Gilles; PARVANOV Antonia; PAULSEN Marit; PERELLO RODRIGUEZ Andres; PETERLE Alojz; PIRILLO Mario; POC Pavel; PRODI Vittorio; REIMERS Britta; RIES Frédérique; RIVASI Michèle; RIVELLINI Crescenzo; ROSBACH Anna; ROSSI Oreste; ROTH-BEHRENDT Dagmar; ŠADURSKIS K rlis; SARBU Daciana Octavia; SCHALDEMOSE Christel; SCHLYTER Carl; SCHNELHARDT Horst; SCHNIEBER-JASTRAM Birgit; SCOTTA' Giancarlo; SEEBER Richard; SKYLAKAKIS Theodoros; 'renate.sommer@europarl.europa.eu'; 'boguslaw.sonik@europarl.europa.eu'; SOPHOCLEOUS Sophocles; SOUSA Alda; STADLER Ewald; STAES Bart; STEVENSON Struan; TABAJDI Csaba; T N SESCO Claudiu Ciprian; TATARELLA Salvatore; TAYLOR Rebecca; THEOCHAROUS Eleni; THYSSEN Marianne; ULMER Thomas; ULVSKOG Marita; URUTCHEV Vladimir Andreev; VAN BREMPT Kathleen; WEISGERBER Anja; WESTLUND Asa; WILLMOTT Glenis; WILS Sabine; YANNAKOUDAKIS Marina; ZABORSKA Anna; ZANONI Andrea
Subject: FW: URGENT-ENVI vote on the Tobacco products Directive on 10 July

Dear Member of the Committee on the Environment, Public Health and Food Safety

RE: ENVI vote on the Tobacco products Directive on 10 July

Ahead of the Wednesday 10 July vote on the draft report on the Tobacco Products Directive, we are contacting you as representatives of the health community in your country.

We are extremely concerned about the opinions that have emanated from other European Parliament Committees. We are aware that your colleagues in most of these Committees do not have people's health as their first priority. But as a member of the ENVI Committee, your priority is the health of all citizens of the EU.

We are calling on your support for a strong Tobacco Products Directive.

In particular, we call on two crucial votes from you:

- Please [vote in favour of compromise amendment 39](#) which maintains the size of **75% of the front and the back of the pack**.
- Please [vote against compromise amendment 38](#) which reduces the size of warnings to **65% of the front and the back of the pack**.

Why?

- 70% of smokers start before the age of 18 and 94% before the age of 25 years.
- Pictorial warnings of 75% or more are not just proven to be more **effective in reducing the attractiveness of tobacco products to children and young people**; they are also in force in several countries around the world where significant reductions in youth smoking were registered after their introduction.
- Pictorial warnings covering 75% of the front and the back of the pack **have NOT been legally challenged anywhere in the world**.
- **75% of all European citizens are in favour** of this measure

The Tobacco Products Directive is one of the **last major pieces of EU regulation that will be adopted before next year's elections** to the European Parliament. The directive has the potential to stop young people from taking up the deadly habit of smoking, with its devastating effects that we witness in our everyday work. That is why **your vote on this crucial piece of legislation will be your legacy to Europe's young people** and your contribution to reducing death and disease from chronic diseases such as cancer, heart attacks, respiratory illness and diabetes.

We also urge you to make sure that **flavours that make cigarettes more attractive and palatable are not allowed** and that the so-called “**slim**” **cigarettes are no-longer on the market** to seduce young girls, in particular.

Also, we call on you to vote for amendments that **include standard packs and the strengthening of traceability and security features for combating illicit trade**.

The attached document provides a more comprehensive list of the amendments and compromise amendments which we consider as the most important.

The public health community in your country and in the whole of Europe counts on your support and look forward to your vote for a Tobacco Products Directive that places the health of European citizens above the interests of the tobacco industry.

Yours sincerely,

Lilia Andrade, Pneumologist
Centro Hospitalar Baixo Vouga Aveiro, Portugal
Member of the Tobacco Eviction Committee of the Portuguese Pneumology Society

--

Comissão de Tabagismo da Sociedade Portuguesa de Pneumologia
<http://www.sppneumologia.pt/content/comissao-de-trabalho-tabagismo>

STAES Bart OFFICE

From: Fleur van Bladeren <FBladeren@kwfkankerbestrijding.nl>
Sent: 08 July 2013 23:10
To: STAES Bart
Subject: RE: ENVI stemming tabaksrichtlijn woensdag 10 juli as

Super!
Succes woensdag en daarna een fijn reces!
Groet Fleur

	<p>Fleur van Bladeren <i>Senior Beleidsmedewerker</i></p> <p>KWF Kankerbestrijding Delflandlaan 17 Postbus 75508 1070 AM Amsterdam T 0205700519 M 0650613553 E FBladeren@kwfkankerbestrijding.nl W www.kwfkankerbestrijding.nl</p> <p>   </p>
---	--

Van: STAES Bart [mailto:bart.staes@europarl.europa.eu]
Verzonden: maandag 8 juli 2013 23:09
Aan: Fleur van Bladeren
Onderwerp: Re: ENVI stemming tabaksrichtlijn woensdag 10 juli as

U kan op me rekenen!

Bart Staes

Op 8 jul. 2013 om 22:53 heeft "Fleur van Bladeren" <FBladeren@kwfkankerbestrijding.nl> het volgende geschreven:

Geachte heer Staes,

Aanstaande woensdag zult u in de ENVI commissie stemmen over de Herziening van de Europese Tabaksrichtlijn. KWF Kankerbestrijding is sterk voorstander van een nieuwe aangescherpte tabaksrichtlijn. Daarom vragen we, aanvullend op eerdere verzoeken die u van ons en onze samenwerkingspartners heeft ontvangen, nogmaals uw aandacht voor het nemen van de juiste beslissingen ten behoeve van de volksgezondheid. Wij vragen u dit mede namens onze Nederlandse partners in tabaksontmoediging Hartstichting, Longfonds, Partnership Stop met Roken (samenwerkingsverband van zorgprofessionals) en STIVORO.

U staat voor de volksgezondheid, dat is het uitgangspunt van uw handelen. De andere commissies die zich over de tabaksrichtlijn buigen hebben volksgezondheid niet als belangrijkste uitgangspunt. Hun standpunten ten aanzien van de (aanpassingen van de) richtlijn baren ons dan ook zorgen.

Wij hopen van harte dat u woensdag **met uw stem** een **belangrijke bijdrage** levert aan een **gezonde generatie**. Een generatie die niet makkelijk meer ten prooi valt aan de misleiding en verleiding van de tabaksindustrie en een leven lang verslaafd is aan een dodelijk product. Wij vragen u de belangen voor de volksgezondheid voorop te stellen bij de stemming. De volksgezondheid van alle EU burgers, maar met name onze toekomst – de jeugd.

Uit de omvangrijke lijst van amendementen zijn er 2 cruciale amendementen waarin uw stem echt het verschil kan maken:

- **Stem u alstublieft voor amendement 39:** dit beschrijft dat de gecombineerde gezondheidswaarschuwing **75% van de voor- en achterkant van de verpakking** bedekt

- **Stemt u alstublieft tegen amendement 38:** dit beschrijft dat de gecombineerde gezondheidswaarschuwing **65% van de voor- en achterkant van de verpakking** bedekt.

Waarom 75% en niet 65%?

- 70% van de rokers begint voor zijn 18^e en 94% voordat hij 25 jaar is.
- Fotowaarschuwingen van 75% of meer zijn niet alleen **effectiever in het verminderen van de aantrekkelijkheid van tabaksproducten** voor kinderen en jongeren, diverse landen in de wereld hebben reeds 75% van de pakjes bedekt met fotowaarschuwingen waardoor het **percentage rokende jongeren significant is gedaald**.
- Fotowaarschuwingen van 75% op voor – en achterzijde zijn **nergens ter wereld juridisch aangevochten**.
- **75% van de Europese burgers is voorstander** van deze maatregel.

De tabaksrichtlijn is een van de laatste grote EU richtlijnen die voor de EP verkiezingen van volgend jaar aangenomen zal worden. De richtlijn zal een belangrijke rol spelen in het voorkomen dat jongeren aan een dodelijke verslaving beginnen. Gevolgen waar een groot deel van onze achterban helaas mee te maken heeft. **Daarom is uw stem van eminent belang en kunt u nu het verschil maken in de levens van heel veel jongeren.** U kunt immers bijdragen aan een nieuwe generatie die gezond en rookvrij kan opgroeien. Zo kunnen we op termijn ook (chronische) ziekten zoals kanker, hart- en vaatziekten, longaandoeningen en diabetes effectief terugdringen. Dit is een van die 'once in a lifetime opportunities' om echt het verschil te kunnen maken. Veel van uw kiezers en het hele gezondheidsveld zullen u prijzen om uw bijdrage.

We roepen u ook op om ervoor te zorgen dat **smaakjes (inclusief menthol) die tabak aantrekkelijker en makkelijker te inhaleren maken niet meer worden toegestaan** en dat de 'slim' sigaretten die vooral bedoeld zijn voor **jonge meisjes, niet meer op de markt worden toegestaan**.

En we roepen u op om **voor de introductie van generieke (standaard) verpakking te stemmen** en de aanscherping van veiligheidsaspecten tbv illegale handel.

Bijgevoegde lijst met amendementen geeft een overzicht van de amendementen die wij en onze Europese gezondheidspartners het belangrijkste vinden.

Wij en onze Nederlandse en Europese gezondheidspartners rekenen op uw hulp voor een effectieve nieuwe tabaksrichtlijn die voorkomt dat jongeren met roken beginnen en een belangrijke bijdrage levert aan de volksgezondheid. Uw stem stelt het volksgezondheid belang boven het belang van de tabaksindustrie.

Met vriendelijke groet,

Fleur van Bladeren

PS, we hebben begrepen dat een aantal argumenten die tegenstanders van aanpassing van de tabaksrichtlijn gebruiken niet wetenschappelijk onderbouwd zijn. Daarom hebben onze Europese partners een [overzicht](#) gemaakt van de feiten en fabels mbt een aantal van de argumenten. Wij sturen u ze graag (nogmaals) toe.

KWF Kankerbestrijding is partner in de Alliantie Nederland Rookvrij!, een actief netwerk waarin partijen zich gezamenlijk hard maken voor een rookvrij Nederland waarin niemand meer (over)lijdt aan de gevolgen van tabaksgebruik.

<image007.png>

Fleur van Bladeren
Senior Beleidsmedewerker

KWF Kankerbestrijding

Delflandlaan 17 | Postbus 75508 | 1070 AM Amsterdam

T 0205700519 | **M** 0650613553 | **E** FBladeren@kwfkankerbestrijding.nl

W www.kwfkankerbestrijding.nl

<image003.gif><image004.gif><image005.gif><image006.gif>

<ENVI Voting Recommendations Tobacco products Directive.docx>

STAES Bart OFFICE

From: Fleur van Bladeren <FBladeren@kwfkankerbestrijding.nl>
Sent: 08 July 2013 22:54
To: STAES Bart
Cc: Cora Honing
Subject: ENVI stemming tabaksrichtlijn woensdag 10 juli as
Attachments: ENVI Voting Recommendations Tobacco products Directive.docx

Geachte heer Staes,

Aanstaande woensdag zult u in de ENVI commissie stemmen over de Herziening van de Europese Tabaksrichtlijn. KWF Kankerbestrijding is sterk voorstander van een nieuwe aangescherpte tabaksrichtlijn. Daarom vragen we, aanvullend op eerdere verzoeken die u van ons en onze samenwerkingspartners heeft ontvangen, nogmaals uw aandacht voor het nemen van de juiste beslissingen ten behoeve van de volksgezondheid. Wij vragen u dit mede namens onze Nederlandse partners in tabaksontmoediging Hartstichting, Longfonds, Partnership Stop met Roken (samenwerkingsverband van zorgprofessionals) en STIVORO.

U staat voor de volksgezondheid, dat is het uitgangspunt van uw handelen. De andere commissies die zich over de tabaksrichtlijn buigen hebben volksgezondheid niet als belangrijkste uitgangspunt. Hun standpunten ten aanzien van de (aanpassingen van de) richtlijn baren ons dan ook zorgen. Wij hopen van harte dat u woensdag **met uw stem een belangrijke bijdrage** levert aan een **gezonde generatie**. Een generatie die niet makkelijk meer ten prooi valt aan de misleiding en verleiding van de tabaksindustrie en een leven lang verslaafd is aan een dodelijk product. Wij vragen u de belangen voor de volksgezondheid voorop te stellen bij de stemming. De volksgezondheid van alle EU burgers, maar met name onze toekomst – de jeugd.

Uit de omvangrijke lijst van amendementen zijn er 2 cruciale amendementen waarin uw stem echt het verschil kan maken:

- **Stemt u alstublieft voor amendement 39:** dit beschrijft dat de gecombineerde gezondheidswaarschuwing **75% van de voor- en achterkant van de verpakking** bedekt
- **Stemt u alstublieft tegen amendement 38:** dit beschrijft dat de gecombineerde gezondheidswaarschuwing **65% van de voor- en achterkant van de verpakking** bedekt.

Waarom 75% en niet 65%?

- 70% van de rokers begint voor zijn 18^e en 94% voordat hij 25 jaar is.
- Fotowaarschuwingen van 75% of meer zijn niet alleen **effectiever in het verminderen van de aantrekkelijkheid van tabaksproducten** voor kinderen en jongeren, diverse landen in de wereld hebben reeds 75% van de pakjes bedekt met fotowaarschuwingen waardoor het **percentage rokende jongeren significant is gedaald**.
- Fotowaarschuwingen van 75% op voor – en achterzijde zijn **nergens ter wereld juridisch aangevochten**.
- **75% van de Europese burgers is voorstander** van deze maatregel.

De tabaksrichtlijn is een van de laatste grote EU richtlijnen die voor de EP verkiezingen van volgend jaar aangenomen zal worden. De richtlijn zal een belangrijke rol spelen in het voorkomen dat jongeren aan een dodelijke verslaving beginnen. Gevolgen waar een groot deel van onze achterban helaas mee te maken heeft. **Daarom is uw stem van eminent belang en kunt u nu het verschil maken in de levens van heel veel jongeren.** U kunt immers bijdragen aan een nieuwe generatie die gezond en rookvrij kan opgroeien. Zo kunnen we op termijn ook (chronische) ziekten zoals kanker, hart- en vaatziekten, longaandoeningen en diabetes effectief terugdringen. Dit is een van die 'once in a lifetime opportunities' om echt het verschil te kunnen maken. Veel van uw kiezers en het hele gezondheidsveld zullen u prijzen om uw bijdrage.

We roepen u ook op om ervoor te zorgen dat **smaakjes (inclusief menthol) die tabak aantrekkelijker en makkelijker te inhaleren maken niet meer worden toegestaan** en dat de 'slim' sigaretten die vooral bedoeld zijn voor **jonge meisjes, niet meer op de markt worden toegestaan**.

En we roepen u op om **voor de introductie van generieke (standaard) verpakking te stemmen** en de aanscherping van veiligheidsaspecten tbv illegale handel.

Bijgevoegde lijst met amendementen geeft een overzicht van de amendementen die wij en onze Europese gezondheidspartners het belangrijkste vinden.

Wij en onze Nederlandse en Europese gezondheidspartners rekenen op uw hulp voor een effectieve nieuwe tabaksrichtlijn die voorkomt dat jongeren met roken beginnen en een belangrijke bijdrage levert aan de volksgezondheid. Uw stem stelt het volksgezondheid belang boven het belang van de tabaksindustrie.

Met vriendelijke groet,
Fleur van Bladeren

PS, we hebben begrepen dat een aantal argumenten die tegenstanders van aanpassing van de tabaksrichtlijn gebruiken niet wetenschappelijk onderbouwd zijn. Daarom hebben onze Europese partners een [overzicht](#) gemaakt van de feiten en fabels mbt een aantal van de argumenten. Wij sturen u ze graag (nogmaals) toe.

KWF Kankerbestrijding is partner in de Alliantie Nederland Rookvrij!, een actief netwerk waarin partijen zich gezamenlijk hard maken voor een rookvrij Nederland waarin niemand meer (over)lijdt aan de gevolgen van tabaksgebruik.



Fleur van Bladeren
Senior Beleidsmedewerker

KWF Kankerbestrijding
Delflandlaan 17 | Postbus 75508 | 1070 AM Amsterdam
T 0205700519 | M 0650613553 | E FBladeren@kwfkankerbestrijding.nl
W www.kwfkankerbestrijding.nl



STAES Bart OFFICE

From: SPP <sppneumologia@mail.telepac.pt>
Sent: 08 July 2013 21:22
To: KACZMAREK Filip; 'karin.kadenbach@europarl.europa.eu'; KALINOWSKI Jarosław; KORHOLA Eija-Riitta; KOUMOUTSAKOS Georgios; KOZLIK Sergej; LEINEN Jo; KRAHMER Holger; LEPAGE Corinne; LIESE Peter; LIOTARD Kartika Tamara; LYUBCHEVA Marusya; MANDERS Toine; MASTALKA Jiri; MAZEJ KUKOVI Zofija; MCAVAN Linda; McGUINNESS Mairead; MERKIES Judith A.; MIKOLASIK Miroslav; MIZZI Marlene; MIZZI Marlene; MORK NAIT -MIKUL NIEN Radvil ; NICHOLSON James; NUTTALL Paul; 'eva.ortizvilella@europarl.europa.eu'; OUZKY Miroslav; rikka.pakarinen@europarl.europa.eu; PALECKIS Justas Vincas; PANAYOTOV Vladko Todorov; PARGNEAUX Gilles; PARVANOV Antonia; PAULSEN Marit; PERELLO RODRIGUEZ Andres; PETERLE Alojz; PIRILLO Mario; POC Pavel; PRODI Vittorio; REIMERS Britta; RIES Frédérique; RIVASI Michèle; RIVELLINI Crescenzo; ROSBACH Anna; ROSSI Oreste; ROTH-BEHRENDT Dagmar; ŠADURSKIS K rlis; SARBU Daciana Octavia; SCHALDEMOSE Christel; SCHLYTER Carl; SCHNELLHARDT Horst; SCHNIEBER-JASTRAM Birgit; SCOTTA' Giancarlo; SEEBER Richard; SKYLAKAKIS Theodoros; 'renate.sommer@europarl.europa.eu'; 'boguslaw.sonik@europarl.europa.eu'; SOPHOCLEOUS Sophocles; SOUSA Alda; STADLER Ewald; STAES Bart; STEVENSON Struan; TABAJDI Csaba; T N Sescu Claudiu Ciprian; TATARELLA Salvatore; TAYLOR Rebecca; TAYLOR Rebecca; THEOCHAROUS Eleni; THYSSEN Marianne; ULMER Thomas; ULVSKOG Marita; URUTCHEV Vladimir Andreev; VAN BREMPT Kathleen; WEISGERBER Anja; WESTLUND Asa; WILLMOTT Glenis; WILS Sabine; YANNAKOUDAKIS Marina; ZABORSKA Anna; ZANONI Andrea
Subject: ENVI vote on the Tobacco products Directive on 10 July

Dear Member of the Committee on the Environment, Public Health and Food Safety

RE: ENVI vote on the Tobacco products Directive on 10 July

Ahead of the Wednesday 10 July vote on the draft report on the Tobacco Products Directive, we are contacting you as representatives of the health community in your country.

We are extremely concerned about the opinions that have emanated from other European Parliament Committees. We are aware that your colleagues in most of these Committees do not have people's health as their first priority. But as a member of the ENVI Committee, your priority is the health of all citizens of the EU.

We are calling on your support for a strong Tobacco Products Directive.

In particular, we call on two crucial votes from you:

- Please vote in favour of compromise amendment 39 which maintains the size of 75% of the front and the back of the pack.
- Please vote against compromise amendment 38 which reduces the size of warnings to 65% of the front and the back of the pack.

Why?

- 70% of smokers start before the age of 18 and 94% before the age of 25 years.
- Pictorial warnings of 75% or more are not just proven to be more effective in reducing the attractiveness of tobacco products to children and young people; they are also in force in several countries around the world where significant reductions in youth smoking were registered after their introduction.

- Pictorial warnings covering 75% of the front and the back of the pack have NOT been legally challenged anywhere in the world.
- 75% of all European citizens are in favour of this measure

The Tobacco Products Directive is one of the last major pieces of EU regulation that will be adopted before next year's elections to the European Parliament. The directive has the potential to stop young people from taking up the deadly habit of smoking, with its devastating effects that we witness in our everyday work. That is why your vote on this crucial piece of legislation will be your legacy to Europe's young people and your contribution to reducing death and disease from chronic diseases such as cancer, heart attacks, respiratory illness and diabetes.

We also urge you to make sure that flavours that make cigarettes more attractive and palatable are not allowed and that the so-called "slim" cigarettes are no-longer on the market to seduce young girls, in particular.

Also, we call on you to vote for amendments that include standard packs and the strengthening of traceability and security features for combating illicit trade.

The attached document provides a more comprehensive list of the amendments and compromise amendments which we consider as the most important.

The public health community in your country and in the whole of Europe counts on your support and look forward to your vote for a Tobacco Products Directive that places the health of European citizens above the interests of the tobacco industry.

Yours sincerely,

Carlos Robalo Cordeiro
President of the Portuguese Society of Pneumology



Sociedade Portuguesa de Pneumologia

Rua Ivone Silva, 6- 6ºEsq

1069-130 Lisboa

Tel: 217962074

Fax: 217962075

Telemóvel Secretariado: 926369825

e-mail: sppneumologia@mail.telepac.pt

www.sppneumologia.pt

STAES Bart OFFICE

From: Richard Hyslop <richard@endeavourpublicaffairs.co.uk>
Sent: 08 July 2013 20:51
To: STAES Bart
Subject: Smoking is a moral issue for electronic cigarette manufacturers and politicians

Please find below a letter from our client Totally Wicked Ltd regarding the vote in ENVI on the revision of the Tobacco Products Directive.

Dear Mr Staes,

Vote on the revision of the Tobacco Products Directive (McAvan, S&D, UK)

The market for e-cigarettes exists because tobacco cigarettes exist. If you take away tobacco cigarettes you take away the market for e-cigarettes. It is as simple as that.

It is through smoking tobacco cigarettes that people become addicted to nicotine. E-cigarettes simply deliver clean nicotine – without the tar, carbon monoxide, and volatile hot gasses of tobacco cigarettes. For people who switch from tobacco cigarettes, they hugely reduce risk.

Survey evidence and research carried out by scientific and public health professionals, comes to the same conclusion: e-cigarettes are not a gateway to smoking and 99 per cent of e-cigarettes users are people who have switched from smoking tobacco cigarettes.

Tobacco cigarettes are the gateway to smoking, not e-cigarettes, and every year in the EU 700,000 people die prematurely as a direct result of smoking tobacco cigarettes. If MEPs are genuinely concerned about public health then they will vote on Wednesday to ban tobacco cigarettes and we will happily close down our business. However, while tobacco cigarettes continue to be freely sold we have a moral obligation to manufacture and sell e-cigarettes, because they offer a proven way for smokers to satisfy their nicotine craving by switching from a product containing several thousand chemical compounds and hundreds of toxic ones to one that contains simply nicotine, propylene glycol, and simple flavourings.

If policy makers are unwilling to ban tobacco cigarettes then they too have a moral obligation, a moral obligation to ensure that any regulatory regime they introduce to regulate electronic cigarettes continues to allow them to be sold freely and in a way that is attractive to existing tobacco cigarette smokers, therefore:

Do not vote to regulate electronic cigarettes as a medicinal product

As we clearly set out [here](#), e-cigarettes are not a medicinal product and regulating them as such constitutes a ban as the Parliament's own Legal Affairs committee [has made clear](#).

The European Commission made it [clear](#) in 2008 that it would be very difficult to regulate e-cigarettes as a medicinal product. [Four European courts](#) have also rejected the medical definition and there is [considerable case law](#) from the European Court of Justice that suggests it would fail at the EU level too.

Do not vote to ban flavours

As we set out [here](#), a ban on flavours will simply lead to more people smoking. The desire to remove all flavourings is aimed at making e-cigarettes less appealing to non-smokers and in particular younger people. However research from a variety of eminent bodies including ASH, the American Cancer Society, and the Consumer Advocates for Smoke Free Alternatives Association all demonstrate that young people and non-smokers are not attracted to e-cigarettes in the first place. Remember, it is the positive discriminators

between e-cigarettes and tobacco cigarettes that enable electronic cigarettes to be credible lifesaving saving alternatives to conventional cigarettes. These should be reinforced not condemned.

Do not vote for the introduction of arbitrary restrictions on nicotine levels

A typical smoker, smoking 20 cigarettes a day, is likely to need between 18 to 24 milligrams of nicotine per millilitre for an electronic cigarette to offer a plausible alternative to conventional tobacco products. The market effect of the health ministers' (one milligram of nicotine per millilitre) and Commission's (two to four milligrams of nicotine per millilitre) proposal would be that consumers would be denied the choice which is currently available and without any intervention is rapidly transforming the smoking demographic to a significantly safer alternative in the e-cigarette. Note also, that the UK's Medicines and Healthcare Regulatory Agency (MHRA) has tested the nicotine strength of a range of e-cigarettes and concluded that: '...none of the tested products (e-cigarettes) delivered nicotine levels as high as conventional cigarettes'.

Do vote for rigorous regulation of e-cigarettes as a consumer product

Totally Wicked is a responsible business. We do not knowingly sell our products to those under the age of 18 or to non-smokers.

The products we manufacture and sell are already highly regulated as a consumer product, and the flavours used in our UK manufactured fluids are regulated by the Food Standards Agency. Importantly, the nicotine we use is from a UK supplier of European and USA pharmacopeia standard assured source. In short we do not fear appropriate regulation; actually, we positively embrace it.

The choice is between existing or strengthened consumer regulation or moving to the stricter and damaging regime of medicinal regulation. What problem do policy makers see that requires further regulation?

Cigarettes are incredibly harmful, yet their toxicity is barely regulated with only peripheral measures regarding additives and flavours. Over-regulating the low-risk alternatives will only serve to protect the cigarette industry from competition and contribute to death and disease.

In revising the TPD MEPs should be guided by one key principle: lowering the rates of death and disease caused by smoking tobacco cigarettes. Do policy makers really want to protect an industry that kills 700,000 people at the expense of a market-based, consumer-led public health revolution that has the potential to save millions of lives?

Yours sincerely

Fraser Cropper

Chief Executive Officer
Totally Wicked Ltd

STAES Bart OFFICE

From: José Pedro Boléo-Tomé <jpboleotome@gmail.com>
Sent: 08 July 2013 20:48
To: KACZMAREK Filip; 'karin.kadenbach@europarl.europa.eu'; KALINOWSKI Jarosław; KORHOLA Eija-Riitta; KOUMOUTSAKOS Georgios; KOZLIK Sergej; LEINEN Jo; KRAHMER Holger; LEPAGE Corinne; LIESE Peter; LIOTARD Kartika Tamara; LYUBCHEVA Marusya; MANDERS Toine; MASTALKA Jiri; MAZEJ KUKOVI Zofija; MCAVAN Linda; McGUINNESS Mairead; MERKIES Judith A.; MIKOLASIK Miroslav; MIZZI Marlene; MORK NAIT -MIKUL NIEN Radvil; NICHOLSON James; NUTTALL Paul; 'eva.ortizvilella@europarl.europa.eu'; OUZKY Miroslav; rikka.pakarinen@europarl.europa.eu; PALECKIS Justas Vincas; PANAYOTOV Vladko Todorov; PARGNEAUX Gilles; PARVANOVVA Antonyia; PAULSEN Marit; PERELLO RODRIGUEZ Andres; PETERLE Alojz; PIRILLO Mario; POC Pavel; PRODI Vittorio; REIMERS Britta; RIES Frédérique; RIVASI Michèle; RIVELLINI Crescenzo; ROSBACH Anna; ROSSI Oreste; ROTH-BEHRENDT Dagmar; ŠADURSKIS K rlis; SARBU Daciana Octavia; SCHALDEMOSE Christel; SCHLYTER Carl; SCHNELHARDT Horst; SCHNIEBER-JASTRAM Birgit; SCOTTA' Giancarlo; SEEBER Richard; SKYLAKAKIS Theodoros; 'renate.sommer@europarl.europa.eu'; 'boguslaw.sonik@europarl.europa.eu'; SOPHOCLEOUS Sophocles; SOUSA Alda; STADLER Ewald; STAES Bart; STEVENSON Struan; TABAJDI Csaba; T N SESCOU Claudiu Ciprian; TATARELLA Salvatore; TAYLOR Rebecca; THEOCHAROUS Eleni; THYSSEN Marianne; ULMER Thomas; ULVSKOG Marita; URUTCHEV Vladimir Andreev; VAN BREMPT Kathleen; WEISGERBER Anja; WESTLUND Asa; WILLMOTT Glenis; WILS Sabine; YANNAKOUDAKIS Marina; ZABORSKA Anna; ZANONI Andrea
Subject: ENVI vote on the Tobacco products Directive on 10 July

Dear Member of the Committee on the Environment, Public Health and Food Safety

Ahead of the Wednesday 10 July vote on the draft report on the Tobacco Products Directive, we are contacting you as representatives of the health community in your country.

We are extremely concerned about the opinions that have emanated from other European Parliament Committees. We are aware that your colleagues in most of these Committees do not have people's health as their first priority. But as a member of the ENVI Committee, your priority is the health of all citizens of the EU.

We are calling on your support for a strong Tobacco Products Directive.

In particular, we call on two crucial votes from you:

- Please [vote in favour of compromise amendment 39](#) which maintains the size of **75% of the front and the back of the pack**.
- Please [vote against compromise amendment 38](#) which reduces the size of warnings to **65% of the front and the back of the pack**.

Why?

- 70% of smokers start before the age of 18 and 94% before the age of 25 years.
- Pictorial warnings of 75% or more are not just proven to be more **effective in reducing the attractiveness of tobacco products to children and young people**; they are also in force in several countries around the world where significant reductions in youth smoking were registered after their introduction.
- Pictorial warnings covering 75% of the front and the back of the pack **have NOT been legally challenged anywhere in the world**.
- **75% of all European citizens are in favour** of this measure

The Tobacco Products Directive is one of the **last major pieces of EU regulation that will be adopted before next year's elections** to the European Parliament. The directive has the potential to stop young people from taking up the deadly habit of smoking, with its devastating effects that we witness in our everyday work. That is why **your vote on this crucial piece of legislation will be your legacy to Europe's young people** and your contribution to reducing death and disease from chronic diseases such as cancer, heart attacks, respiratory illness and diabetes.

We also urge you to make sure that **flavours that make cigarettes more attractive and palatable are not allowed** and that the so-called "slim" cigarettes are **no-longer on the market** to seduce young girls, in particular.

Also, we call on you to vote for amendments that **include standard packs and the strengthening of traceability and security features for combating illicit trade.**

The public health community in your country and in the whole of Europe counts on your support and look forward to your vote for a Tobacco Products Directive that places the health of European citizens above the interests of the tobacco industry.

Yours sincerely,

José Pedro Boléo-Tomé

Pulmonologist

Hospital Prof.Dr.Fernando Fonseca - Amadora, Portugal

Secretary, Tobacco Committee of the Portuguese Society of Pneumology

STAES Bart OFFICE

From: natercia@net.sapo.pt
Sent: 08 July 2013 20:34
Subject: URGENT-ENVI vote on the Tobacco products Directive on 10 July

Dear Member of the Committee on the Environment, Public Health and Food Safety

ENVI vote on the Tobacco products Directive on 10 July

Ahead of the Wednesday 10 July vote on the draft report on the Tobacco Products Directive, we are contacting you as representatives of the health community in your country.

We are extremely concerned about the opinions that have emanated from other European Parliament Committees. We are aware that your colleagues in most of these Committees do not have people's health as their first priority. But as a member of the ENVI Committee, your priority is the health of all citizens of the EU.

We are calling on your support for a strong Tobacco Products Directive.

In particular, we call on two crucial votes from you:

- Please [vote in favour of compromise amendment 39](#) which maintains the size of **75% of the front and the back of the pack**.
- Please [vote against compromise amendment 38](#) which reduces the size of warnings to **65% of the front and the back of the pack**.

Why?

- 70% of smokers start before the age of 18 and 94% before the age of 25 years.
- Pictorial warnings of 75% or more are not just proven to be more **effective in reducing the attractiveness of tobacco products to children and young people**; they are also in force in several countries around the world where significant reductions in youth smoking were registered after their introduction.
- Pictorial warnings covering 75% of the front and the back of the pack **have NOT been legally challenged anywhere in the world**.
- **75% of all European citizens are in favour** of this measure

The Tobacco Products Directive is one of the **last major pieces of EU regulation that will be adopted before next year's elections** to the European Parliament. The directive has the potential to stop young people from taking up the deadly habit of smoking, with its devastating effects that we witness in our everyday work. That is why **your vote on this crucial piece of legislation will be your legacy to Europe's young people** and your contribution to reducing death and disease from chronic diseases such as cancer, heart attacks, respiratory illness and diabetes.

We also urge you to make sure that **flavours that make cigarettes more attractive and palatable are not allowed** and that the so-called "**slim**" **cigarettes are no-longer on the market** to seduce young girls, in particular.

Also, we call on you to vote for amendments that **include standard packs and the strengthening of traceability and security features for combating illicit trade**.

The public health community in your country and in the whole of Europe counts on your support and look forward to your vote for a Tobacco Products Directive that places the health of European citizens above the interests of the tobacco industry.

Yours sincerely,

Natércia Miranda

Public Health Specialist
National Health Institute of Portugal

----- Fim de mensagem reenviada -----

STAES Bart OFFICE

From: Ana Figueiredo <amrfigueiredo@gmail.com>
Sent: 08 July 2013 20:08
To: KACZMAREK Filip; 'karin.kadenbach@europarl.europa.eu'; KALINOWSKI Jarosław; KORHOLA Eija-Riitta; KOUMOUTSAKOS Georgios; KOZLIK Sergej; LEINEN Jo; KRAHMER Holger; LEPAGE Corinne; LIESE Peter; LIOTARD Kartika Tamara; LYUBCHEVA Marusya; MANDERS Toine; MASTALKA Jiri; MAZEJ KUKOVI Zofija; MCAVAN Linda; McGUINNESS Mairead; MERKIES Judith A.; MIKOLASIK Miroslav; MIZZI Marlene; MORK NAIT -MIKUL NIEN Radvil ; NICHOLSON James; NUTTALL Paul; 'eva.ortizvilella@europarl.europa.eu'; OUZKY Miroslav; rikka.pakarinen@europarl.europa.eu; PALECKIS Justas Vincas; PANAYOTOV Vladko Todorov; PARGNEAUX Gilles; PARVANOVA Antonyia; PAULSEN Marit; PERELLO RODRIGUEZ Andres; PETERLE Alojz; PIRILLO Mario; POC Pavel; PRODI Vittorio; REIMERS Britta; RIES Frédérique; RIVASI Michèle; RIVELLINI Crescenzo; ROSBACH Anna; ROSSI Oreste; ROTH-BEHRENDT Dagmar; ŠADURSKIS K rlis; SARBU Daciana Octavia; SCHALDEMOSE Christel; SCHLYTER Carl; SCHNELLHARDT Horst; SCHNIEBER-JASTRAM Birgit; SCOTTA' Giancarlo; SEEBER Richard; SKYLAKAKIS Theodoros; 'renate.sommer@europarl.europa.eu'; 'boguslaw.sonik@europarl.europa.eu'; SOPHOCLEOUS Sophocles; SOUSA Alda; STADLER Ewald; STAES Bart; STEVENSON Struan; TABAJDI Csaba; T N SESCO Claudiu Ciprian; TATARELLA Salvatore; TAYLOR Rebecca; THEOCHAROUS Eleni; THYSSEN Marianne; ULMER Thomas; ULVSKOG Marita; URUTCHEV Vladimir Andreev; VAN BREMPT Kathleen; WEISGERBER Anja; WESTLUND Asa; WILLMOTT Glenis; WILS Sabine; YANNAKOUDAKIS Marina; ZABORSKA Anna; ZANONI Andrea
Subject: URGENT-ENVI vote on the Tobacco products Directive on 10 July

Dear Member of the Committee on the Environment, Public Health and Food Safety

RE: ENVI vote on the Tobacco products Directive on 10 July

Ahead of the Wednesday 10 July vote on the draft report on the Tobacco Products Directive, we are contacting you as representatives of the health community in your country.

We are extremely concerned about the opinions that have emanated from other European Parliament Committees. We are aware that your colleagues in most of these Committees do not have people's health as their first priority. But as a member of the ENVI Committee, your priority is the health of all citizens of the EU.

We are calling on your support for a strong Tobacco Products Directive.

In particular, we call on two crucial votes from you:

- Please [vote in favour of compromise amendment 39](#) which maintains the size of **75% of the front and the back of the pack**.
- Please [vote against compromise amendment 38](#) which reduces the size of warnings to **65% of the front and the back of the pack**.

Why?

- 70% of smokers start before the age of 18 and 94% before the age of 25 years.
- Pictorial warnings of 75% or more are not just proven to be more **effective in reducing the attractiveness of tobacco products to children and young people**; they are also in force in several countries around the world where significant reductions in youth smoking were registered after their introduction.
- Pictorial warnings covering 75% of the front and the back of the pack **have NOT been legally challenged anywhere in the world**.
- **75% of all European citizens are in favour** of this measure

The Tobacco Products Directive is one of the **last major pieces of EU regulation that will be adopted before next year's elections** to the European Parliament. The directive has the potential to stop young people from taking up the deadly habit of smoking, with its devastating effects that we witness in our everyday work. That is why **your vote on this crucial piece of legislation will be your legacy to Europe's young people** and your contribution to reducing death and disease from chronic diseases such as cancer, heart attacks, respiratory illness and diabetes.

We also urge you to make sure that **flavours that make cigarettes more attractive and palatable are not allowed** and that the so-called “**slim**” **cigarettes are no-longer on the market** to seduce young girls, in particular.

Also, we call on you to vote for amendments that **include standard packs and the strengthening of traceability and security features for combating illicit trade.**

The attached document provides a more comprehensive list of the amendments and compromise amendments which we consider as the most important.

The public health community in your country and in the whole of Europe counts on your support and look forward to your vote for a Tobacco Products Directive that places the health of European citizens above the interests of the tobacco industry.

Yours sincerely,

Ana Figueiredo, Pneumologist

Centro Hospitalar e Universitário de Coimbra, Portugal

President of the Tobacco Eviction Committee of the Portuguese Pneumology Society

STAES Bart OFFICE

From: Annie Van Praet <ADB@vbo-feb.be> on behalf of Olivier Joris <OJ@vbo-feb.be>
Sent: 08 July 2013 16:42
To: STAES Bart
Cc: Mail_Europa
Subject: Herziening van de richtlijn voor tabaksproducten (2001/37/CE)
Attachments: Olivier Joris.vcf; Lettre à Mme A. Delvaux 08 07 2013.pdf; Lettre à Mme F. Ries 08 07 2013.pdf

Importance: High

Mijnheer de Volksvertegenwoordiger,
Geachte heer Staes,

Als bijlage sturen wij u de brief die onze Bestuurder-Secretaris-generaal, dhr. Philippe Lambrecht, aan mevrouw Delvaux en mevrouw Ries, effectieve leden van de ENVI-Commissie, heeft gestuurd met het oog op de stemming tijdens de vergadering van de ENVI-Commissie op 10 en 11 juli 2013, over de herziening van de richtlijn voor tabaksproducten.

Wij danken u alvast voor de aandacht die u aan dit schrijven zult willen besteden.

Met de meeste hoogachting,

Olivier Joris



Rue Ravensteinstraat 4
1000 BRUXELLES/BRUSSEL
T + 32 2 515 08 11
www.vbo-feb.be

Olivier Joris
Responsable Département Européen
Hoofd Europees Departement

oj@vbo-feb.be
T + 32 (0)2 515 08 34
GSM + 32 (0)477 55 64 08



REINVENT
YOUR BUSINESS

VBO FORUM FEB
17/09/2013 THE EGG/BXL
WWW.REINVENTYOURBUSINESS.BE



VBO FEB
Verband van Belgische Ondernemingen
Fédération des Entreprises de Belgique

STAES Bart OFFICE

From: Amandine Labé <amandine.labe@magazinemedia.eu>
Sent: 08 July 2013 16:11
To: Max Abendroth
Subject: Vote in ENVI on the report of Mrs McAvan on the Tobacco Products Directive: magazine publishers' concerns

Dear MEP of the ENVI committee,

We are contacting you as EMMA, the European Magazine Media Association, ahead of the vote from 10 July on the draft report of MEP Linda McAvan on the proposal for a directive on the approximation of the laws, regulations and administrative provisions of the Member States concerning the manufacture, presentation and sale of tobacco and related products (COM(2012)0788).

In this regard we would like to express some concerns related to possible unwanted side-effects of the proposal to financing and distributing a free, independent, diverse and vibrant press in Europe.

1. **1. Impact of strict labelling requirements on the financing of the press**

EMMA is concerned by the possible indirect economic impact on the magazine industry value chain of limitations to freedom of commercial speech foreseen in the review of the Directive.

Advertising plays a key role in financing magazines. Nowadays revenues from advertising represent about 50% of the income of printed magazines and even up to 100% of the income of online magazines.

The introduction of very big health warnings or even worse plain packaging would make it very difficult to advertise the tobacco product. In some Member States, like Belgium and Germany, trade journals are still allowed to carry advertising for tobacco products. These specialised B2B titles are not intended to be sold to consumers. They are for instance magazines targeted at tobacco retailers, so it is logical that they can continue carrying information and advertising relevant to their readers' business.

Plain packaging and extended graphic health warnings would leave no adequate room for differentiation and recognition of different products so that even a minimal economic competition at the point of sale is made largely unfeasible. Indirectly, at the same time any advertising would be made practically inconceivable, since the recognition of the advertised products based on its packaging and its brand is one of the essential preconditions of any advertising.

If advertisers had to show a product that has to be linked with negative information – like for example a graphic health warning – they will most likely abstain from placing advertisements in magazines and rely on other channels to market their products. For some B2B titles sent for free to press and tobacco retailers and relying only on advertising revenues to survive, this would automatically lead to closedowns. For other titles, this would lead to major financial difficulties and potential redundancies.

2. **2. Delegated acts**

As many MEPs expressed it in amendments, EMMA is concerned by the high number of delegated acts that the Commission proposes. We are of the view that this very important topic for EU consumers should go through the co-decision procedure to enable the European Parliament to have a say on the matter.

3. **3. Impact of some amendments on magazines' distribution**

The introduction of specific requirements for the presentation of tobacco products at retailers' shops and kiosks could be extremely detrimental to press diversity.

Many retailers of tobacco products, like specialized retailers, kiosks and neighboring stores, sell alongside tobacco products also magazines and are indispensable press distribution channels. Further requirements regarding the presentation of tobacco products, like for example a ban on displaying tobacco products in the sales room, would necessitate in many cases significant changes to the design and arrangement of the retail outlet.

The rearrangement of sales rooms and retailers' outlets and the difficulties to provide a broad range of products would imply an unsustainable economic burden to retailers, especially to the detriment of the smaller ones. This could mean the closedown of these shops and as a consequence, a limited availability of press products for EU citizens across the countries.

For the reasons mentioned above, EMMA asks for a careful consideration of all the unwanted side-effects that the review of the Tobacco Products Directive could provoke on other economic sectors and the magazine sector in particular.

We thank you for your time and consideration.

Yours sincerely,

Max von Abendroth

Amandine Labé

EMMA Executive Director

EMMA EU Affairs Officer

max.abendroth@magazinemedi.eu

amandine.labe@magazinemedi.eu

+32 2 536 06 04

+32 2 536 06 08

EMMA, the European Magazine Media Association, is the representative trade association of European magazine publishers providing content on all platforms. In total, we represent the interests of 15,000 publishing companies across Europe, producing more than 50,000 titles per year across a variety of platforms, including print, web, tablet and mobile.

STAES Bart OFFICE

From: Catherine Hartmann <catherine.hartmann@copdcoalition.eu>
Sent: 08 July 2013 14:51
To: ANDERSON Martina; ANTONESCU Elena Oana; ARIAS ECHEVERRIA Pablo; ARSENIS Kriton; AUCONIE Sophie; AUKEN Margrete; AYALA SENDER Inés; AYUSO Pilar; BĀNKI Erik; BARTOLOZZI Paolo; BÉLIER Sandrine; BERLATO Sergio; BLOOM Godfrey; BOKROS Lajos; BONANINI Franco; BORSELLINO Rita; CABRNOCH Milan; CALLANAN Martin; CHILDERS Nessa; CHRYSOGELOS Nikos; CLIVETI Minodora; COCHET Yves; CYMA SKI Tadeusz; chris@chrisdaviesmep.org.uk; DE LANGE Esther; DE VEYRAC Christine; DE VILLIERS Philippe; DELVAUX Anne; DEMESMAEKER Mark; EICKHOUT Bas; ESTRELA Edite; EVANS Jill; FERNANDES José Manuel; FERREIRA João; FJELLNER Christofer; FLORENZ Karl-Heinz; FORD Victoria Grace; FOSTER Jacqueline; FRANCO Gaston; GARCÍA-HIERRO CARABALLO Dolores; GARDINI Elisabetta; GERBRANDY Gerben-Jan; GIEREK Adam; GIRLING Julie; GRIFFIN Nick; GROOTE Matthias; GROSSETETE Francoise; GUTIERREZ-CORTINES Cristina; HARMS Rebecca; HASSI Satu; HAUG Jutta; HERRANZ GARCIA Esther; HIBNER Jolanta Emilia; IVAN C t lin-Sorin; JORDAN Romana; JØRGENSEN Dan; JUVIN Philippe; KACZMAREK Filip; KADENBACH Karin; KALINOWSKI Jarosław; KORHOLA Eija-Riitta; KOUMOUTSAKOS Georgios; KOZLIK Sergej; KRAHMER Holger; LEINEN Jo; LEPAGE Corinne; LIESE Peter; LIOTARD Kartika Tamara; LYUBCHEVA Marusya; MANDERS Toine; MASTALKA Jiri; MAZEJ KUKOVI Zofija; MCAVAN Linda; McGUINNESS Mairead; MERKIES Judith A.; MIKOLASIK Miroslav; MIZZI Marlene; MORK NAIT - MIKUL NIEN Radvil ; NICHOLSON James; NUTTALL Paul; ORTIZ VILELLA Eva; OUZKY Miroslav; rikka.pakarinen@europarl.europa.eu; PALECKIS Justas Vincas; PANAYOTOV Vladko Todorov; PARGNEAUX Gilles; PARVANOV Antonia; PAULSEN Marit; PERELLO RODRIGUEZ Andres; PETERLE Alojz; PIRILLO Mario; POC Pavel; PRODI Vittorio; REIMERS Britta; RIES Frédérique; RIVASI Michèle; RIVELLINI Crescenzo; ROSBACH Anna; ROSSI Oreste; ROTH-BEHRENDT Dagmar; ŠADURSKIS K rlis; SARBU Daciana Octavia; SCHALDEMOSE Christel; SCHLYTER Carl; SCHNELLHARDT Horst; SCHNIEBER-JASTRAM Birgit; SCOTTA' Giancarlo; SEEBER Richard; SKYLAKAKIS Theodoros; SOMMER Renate; SONIK Boguslaw; SOPHOCLEOUS Sophocles; SOUSA Alda; STADLER Ewald; STAES Bart; STEVENSON Struan; TABAJDI Csaba; T N SESCO Claudiu Ciprian; TATARELLA Salvatore; TAYLOR Rebecca; THEOCHAROUS Eleni; THYSSEN Marianne; ULMER Thomas; ULVSKOG Marita; URUTCHEV Vladimir Andreev; VAN BREMPT Kathleen; WEISGERBER Anja; WESTLUND Asa; WILLMOTT Glenis; WILS Sabine; YANNAKOUDAKIS Marina; ZABORSKA Anna; ZANONI Andrea

Cc: STIHLER Catherine
Subject: ENVI vote on the Tobacco products Directive on 10 July
Attachments: ENVI Voting Recommendations - final.pdf

Dear Member of the Committee on the Environment, Public Health and Food Safety

Ahead of the Wednesday 10 July vote on the draft report on the Tobacco Products Directive, we are contacting you as representatives of part of the health community.

We are extremely concerned about the opinions that have emanated from other European Parliament Committees. We are aware that your colleagues in most of these Committees do not have people's health as their first priority. But as a member of the ENVI Committee, your priority is the health of all citizens of the EU.

We are calling on your support for a strong Tobacco Products Directive.

In particular, we call on two crucial votes from you:

- Please **vote in favour of compromise amendment 39** which maintains the size of **75% of the front and the back of the pack**.
- Please **vote against compromise amendment 38** which reduces the size of warnings to **65% of the front and the back of the pack**.

Why?

- 70% of smokers start before the age of 18 and 94% before the age of 25 years.
- Pictorial warnings of 75% or more are not just proven to be more **effective in reducing the attractiveness of tobacco products to children and young people**; they are also in force in several countries around the world where significant reductions in youth smoking were registered after their introduction.
- Pictorial warnings covering 75% of the front and the back of the pack **have NOT been legally challenged anywhere in the world.**
- **75% of all European citizens are in favour** of this measure

The Tobacco Products Directive is one of the **last major pieces of EU regulation that will be adopted before next year's elections** to the European Parliament. The directive has the potential to stop young people from taking up the deadly habit of smoking, with its devastating effects that we witness in our everyday work. That is why **your vote on this crucial piece of legislation will be your legacy to Europe's young people** and your contribution to reducing death and disease from chronic diseases such as cancer, heart attacks, respiratory illness and diabetes.

We also urge you to make sure that **flavours that make cigarettes more attractive and palatable are not allowed** and that the so-called **"slim" cigarettes are no-longer on the market** to seduce young girls, in particular.

Also, we call on you to vote for amendments that **include standard packs and the strengthening of traceability and security features for combating illicit trade.**

The attached document provides a more comprehensive list of the amendments and compromise amendments which we consider as the most important.

The public health community in your country and in the whole of Europe counts on your support and look forward to your vote for a Tobacco Products Directive that places the health of European citizens above the interests of the tobacco industry.

Yours sincerely,

PS: It has come to our attention that a number of arguments against the tobacco products are not backed up by the evidence. To that end we have put the link to a [leaflet](#) that distinguishes between facts and fiction.

Catherine Hartmann
 Secretary General
 European COPD Coalition (ECC)
 Rue de Trèves, 49-51, Box 13
 B-1040 Brussels, Belgium
 catherine.hartmann@copdcoalition.eu
www.copdcoalition.eu

Follow us on [Facebook](#)

Tel: +32 (0) 2 230 5933 and +32 (0)2 741.24.75

Show your support to our Call to Action by signing it: http://www.copdcoalition.eu/what_we_do/call-to-action

COPD stands for Chronic Obstructive Pulmonary Disease. COPD is a long-term lung and airways disease that is not curable. COPD causes wheezing, shortness of breath, chest tightness, and other symptoms. It also creates damages in the tiny air sacs at the tips of the airways. This makes it hard to move air in and out of the lungs. COPD is a chronic disease that includes chronic bronchitis and emphysema.

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this email in error please notify the system manager. Please notify the sender immediately by e-mail if you have received this e-mail by mistake and delete this e-mail from your system. If you are not the intended recipient you are notified that disclosing, copying, distributing or taking any action in reliance on the contents of this information is strictly prohibited.

STAES Bart OFFICE

From: Roberta Savli <roberta.savli@efanet.org>
Sent: 08 July 2013 13:19
Subject: EFA - ENVI vote on the tobacco products directive & perspective of patients with respiratory diseases
Attachments: TPD - voting recommendations from patients perspective.pdf

Dear Member of the ENVI Committee,

On the 10th of July, you will be voting on the draft report on the proposal for a directive of the European Parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the Member States concerning the manufacture, presentation and sale of tobacco and related products – [2012/0366\(COD\)](#) – *rapporteur* Mrs. McAvan MEP.

As a representative of patients with allergy, asthma and chronic obstructive pulmonary disease (COPD), we are very much concerned about tobacco use and marketing in Europe and the effects it has on citizens' health. Tobacco is a major source of nuisance and exacerbation for people with asthma, allergy and COPD. In particular, the World Health Organisation (WHO) estimates that tobacco smoke is the primary cause of **COPD** in developed countries. Lifelong smokers have a 50% probability of developing COPD during their lifetime; along the same line, there is also evidence that the risk of developing COPD falls by about half with smoking cessation. Research shows that smoking and exposure to second hand smoke is a major factor in provoking **allergic** responses by babies and young children. Smoking in **asthma** is associated with a higher degree of asthma severity, worsening of symptoms, increased hospital admissions, accelerated decline in lung function, limited short-term responses to medicines and poorer asthma control.

We welcomed the [Commission proposal](#) and the subsequent draft report of the *rapporteur* at the European Parliament as a unique opportunity for the European Union to strengthen its legislative environment with regard to tobacco products and for the EU and the Member States to fulfil their international obligations under the Framework Convention on Tobacco Control (FCTC). However, we would like to draw your attention to and ask for your support on a number of important amendments that would significantly strengthen the document.

Support public health concern

We are extremely concerned about the opinions that have emanated from other European Parliament Committees. As a member of the ENVI Committee, your priority is the health of all citizens of the EU. Tobacco is a proven carcinogen and its use has negative consequences especially for vulnerable groups, such as children and patients whose rights need to be protected.

Support compromise amendments 7, 10, 26, 29, 32, 41, 43, 56, 65 & amendments 75, 116, 10, 16

Support the introduction of plain standardised packaging

Packaging is the main marketing channel tobacco producers use to attract and retain users. Plain standardised packaging (harmonising the size and shape of tobacco packages, removing attractive colours and standardising the branding) is proven to reduce the appeal of tobacco to children and young people and to reinforce the health warning messages. Contrary to the tobacco industry claims, standardised packaging is compatible with EU and international law. It is easily implementable, does not cost any money to governments and works for public health.

Support compromise amendments 51, 61 & amendments 5, 154, 33, 35, 36

Support mandatory combined health warnings covering 75% of the front and back of tobacco products packages

Graphic warnings are more effective than text-only messages and increasing the size of these messages enhances the effectiveness of the warning. Moreover, pictorial warnings covering 75% of the front and the back of the pack **have NOT been legally challenged anywhere in the world.**

Support compromise amendments 34, 39

Reject compromise amendment 38, amendments 651-676, 685-718, 724-732, 733-754

Support the ban on flavourings

The tobacco industry uses certain flavourings in the manufacturing of tobacco products in order to make them more palatable, decrease the irritation they cause and increase their smoothness and attractiveness, as well as to create the misleading impression that they are less harmful.

Support compromise amendment 33

Support the ban on slim cigarettes

Slim cigarettes are misleading (the consumers of “slims” perceive them as less harmful than regular cigarettes) and directly marketed to young women.

Support compromise amendment 46

Support the ban on oral tobacco products

Snus like all tobacco products is addictive and presents hazards to health. While it is a traditional product in Sweden, the rest of Member States are not familiar with it, so we urge you to maintain the status quo on snus – allow it in Sweden but not introduce it on the EU market.

Support compromise amendment 54

Reject amendments 169, 170, 171, 249, 250

Support the strengthening of the traceability and security features of tobacco packs

Illicit trade is a considerable burden in terms of tax loss and the availability of cheaper tobacco products that evade tax and duties. Traceability and identification features of tobacco packs are ones of the most effective measures Member States can use to tackle this problem.

Support compromise amendments 11, 52

Support the ban on online sales of tobacco products

The ban on online sale and free distribution of products will protect EU consumers (children and young people in particular) from the consequences of easily accessible, harmful products.

Support compromise amendments 14, 25, 55 & amendments 63, 9, 603, 1109

Support the regulation of e-cigarettes

Over the last few years an array of new nicotine containing products has been developed. These products should be seen as the other nicotine replacement treatments and need to be properly regulated for ensuring appropriate safeguards in terms of quality, safety and efficacy.

Support compromise amendment 15 & amendments 296, 1250

For all references and additional information, please check EFA’s position paper available on our website at: <http://www.efanet.org/wp-content/uploads/2013/06/EFA-position-on-TPD.pdf>.

We urge you to take the above-mentioned concerns into account for your vote in July. We thank you in advance for your availability and support.

Yours sincerely,

Breda Flood
EFA President

STAES Bart OFFICE

From: ACG <admin@a-cg.com>
Sent: 08 July 2013 12:43
To: ACG
Subject: 'TOBACCO PRODUCTS DIRECTIVE - VOTE AGAINST EXTREME MEASURES ON 10 JULY!
Attachments: 13-07-08 TPD_ACG_ENVI.pdf



The Anti-Counterfeiting Group - ACG - is a not for profit trade association founded in the UK in 1980. It campaigns against the trade in fakes on behalf of consumers and legitimate business interests, in partnership with government and law enforcement agencies, and other rights organisations. Our ultimate aim is to change society's perception of counterfeiting as a harmless activity, by exposing the worldwide economic and social cost of intellectual property crime. www.a-cg.org

We write to you on behalf of our members, who make practically every kind of product you can think of, and are under constant attack from the serious organised criminals who counterfeit their goods on a global scale.

The EU Commission's **Proposal for a revised Tobacco Products Directive** ('the TPD') potentially affects all our members, especially if the practice of trying to legislate against IP rights in order to address unrelated health issues continues to gather momentum. If it succeeds, other health-sensitive products, such as foodstuffs, will also become targets for such attempts - for example, alcoholic drinks are already in the frame for packaging changes in the UK.

We wish to make the following points ahead of the ENVI Committee's vote on 10 July. Given our remit, we are not in a position to engage in the debate about e-cigarettes and vaporisers, and will confine our comments to issues of immediate relevance to our members' interests.

Smoking is a threat to public health not because of too much branding, or insufficient health warnings, nor because the packaging is too attractive or certain types of cigarette could be regarded as undesirable (menthol or slims, for example, which the TPD seeks to ban).

It is an addiction which needs concerted investment (a) in education to discourage young people from take-up and (b) in providing proper support for existing smokers to quit. We fully support any initiative with these objectives.

But more regulation is not the answer, as evidenced by the limited effect of existing legislation on the smoking problem. Tobacco is already one of the most heavily regulated markets, but counterfeiting of tobacco products, and their consumption, has continued to rise and will be further fuelled by the TPD (18% of the fake goods seized by EU Customs in 2011 were cigarettes^[1]).

The implications of an increase are serious, while there is no hard evidence to justify the impact on industry and the increased threats posed by the illicit tobacco trade.

As the EU's 2020 Strategy underlines^[2], the protection of IP rights is a cornerstone of the EU economy and a key driver for its further growth in areas such as research, innovation and employment. Effective IPR enforcement is also essential for health and safety, as counterfeit products can pose a serious threat to citizens.

EVIDENCE

There is no reliable and objective evidence:

(a) to suggest that the risks, and effects on legitimate rights, can be balanced by an equivalent impact on smoking;

(B) to support the claim that packaging plays any part in the decision to start or continue to smoke.

But there is, for example, a significant body of independent and peer-reviewed research into what causes young people to start smoking. Peer pressure, parental influence, social and cultural norms, price and access are all identified as causal factors, but packaging and product shape are never cited (see for example the UK's NHS study *Smoking, Drinking and Drug Use Among Young People in England - 2010* <http://www.ic.nhs.uk/pubs/sdd10fullreport>).

- health warnings have already achieved their aim - numerous court decisions have found that awareness of the health risks of smoking in the EU is universally high
- studies supporting more regulation confuse the decision to smoke with the decision for smokers which brand to choose

In particular, we ask the Committee to recognise that **the TPD is based on unfounded and outdated notions of smoking behaviour** (that packaging influences take-up and prevalence) and that:

- it is not based on any reliable evidence that its measures will reduce smoking
- it will fail to achieve the goal of reducing smoking because it will not address the real issues behind the health problem
- it will undermine the very health objectives it claims to be serving, leading to cheaper legitimate product and more illicit product becoming more available e.g. to the youth market
- it will cause serious damage to free and fair competition and innovation, limit consumer choice and lead to down-trading
- it is also constitutionally flawed and infringes fundamental rights

RISKS

The illegal trade in tobacco products is already an extremely serious problem in Europe, resulting in tax losses of around €10 billion annually, providing organised crime with huge profits, and accounting for over one in ten cigarettes smoked in the EU.

The TPD risks **further increasing this illicit trade** by:

- banning packaging that counterfeiters currently find difficult to copy (such as bevel edge packs or slide packs)
- banning whole categories of products that are currently used by millions of consumers
- allowing Member States to introduce their own plain packaging legislation
- creating a new demand for fake products in the 'original' packaging

These measures will provide new opportunities for criminals to satisfy consumer demand with smuggled and/or counterfeit product.

THE CONSEQUENCES of increased illicit consumption include:

- reduced tax and VAT revenue from the lawful sale of tobacco products
- increased health risks from fake cigarettes
- insufficient resources to tackle the growth in illicit trade
- making illicit tobacco products more widely available outside regulated channels, at prices far below that of legal product, and e.g. more accessible to minors

TRACK AND TRACE proposals will not address the problem

There has been no cost-benefit analysis done on the traceability and security features of the TPD, which extends the scope of these requirements to the entire supply chain (except retail):

- covert security features do not prevent counterfeiting of the pack and visible markings
- implementation costs will be exorbitant
- enforcement will be very difficult
- the TPD's target is only the intra-EU illicit trade (one third of the problem)
- the other two-thirds which are smuggled into the EU and sold through illicit channels will not be impacted
- all track and trace provisions should be aligned with the EU's international law obligations and international protocols

In conclusion, we call on the ENVI Committee members **to vote against extreme measures** such as those introducing **plain packaging**, excessively large **health warning labels** on packaging, **banning** of **menthol** and **slim** cigarettes, and **arbitrary prohibition of trade marks and branding** as proposed in Article 12.

If adopted, these measures would:

- undermine the legal protection for IP and other fundamental rights
- interfere to an excessive extent with legitimate trade
- increase the threat to public health from counterfeiting
- further fund organised crime

Your vote will protect the safety of our citizens and the principles of free trade which are so important for EU industry, and our future growth.

Yours sincerely



Ruth Orchard
Director-General, ACG
E: ruth.orchard@a-cg.com
T: 01494 449165

[1] http://ec.europa.eu/taxation_customs/customs/customs_controls/counterfeit_piracy/statistics/index_en.htm

[2] http://ec.europa.eu/europe2020/index_en.htm

STAES Bart OFFICE

From: emmanuelle beguinot <emmanuelle.beguino@wanadoo.fr>
Sent: 08 July 2013 11:45
To: STAES Bart; STEVENSON Struan; TABAJDI Csaba; T N SESCO Claudiu Ciprian; TATARELLA Salvatore; TAYLOR Rebecca; THEOCHAROUS Eleni; THYSSEN Marianne; ULMER Thomas; ULVSKOG Marita
Cc: MARTINET Yves
Subject: ENVI vote on the Tobacco products Directive on 10 July
Attachments: Courrier Commission Envi.pdf; Recommandations Vote Envi.pdf

Please find enclosed this letter from Pr Yves Martinet, President of the National Committee for Tobacco Control in France.



[Découvrez la nouvelle campagne du CNCT](#)

Suivez-nous sur [Facebook](#) et [Twitter](#) !

2013-07-08

STAES Bart OFFICE

From: Richard Hyslop <richard@endeavourpublicaffairs.co.uk>
Sent: 08 July 2013 10:05
To: "Undisclosed-Recipient;"@ham03.websitewelcome.com
Subject: Open letter from electronic cigarette users from across the European Union
Attachments: Open letter from electronic cigarette users from across the European Union.pdf

Dear ENVI committee member,

Please find below and attached an open letter from electronic cigarette users from across the European Union to Matthias Groote MEP, Chairman of the European Parliament's ENVI committee.

Open letter from electronic cigarette users from across the European Union

Monday 08 July 2013

Dear Mr Groote,

We are writing to you in your capacity as Chairman of the European Parliament's Environment, Public Health, and Food Safety Committee, as former tobacco smokers from across the EU who have quit or reduced smoking through the use of e-cigarettes.

For between five and seven million people throughout the EU, e-cigarettes have and continue to provide a viable alternative to smoking tobacco cigarettes. They have enabled them to leave smoking behind, either on a full or part-time basis. These people, like us, are now smoking far fewer or no cigarettes. Figures from the United States show that in one year alone, Altria, the company behind cigarette brands like Marlboro, saw a six and a half per cent decline in cigarette sales, directly attributed to a rise in the use of e-cigarettes. If e-cigarettes are allowed to continue to flourish, just imagine how many fewer cigarettes will be sold and lives saved as millions more people like us switch from smoking tobacco cigarettes to using e-cigarettes.

However, we are genuinely concerned that the positive story of e-cigarettes may be about to come to an abrupt halt.

As you will be aware, proposals to amend the Tobacco Products Directive state that e-cigarettes should only be placed on the market if they are authorised pursuant to Directive 2001/83/EC (the Medicinal Products Directive).

By regulating e-cigarettes as a medicinal product, and by banning flavours, the Commission and its supporters in Parliament and Council are effectively banning e-cigarettes, as the Parliament's own Legal Affairs Committee has made clear.

E-cigarettes are not a medicinal product and as users we do not see ourselves as ill or in treatment; we are not.

We are adults and the e-cigarettes that we use are regulated as a consumer product by at least 17 Directives at the EU level and by a variety of other legislation at the Member State level. They are safe, by contrast tobacco cigarettes kill 700,000 people each and every year and neither the Commission nor Parliament is proposing to ban them!

The key health benefit of e-cigarettes is determined by how many smokers switch to them or use them as a staging post to quitting completely. It is therefore vital that e-cigarettes continue to be regulated as a consumer product.

Many of us have tried numerous times to quit smoking using conventional nicotine replacement therapies and have failed, however with e-cigarettes we have all cut down our smoking or stopped completely.

Without anyone in the professional public health field doing anything and without spending any public money, smokers like us have been quitting, switching, and cutting down through the use of e-cigarettes. This is something that should be celebrated not a cause for concern.

E-cigarettes are however not some form of more effective nicotine replacement therapy, they are totally different. E-cigarettes deliver clean nicotine – without the tar, carbon monoxide, and volatile hot gases of cigarettes – and as a way of taking nicotine they are pretty near harmless to health. In short, for people like us who switch from cigarettes, they hugely reduce risk, while satisfying our need for nicotine and some of the behavioural aspects of smoking.

We believe that making the informed choice of switching from smoking tobacco cigarettes to using e-cigarettes has dramatically improved our health and our chances of living longer, healthier lives. With this in mind we would like to ask members of your committee this very simple question. Why would the EU want to intervene to prevent or obstruct a smoker having access to products that could potentially save his or her life? The reality is that every barrier placed in the way of e-cigarettes should be viewed in this light and with its consequences for health.

Do MEPs really want to protect an industry that kills 700,000 people at the expense of a market-based, consumer-led public health revolution that has the potential to save millions of lives?

E-cigarettes have the astonishing potential to disrupt the business model of the established tobacco industry. However, rather than encouraging this, these proposals subject them to disproportionate and discriminatory regulation by misclassifying them as medicines, thus increasing costs and compliance burdens, imposing restrictions, driving out innovation, and potentially destroying existing supply chains.

As users of e-cigarettes, we urge members of your committee to reject Article 18 of the Commission's proposal. We believe it is poorly thought through, contains an arbitrary and pointless threshold, takes an easy short cut by applying medicines regulation rather than designing appropriate regulation, and has been prepared without proper consultation of the industry and users like us.

Members of your committee should insist that the Commission starts again and does a thorough job, looking properly at all the regulatory options and only once it has done the necessary work, bring forward proposals. In the meantime, Member States should enforce the existing legislation properly and report on what they are doing.

For the sake of seven million e-cigarette users and the millions of potential e-cigarette users we urge you to do the right thing.

Yours sincerely

Peter Abbott
United Kingdom

Julie Abbott
United Kingdom

Rianne Abul
United Kingdom

Lorraine Adams

United Kingdom

Mike Adkins

United Kingdom

Tiemo Aigner

Germany

Neil Akrigg

United Kingdom

Justin Aldis

United Kingdom

Andre Alfter

Germany

Grahame Almond

United Kingdom

Georgine Alt

Germany

Jane Altham

United Kingdom

Matt Anderson

United Kingdom

Nicholas Anderton

United Kingdom

Angkana Angkinantana

France

David Anscomb

United Kingdom

Nilo Aquino

United Kingdom

Paul Arden-Taylor

United Kingdom

Darren Armitage

United Kingdom

Craig Arnall

United Kingdom

Nadja Arnautovic

Germany

John Arundel
United Kingdom

Chris Ashman
United Kingdom

Chris Ashley
United Kingdom

Michael Ashton
United Kingdom

Lene Askøe Andersen
Denmark

Muhammad Aslam
United Kingdom

Tony Atkinson
United Kingdom

Kim Bailey
United Kingdom

Linda Bailey
United Kingdom

Colin Baines
United Kingdom

Chris Baird
United Kingdom

Andrew Baldwin
United Kingdom

Ellie Baldwin
United Kingdom

Kirsty Balicao
United Kingdom

Michael Balicao
United Kingdom

Ester Balinger
United Kingdom

Karen Ball
United Kingdom

Roger Ball
United Kingdom

Andrew Bamford
United Kingdom

Robert Bancroft
United Kingdom

Bob Barkany
United Kingdom

Aileen Barnard
United Kingdom

John Barnard
United Kingdom

Anne Barnes
United Kingdom

Campbell Barr
United Kingdom

Anne Barrie
United Kingdom

Victoria Barrow
United Kingdom

Michael Barton
United Kingdom

Karl Bartoni
United Kingdom

Robert Batchelor
United Kingdom

Martyn Bates
United Kingdom

Michael Bates
United Kingdom

Sandra Bates
United Kingdom

Robert Bateson
United Kingdom

Imogen Baxter
United Kingdom

Richard Beaman
United Kingdom

Andrew Beardsworth
United Kingdom

John Beck
United Kingdom

Michael Becker
Germany

Stephen Beckett
United Kingdom

Paul Behan
United Kingdom

Hans Peter Behlen
Germany

Peter Behlen
Germany

Stephan Belcaid
Germany

Stephan Belcaid
Germany

Angus Bell
United Kingdom

Ian Bell
United Kingdom

Jason Bell
United Kingdom

David Benson
United Kingdom

Aaron Bentley
United Kingdom

Martin Bennett
United Kingdom

Steven Bennett
Belgium

Richard Berhall
United Kingdom

Denise Best
United Kingdom

Ian Bill

United Kingdom

James Bird

United Kingdom

Johanna Birkenseher

Germany

Christina Bishop

United Kingdom

E Biss

United Kingdom

Tamara Black

United Kingdom

Doris Blades

United Kingdom

Les Blades

United Kingdom

Andrew Blake

United Kingdom

Theresa Blakemore

United Kingdom

Pauline Bland

United Kingdom

Chris Blee

United Kingdom

Felix Bloedorn

Germany

William Bloomer

United Kingdom

Shay Boast

United Kingdom

Sebastian Bock

Germany

Elke Bollin

Germany

Daniel Bond

United Kingdom

Luciano Boni

Italy

Derek Booth

United Kingdom

Stephen Bostock

United Kingdom

Frans Boudewijns

Netherlands

Jonathan Bowen

United Kingdom

Joanna Bower

United Kingdom

David Bowie

United Kingdom

Helene Bowman-Brown

United Kingdom

Wes Boyes

United Kingdom

Mark Bradley

United Kingdom

Ian Bray

United Kingdom

Andreas Breuer

Germany

Benjamin Brewis

United Kingdom

V G Brewis

United Kingdom

Rachael Bridgman

United Kingdom

Vincent Brindle

United Kingdom

Thomas Brinkmann

Germany

Paul Broadie

United Kingdom

Martin Broderick
United Kingdom

Daniela Bröhl
Germany

Martin Brooksbank
United Kingdom

Daniel Brosch
Germany

Alexander Brown
United Kingdom

Ann Brown
United Kingdom

David Brown
United Kingdom

David Brown
United Kingdom

Kelly Brown
United Kingdom

Michael Brown
United Kingdom

Sally Brown
United Kingdom

Wayne Brown
United Kingdom

Gary Bryan
United Kingdom

Liam Bryan
United Kingdom

Edna Bullen
United Kingdom

Sian Burdge
United Kingdom

Benjamin Burger
Germany

Alex Burke
United Kingdom

Candice Burke
United Kingdom

Stevena Burke
United Kingdom

Sheridin Burn
United Kingdom

Heidi Burnett
United Kingdom

Martin Burnett
United Kingdom

Raymond Burns
United Kingdom

John Burr
United Kingdom

Jonathan Burt
United Kingdom

Chris Butler
United Kingdom

Leigh Buxton
United Kingdom

Jane Byfield
United Kingdom

Jeffrey Caldicott
United Kingdom

Anthony Callon
United Kingdom

Salvatore Calvano
Germany

Sue Campbell
United Kingdom

Paul Canham
United Kingdom

Gabriela Cantemir
United Kingdom

Quinn Capes-Ivy
United Kingdom

Peter Carl
United Kingdom

Kelly Carpenter
United Kingdom

Peter Carter
United Kingdom

Julie Carritt
United Kingdom

Jason Carter
United Kingdom

Jessica Carter
United Kingdom

Michael Carter
United Kingdom

Jo Caryl
United Kingdom

John Cellario
United Kingdom

Ken Chaddock
United Kingdom

Diane Challoner
United Kingdom

Kelly Challoner
United Kingdom

Ray Challoner
United Kingdom

Lee Chambers
United Kingdom

Scott Chambers
United Kingdom

Julian Chandenier
United Kingdom

Alan Chapman
United Kingdom

Alan Chapman
United Kingdom

Ian Charnock
United Kingdom

Paul Checkley
United Kingdom

Michelle Chenery
United Kingdom

Alison Chesters
United Kingdom

Deb Chesters
United Kingdom

Alan Chettle
United Kingdom

Denise Chettle
United Kingdom

Claudia Christie
United Kingdom

Steven Chowns
United Kingdom

Paul Clacher
United Kingdom

Claire Clark
United Kingdom

Ralph Clark
United Kingdom

Sharon Clark
United Kingdom

Alex Clarke
United Kingdom

Christopher Clarke
United Kingdom

James Clarke
United Kingdom

Joe Clarke
United Kingdom

Lolli Clarke
United Kingdom

Peter Clarke
United Kingdom

Ray Clarke
United Kingdom

Anthony Claxton
United Kingdom

Victoria Clegg
United Kingdom

Theresa Clemence
United Kingdom

Veronica Clemence
United Kingdom

Stuart Clements
United Kingdom

Kurt Clemmesen
Germany

Kurt Clemmesen
Germany

Brandon Clubb
Belgium

Jeffrey Coles
United Kingdom

Jeff Coles
United Kingdom

Stephen Coles
United Kingdom

Lee Colgate
United Kingdom

Richard Collins
United Kingdom

Malcolm Cook
United Kingdom

Susan Cook
United Kingdom

Alan Cooper
United Kingdom

Joe Cooper
United Kingdom

S Cooper
United Kingdom

Patrick Congdon
United Kingdom

Teresa Copley
United Kingdom

Anson Cording
Ireland

Jeff Costello
Ireland

Michelle Coulson
United Kingdom

Andy Coulton
United Kingdom

Sara Coulton
United Kingdom

Mark Couperthwaite
United Kingdom

Philip Court
United Kingdom

Simon Cox
United Kingdom

Stephen Crank
United Kingdom

Jane Craske
United Kingdom

Joanne Cross
United Kingdom

Stuart Cross
United Kingdom

Alex Crow
United Kingdom

Michael Crowley
Ireland

Paul Crowley
United Kingdom

Claudia Cunha
United Kingdom

Stephanie Curley
United Kingdom

Valerie Curtis
United Kingdom

Alan Cuzen
United Kingdom

Helle Dahl Nygaard
Denmark

Richard Dalby
United Kingdom

Graham Daly
United Kingdom

Paul Damsell
United Kingdom

Anja Daniel
Germany

Anne-Marie Daniel
United Kingdom

M Darbyshire
United Kingdom

Tina Darrock
United Kingdom

Darren Davidson
United Kingdom

Richard Davidson
United Kingdom

Stewart Davidson
United Kingdom

Adam Davies
United Kingdom

Adrian Davies
United Kingdom

Andrew Davies
United Kingdom

Steve Davies
United Kingdom

Laurence Davis
United Kingdom

Geraldine Dawes
United Kingdom

Paul Dawkins
United Kingdom

Andrew Dawson
United Kingdom

Kevin Dawson
United Kingdom

D Deadman
United Kingdom

Judith Dean
United Kingdom

Nick Dean
United Kingdom

Ian Dennis
United Kingdom

Simon Dennis
United Kingdom

Ash Denscombe
United Kingdom

Franziska Deufel
Germany

Karl Friedrich Deufel
Germany

Karsten Deufel
Germany

Waltraud Deufel
Germany

H Dewhurst
United Kingdom

Martin Diamond
United Kingdom

Paul Diamond
United Kingdom

Stefan Di Mascio
Germany

Jutta Dirr
Germany

Markus Dirschel
Germany

Launa Dodds
United Kingdom

Premgit Doherty
United Kingdom

Lynda Doig
United Kingdom

Christopher Donaghey
United Kingdom

Steff Donaghey
United Kingdom

Jacqueline Donaldson
United Kingdom

Steven Donegan
Spain

Olivia Dong
United Kingdom

Hans Dieter Dormoolen
Germany

David Dorn
United Kingdom

Peter Dornan
United Kingdom

Fiona Douthwaite
United Kingdom

Lee Dowding
United Kingdom

Naomi Dowding
United Kingdom

Mick Downes
United Kingdom

W Dragon
United Kingdom

Michelle Drakes
United Kingdom

Paul Driver
United Kingdom

Christoph Duda
Germany

Jason Duke
United Kingdom

Steven Duncan
United Kingdom

David Duncombe
United Kingdom

David Dunham
United Kingdom

Andy Dunn
United Kingdom

Mark Eccles
United Kingdom

Daniel Edwards
United Kingdom

Gary Edwards
United Kingdom

Gwyneth Edwards
United Kingdom

Therasa Edwards
United Kingdom

Claus Egebo Pedersen
Denmark

William Elmer
United Kingdom

Matt Ely
United Kingdom

Lorna Emmott
United Kingdom

Robert Emmott
United Kingdom

Matthias Endlich
Germany

Albert Engle
Spain

Johannes Engel
Germany

Lilia Engel
Germany

Charlie Enston
United Kingdom

Herbert Erl
Germany

Alwyn Evans
United Kingdom

John Evans
United Kingdom

Lloyd Evans
United Kingdom

Sandra Evans
United Kingdom

Steve Evans
United Kingdom

Christina Evison
United Kingdom

Robert Faint
United Kingdom

Victoria Fairman
United Kingdom

June Falconer
United Kingdom

Stuart Falconer
United Kingdom

John Farnworth
United Kingdom

Peter Farrell
United Kingdom

Andrew Fawcett
United Kingdom

Mark Fay
United Kingdom

Nigel Feetham
United Kingdom

Valentins Feldbergs
United Kingdom

Andreas Felsch
Germany

Claire Fenn
United Kingdom

Paul Fenton
United Kingdom

Patricia Fields
United Kingdom

Tony Fish
United Kingdom

Andrew Fisher
United Kingdom

Graham Fitz
United Kingdom

A Flavell
United Kingdom

A J Flavell
United Kingdom

Joseph Flavell
United Kingdom

Mark Fletcher
United Kingdom

Sue Fletton-Dean
United Kingdom

Dana Ford
United Kingdom

James Ford
United Kingdom

S J Foord
United Kingdom

Rob Forrest
United Kingdom

David Foster
United Kingdom

Ricky Foulkes
United Kingdom

Ian Fowler
United Kingdom

Barry Fox
United Kingdom

Rader Frank
Germany

Philip Freeman
United Kingdom

Emma French
United Kingdom

Dave Frost
United Kingdom

Mayko Fry
United Kingdom

Horst Fuchs
Germany

Michel Fuchs
Germany

Roswitha Fuchs
Germany

Paula Fuentes
United Kingdom

Harald Fürtges

Germany

Michael Gabbey

United Kingdom

Gary Gardiner

United Kingdom

Ena Gardner

United Kingdom

Julie Gardner

United Kingdom

S Gardner

United Kingdom

Andrew Garner

United Kingdom

Jane Garner

United Kingdom

Audrey Garrity

United Kingdom

Anne Garside

United Kingdom

Paul Gartside

United Kingdom

Alex Gasca

Spain

Marilyn Gaunt

United Kingdom

Marilyn Gaunt

United Kingdom

Christa Gawenat

Germany

Hamdalat Gbadamosi

United Kingdom

Manuela Georgi

Germany

Louise Gibbon

United Kingdom

Richard Gibbons
United Kingdom

Marek Gibki
United Kingdom

Wendy Gibson
United Kingdom

Neil Giddins
United Kingdom

Daniel Gille
Germany

François Gisselmann
Belgium

Alan Gledhill
United Kingdom

Sally Goddard
United Kingdom

Brett Godfrey
The Netherlands

Phil Goodsall
United Kingdom

Sandra Gottwald
Germany

Peter Graham
United Kingdom

Barry Grant
United Kingdom

Vicky Grant
United Kingdom

Wayne Graves
United Kingdom

James Gray
United Kingdom

Nicola Gray
United Kingdom

Andrew Green
United Kingdom

Boston Green
United Kingdom

Ray Green
United Kingdom

Nathan Gregory
United Kingdom

Kevan Gresham
United Kingdom

Nik Grey
United Kingdom

Tracey Grey
United Kingdom

Jackie Grimbaldeston
Spain

Matthias Grote
Germany

Christine Grunwald
Germany

Francisco Guimaraes
United Kingdom

Michael Haahr
Denmark

Kerstin Hackel
Germany

Justin Haddon
United Kingdom

Toni Hagen
Denmark

Lewis Haley
United Kingdom

Julian Hall
United Kingdom

Vicki Hall
United Kingdom

Adrian Hammonds
United Kingdom

Chaim Hanstater
United Kingdom

Ian Hardie
United Kingdom

Susan Hardie
United Kingdom

Liam Hardy
United Kingdom

Andy Hare
United Kingdom

Sonja Harfolk
Germany

Keith Harper
United Kingdom

Robert Harpham
United Kingdom

Heather Harris
United Kingdom

Pauline Harris
United Kingdom

Neil Harrison
United Kingdom

Darren Hartley
United Kingdom

Michael Hartung
United Kingdom

John Haskett
United Kingdom

John Hassall
United Kingdom

Stephen Hatcher
United Kingdom

Stephen Haude
United Kingdom

Daniel Haworth
United Kingdom

Mike Hayward
United Kingdom

Spencer Haywood
United Kingdom

Stephen Heater
United Kingdom

Cathy Heffernan
Ireland

Nicola Heise
United Kingdom

Glen Henderson
United Kingdom

Stacey Hennigan
United Kingdom

Brian Henson
United Kingdom

Gavin Hester
United Kingdom

Margaret Hester
United Kingdom

Gary Hickling
United Kingdom

Ivan Hiett
United Kingdom

Elfriede Hilker
Germany

Jürgen Hilker
Germany

Alex Hill
United Kingdom

Peter Hill
United Kingdom

Jacque Hindley
United Kingdom

Barbara Hinks
United Kingdom

Graham Hinson
United Kingdom

Danny Hinton
United Kingdom

Susan Hodges
United Kingdom

Ian Hodgkinson
United Kingdom

Alan Hodson
United Kingdom

Stig-ove Holand
Norway

Sue Holdaway
United Kingdom

Alison Holden
United Kingdom

Dawn Holden
United Kingdom

Tony Holden
United Kingdom

James Holder
United Kingdom

Paul Holford
United Kingdom

Craig Holmes
United Kingdom

Ian Holmes-Lewis
United Kingdom

Eric Holt
United Kingdom

Angelika Holzer-Brandl
Germany

Catherine Homann
United Kingdom

Catherine Homann
United Kingdom

Darryll Home
United Kingdom

Keith Hopkins
United Kingdom

Jo Hopkinson
Ireland

Brian Hopper
United Kingdom

Andy Horn
United Kingdom

Sven Horstmann
Germany

Carolyn Horton
United Kingdom

Mark Howard
United Kingdom

S Howarth
United Kingdom

Bonnie Howieson
United Kingdom

Peter Hoy
United Kingdom

Alan Hubbard
United Kingdom

William Hueston
United Kingdom

Lesley Hufnagel
United Kingdom

Adam Hughes
United Kingdom

Jim Hughes
United Kingdom

Shirley Hughes
United Kingdom

Nathan Hull
United Kingdom

Ross Humpage
United Kingdom

Andrew Humphries
United Kingdom

Daniel Hunt
United Kingdom

Craig Hunter
United Kingdom

Stephen Hunter
United Kingdom

Travis Hunter
United Kingdom

Christine Hutchings
United Kingdom

Matt Ibbs
United Kingdom

Anthony Iddon
United Kingdom

Alan Iliffe
United Kingdom

Cindy Innerhofer
Germany

Safak Isik
Germany

Paul Jackson
United Kingdom

William Jackson
United Kingdom

Danny Jacobsen
Denmark

Susanne Jähner
Germany

Sarah Jakes
United Kingdom

Terry James
United Kingdom

Richard Jameson
United Kingdom

Doris Janker
Germany

Roland Janker
Germany

Ruth Jay
United Kingdom

Oli Jeal
United Kingdom

Peter Jenkins
United Kingdom

Gwyneth Jennings
United Kingdom

Peter Jensen
Denmark

Robert Jepson
Isle of Man

Anthony Jobling
United Kingdom

Lorna Johns
United Kingdom

Adam Johnson
United Kingdom

James Johnson
United Kingdom

Michael Johnson
United Kingdom

Dr Paula Johnson
United Kingdom

Peter Johnson
United Kingdom

Stella Johnson
United Kingdom

Sharon Johnston
United Kingdom

Andy Jones
United Kingdom

Gary Jones
United Kingdom

Jane Jones
United Kingdom

Jenna Jones
United Kingdom

Melanie Jones
United Kingdom

Michelle Jones
United Kingdom

Richard Jones
United Kingdom

Robert Jones
United Kingdom

Russell Jones
United Kingdom

Sam Jones
United Kingdom

Jon Jørgensen
Denmark

Ulla Jørgensen
Denmark

Stephen Joyce
United Kingdom

Markus Kämmerer
Germany

Richard Keaskin
United Kingdom

Michael Keller
Germany

George Kell-Pearson
United Kingdom

Phill Kelso
United Kingdom

Alex Keogh
United Kingdom

Darren Kerle
United Kingdom

Adam Khan
United Kingdom

Adnan Khan
United Kingdom

Misbah Jamal Khan
United Kingdom

John C. Kibbles
United Kingdom

John Kibbles
United Kingdom

Gillian Kidd
United Kingdom

Sandra Kielty
United Kingdom

Dr Vincent Kielty
United Kingdom

Paul Kinahan
Ireland

Julie King
United Kingdom

Alan Kinsey
United Kingdom

Wendy Kinsey
United Kingdom

Jon Kitchen
United Kingdom

Manfred Klimek
Germany

Kim Knapik
United Kingdom

Katie Knight
United Kingdom

Sascha Kolb

Germany

Bernd Königs

Germany

Frank Köpke

Germany

Carsten Koschker

Germany

Petra Kowalik

Germany

Christian Kramhöller

Germany

Christopher Krauth

Germany

Elisabeth Krautler

United Kingdom

Marcus Kreidler

Germany

Mario Kreidler

Germany

Sabine Kreidler

Germany

Marion Krompholz

Germany

Susanne Kulkies

United Kingdom

Vadim Kunz

Germany

Valentin Kunz

Germany

Benjamin Kuska

Germany

Sandra Kuska

Germany

E Kutavicius

United Kingdom

Tony Kvedaras
United Kingdom

Paul Kynaston
United Kingdom

Nicholas Kyprianou
United Kingdom

Janet L
United Kingdom

Graham Lambden
United Kingdom

Andrew Landeg
United Kingdom

Anita Lane
United Kingdom

Dennis Lane
United Kingdom

Thomas Lang
Germany

Angie Langcaster
United Kingdom

Vanessa Langford
United Kingdom

Andrew Larwood
United Kingdom

Mark Latham
United Kingdom

Michael Latimer
United Kingdom

Dominic Laurelli
United Kingdom

Vanessa Law
United Kingdom

Don Lawrence
United Kingdom

Robin Lawrence
United Kingdom

Liz Lawrie

United Kingdom

Christopher Leak

United Kingdom

William Legge

United Kingdom

Ulrich Lehmann

Germany

Lori Leidig

Sweden

Jackie Leng

United Kingdom

Stefan Lerche

Germany

John Leverton

United Kingdom

Adam Lewis

United Kingdom

Simone Lewis

United Kingdom

Nigel Line

United Kingdom

A. J. Linfoot

United Kingdom

Ian Litchfield

United Kingdom

Lisa Little

United Kingdom

Rick Little

United Kingdom

John Lloyd

United Kingdom

Keith Lloyd

United Kingdom

Kerry Lloyd

United Kingdom

Kerry Lloyd
United Kingdom

John Lock
United Kingdom

Katrin Lockett
United Kingdom

Ian Long
United Kingdom

Samantha Louch
United Kingdom

Anna Lovatt
United Kingdom

James Lovell
United Kingdom

Gordon Lowe
United Kingdom

Michelle Luhr
United Kingdom

Roger Lumley
United Kingdom

Nadia Lungo
United Kingdom

Darren Lunn
United Kingdom

Cédric Lurienne
France

Philip Lynch
United Kingdom

Cathel MacKenzie
United Kingdom

Saul McArthur
United Kingdom

David McCallum
United Kingdom

Carl McConchie
United Kingdom

Joseph McCoy
United Kingdom

Jason McDonnell
United Kingdom

Kerin McEwing
United Kingdom

James McGregor
United Kingdom

Colin McGuire
United Kingdom

Alice McHugh
United Kingdom

Ian McHugh
United Kingdom

Catherine McHugh
United Kingdom

Cory McHugh
United Kingdom

Josh McKeown
United Kingdom

Andrew McKay
United Kingdom

Ross McLardy
United Kingdom

Rebecca McLaughlin
United Kingdom

Liam McLoughlin
United Kingdom

Jean Macdonald
United Kingdom

Jo Macdonald
United Kingdom

Kenny MacIver
United Kingdom

Helen Maguire
Ireland

James Maher
United Kingdom

Stephen Mainwaring
United Kingdom

Mohammad Makda
United Kingdom

Andy Makin
United Kingdom

Leigh Malin
United Kingdom

Natalie Ann Mallinson
United Kingdom

Mike Maloney
United Kingdom

Paul Manchester
United Kingdom

John Manley (Senior Healthcare Scientist)
United Kingdom

Steve Manley
United Kingdom

Tine Mann
Germany

Stephen Manning
United Kingdom

Tamas Margitai
United Kingdom

Nägele Markus
Germany

Kay Marmulla
Germany

Rob Marsh
United Kingdom

William Marshall
United Kingdom

Tim Martin
United Kingdom

Wendy Marshall
United Kingdom

Metodi Maslenkov
United Kingdom

J Mason
United Kingdom

Wayne Mathias
United Kingdom

Dieter Matschey
Germany

Alicia Mathurin-Greene
United Kingdom

Dieter Matschey
Germany

Sharon Maud
United Kingdom

Leon Mayer
United Kingdom

Lee Meadows
United Kingdom

Hulya Meddeb
Germany

Susanne Mehri
Germany

Malcolm Mercer
Ireland

Gemma Meyer
United Kingdom

Sandra Meyer
United Kingdom

Stephan Mikwauschk
Germany

Andreas Middecke
Germany

M Middleton
United Kingdom

Steffen Mietk
Germany

Mark Mildenhall
United Kingdom

G Miller
United Kingdom

Karin Milosavljevic
Germany

William Mitchell
United Kingdom

Trine Mogensen
Denmark

John Molloy
United Kingdom

James Mooney
United Kingdom

Andy Moore
United Kingdom

David Moore
United Kingdom

Emily Moore
United Kingdom

Michael Moore
United Kingdom

Ronald Moore
United Kingdom

Sarah Moore
United Kingdom

Lyn Morgan
United Kingdom

David Morl
United Kingdom

Stacy Morl
United Kingdom

Jason Morris
United Kingdom

Matt Morris
United Kingdom

Michael Morris
Ireland

Steven Morris
United Kingdom

Andy Morrison
United Kingdom

Paula Morrison
United Kingdom

Sue Morrison
United Kingdom

Paul Moss
United Kingdom

Thomas James Moulton
United Kingdom

Leslie Moxhay-Baker
United Kingdom

Nigel Moxon
United Kingdom

Scarlett Moylan
United Kingdom

Jacqui Muir
United Kingdom

Libby Mullen
United Kingdom

Alexander Müller
Germany

Norbert Müllers
Germany

Fred Mundell
United Kingdom

Conor Murphy
Ireland

Carlos Murray
United Kingdom

Isobel Murray
United Kingdom

Matthew Murray
United Kingdom

Ray Myburgh
United Kingdom

Robert Nailen
United Kingdom

Sam Nathaniel
United Kingdom

Daren Naylor
United Kingdom

Liz Naylor
United Kingdom

Andrea Neale
United Kingdom

Heinz Neffgen
Germany

Nils Neimke
Germany

Debra Newcombe
United Kingdom

Tim Newton-Clare
United Kingdom

Jens Nickel
Germany

Alan Nickson
United Kingdom

Martin Nielsen
Denmark

Jonathan Noble
United Kingdom

Karl Nørgaard
Denmark

Garry Norris
United Kingdom

Michael Norris
United Kingdom

Julie Novak
United Kingdom

Julie Novak
United Kingdom

Graham Nunn
United Kingdom

Niall O'Byrne
Ireland

Mark O'Donoghue
United Kingdom

Ryan O'flynn
United Kingdom

Stephen O'Neill
United Kingdom

Paul O'Shea
Ireland

Phillip Oldfield
United Kingdom

Jude Olds
United Kingdom

Vicky Orlik
United Kingdom

Diggory Orr-Ewing
United Kingdom

Jeff Owen
United Kingdom

Paul Owen
United Kingdom

Chris Paddon
United Kingdom

Nicholas Pagett
United Kingdom

Keith Palin
United Kingdom

Claire Parker
United Kingdom

Andrew Parton
United Kingdom

B Partridge
United Kingdom

Lorraine Paterson
United Kingdom

Chloe Patfield
United Kingdom

Elaine Patty
United Kingdom

Barry Peach
United Kingdom

Danny Peacock
United Kingdom

Debbie Peacock
United Kingdom

Jesper Pedersen
Denmark

James Pegg
United Kingdom

Jacqueline Penn
United Kingdom

Ludovic Pérez
France

Christian Perk
Germany

Neil Phillips
United Kingdom

Richard Phillips
United Kingdom

Robert Piteus
Belgium

Alexander Plugge
Germany

Enrico Poggemöller
Germany

Stephen Pollard
United Kingdom

Richard Potts
United Kingdom

Tim Poulter
United Kingdom

Chris Price
United Kingdom

Dirk Püttmann
Germany

Christopher Pye
United Kingdom

Darren Quinn
Ireland

Steven Raith
United Kingdom

Waqas Raja
United Kingdom

Daniel-Francisco Ramirez-Garcia
United Kingdom

Dawn Randall
United Kingdom

Linda Ransom
United Kingdom

Brian Rawson
United Kingdom

Phil Rawson
United Kingdom

Jason Reeve
United Kingdom

Lisa Reeve
United Kingdom

Alan Reeves
United Kingdom

Alexander Reich
Germany

James Reid
United Kingdom

Andreas Reiser
Germany

Joanna Revett
United Kingdom

Sarah Reygate
United Kingdom

Sebastian Rhein
Germany

Ross Richards
United Kingdom

Alan Richardson
United Kingdom

Jason Robb
United Kingdom

Lee Roberts
United Kingdom

Penny Roberts
United Kingdom

Charlotte Robinson
United Kingdom

Tommy Rødland
Norway

Vic Rodley
United Kingdom

Kath Rogers
United Kingdom

Katherine Rogers
United Kingdom

Peter Rogerson
United Kingdom

Kurt Rührken
Germany

Steve Rosenwould
United Kingdom

Stefan Roski
Germany

Michael Roßner
Germany

Donald Ross
United Kingdom

Andy Rouse
United Kingdom

Anthony Rowe
United Kingdom

Neil Rowe
United Kingdom

Symon Rowland
United Kingdom

P E Royle
United Kingdom

Marc Rudzinski
Germany

Michaela Rudzinski
Germany

Steven Rumsey
United Kingdom

Pete Rushton
United Kingdom

Alan Russell
United Kingdom

John Ryder
United Kingdom

Sarah Saddington
United Kingdom

Amit Sagar
United Kingdom

Philip Sagar
United Kingdom

Mark Saint

United Kingdom

Vince Saiya

United Kingdom

Chris Salt

United Kingdom

Neil Samaraweera

Denmark

Nick Samworth

United Kingdom

Jon Sanger

United Kingdom

Francisco Santos

United Kingdom

Sergej Sarcinski

Germany

Isik Sarikaya

United Kingdom

Anna Saul

United Kingdom

Chellie Saunders

Ireland

Darren Saunders

United Kingdom

Lothar Sauter

Germany

Maurice Schade

Germany

Daniel Schindler

Germany

Michael Schmidt

Denmark

Niels Schmidt

Denmark

Patrick Schmid

Germany

Alison Schnabel
United Kingdom

Antony Schnabel
United Kingdom

Frank Schnackenberg
Germany

Andreas Schönenberger
Germany

Dennis Schuster
Germany

Alex Schwarzkop
Germany

Andrew Scotchmer
United Kingdom

Carole Scott
United Kingdom

Mike Scott
United Kingdom

Stevie Scott
United Kingdom

Dominic Search
United Kingdom

Chris Sennett
United Kingdom

Antea Sersic
Croatia

Kevin Shakeshaft
United Kingdom

Simon Shaw
United Kingdom

Linda Sheils
United Kingdom

Victoria Shelton-Davies
United Kingdom

David Sher
United Kingdom

Adam Sheridan
Belgium

Helen Shields
United Kingdom

Michael Shirtcliffe
United Kingdom

Olaf Sieder
Germany

Alec Sillifant
United Kingdom

Lance Simcox
United Kingdom

Morten Achton Simonsen
Denmark

Mark Simpson
United Kingdom

Sam Simpson
United Kingdom

Margaret Sinclair
United Kingdom

Phil Sivills
United Kingdom

Peter Skinner
United Kingdom

Andy Slater
United Kingdom

Mark Slawson
United Kingdom

Ramunas Slekaitis
Lithuania

Paul Sloman
United Kingdom

Wilhelm Slot
Belgium

Cindy Smalldridge

United Kingdom

Edward Smeeth

United Kingdom

Jamie Smith

United Kingdom

Kate Smith

United Kingdom

Keith Smith

United Kingdom

Kirsty Smith

United Kingdom

Roy Smith

United Kingdom

Tony Smith

United Kingdom

Stephen Smout

United Kingdom

Alan Snaddon

United Kingdom

Paul Snow

United Kingdom

Liam Sockett

United Kingdom

Bryan Sokell

United Kingdom

Tamas Solymosi

United Kingdom

André Sommer

Germany

Anni Sørensen

Denmark

Elsemarie Sørensen

Denmark

Leif Stig Sørensen

Denmark

Chris Speller

United Kingdom

Anna Spencer

United Kingdom

David Spencer

United Kingdom

John Spencer

United Kingdom

Audrey Spiers

United Kingdom

Graham Spiers

United Kingdom

Kazimieras Stankevicius

Lithuania

Leah Steele

United Kingdom

Henrik Steentoft

Denmark

Andreas Steffen

Germany

Dorit Steffen

Germany

Bernhard Stellmacher

Germany

Simon Stephenson

United Kingdom

Kelly Stevens

United Kingdom

Kenneth Stevens

United Kingdom

Malgorzata Stevens

United Kingdom

Richard Stevens

United Kingdom

Neil Stewart

United Kingdom

Peter Stigaard

Denmark

Professor Mark Stiles

United Kingdom

David Storey

United Kingdom

Paul Stott

United Kingdom

Armin Strube

Germany

Kayleigh Suddick

United Kingdom

Ali Sufi

Denmark

Stuart Sullivan

United Kingdom

Ian Sutton

United Kingdom

Clive Swainston

United Kingdom

Anita Sylvan

United Kingdom

Mat Sylvester

United Kingdom

Andy Talbot

United Kingdom

Samuel Tang

United Kingdom

Glynis Tate

United Kingdom

Chris Taylor

United Kingdom

Colin Taylor

United Kingdom

Colin Taylor

United Kingdom

David Taylor

United Kingdom

Emma Taylor

United Kingdom

Michael Taylor

United Kingdom

Sam Taylor

United Kingdom

Jonathan Taylor-Yorke

United Kingdom

Jan Thamer

Germany

Torsten Thiemann

Germany

Andy Thomas

United Kingdom

Linda Thomas

United Kingdom

Sandra Thomas

United Kingdom

Claire Thompson

United Kingdom

D C Thompson

United Kingdom

Mark Thompson

United Kingdom

Christian Timmer

Germany

Hannes Tismer

Germany

Stephan Tissen

Germany

Matthew Tomlinson

United Kingdom

Joan Toner

United Kingdom

Veronika Toplak

United Kingdom

Aarne Toukola

Finland

Sari Toukola

Finland

Dave Tranter

United Kingdom

Paul Travers

United Kingdom

Andreas Travnicek

Germany

Markus Travnicek

Germany

Ruth Trebilcock

United Kingdom

Richard Trotter

United Kingdom

Florian Trum

Germany

Jane Tryner

United Kingdom

Ann Tunnicliffe

United Kingdom

David Turner

United Kingdom

Joy Turner

United Kingdom

Melanie Turner

United Kingdom

William Twigg

United Kingdom

Sue Twyman

United Kingdom

Robert Tyrrell

United Kingdom

Robert Tyrrell

United Kingdom

Steve Upton

United Kingdom

Holger Vahldiek

Germany

Setmani Valenzuela

Spain

James Varney

United Kingdom

James Varney

United Kingdom

Sarah Vautour

United Kingdom

Andy Veale

United Kingdom

Steven Vearncombe

United Kingdom

Dragan Veljic

Germany

Klaus Verkamp

Germany

Ralf Vermaasen

Germany

Aniko Vero

United Kingdom

Marie Vidler

United Kingdom

Robert Willis

United Kingdom

James Vivian

United Kingdom

Vladimir Voisei

United Kingdom

Vera Waage

Denmark

Neil Wagstaff

United Kingdom

Frank Waites

United Kingdom

Florian Walhöfer

Germany

Ian Walker

United Kingdom

Karen Walker

United Kingdom

Mark Walker

Ireland

Neil Walker

United Kingdom

Philip Walmsley

United Kingdom

Matthew Walters

United Kingdom

Corbinian Wandel

Germany

Sascha Wander

Germany

Kevin Ward

United Kingdom

Robert Waring

United Kingdom

Ben Waters

United Kingdom

Filippo Waters

United Kingdom

Patricia Waters

United Kingdom

Lisa Watson

United Kingdom

Matthew Watten

United Kingdom

Chris Webb

United Kingdom

Matt Webb

United Kingdom

Denis Weber

Germany

Heidi Wegner

Germany

Konstantin Weigel

Germany

Bernhard Welle

Germany

Matthias Wessel

Germany

Tommy Westergård

Finland

Dionne Westwood

United Kingdom

Nick Westwood

United Kingdom

Mike Whitbread

United Kingdom

Alan White

United Kingdom

Collyne White

United Kingdom

L D White

United Kingdom

Matthew Whiteley

United Kingdom

David Whitelock

United Kingdom

Robin Whiting

United Kingdom

Paul Whittemore

United Kingdom

Chris Whittle

United Kingdom

Paul Wickham

Ireland

Vivien Wickham

United Kingdom

Matthias Wildenauer

Germany

Andrew Wilkes

United Kingdom

Ashley Wilkin

United Kingdom

Alan Wilkinson

United Kingdom

Anthony Williams

United Kingdom

Anthony Williams

United Kingdom

Gary Williams

United Kingdom

Gary Williams

United Kingdom

Paul Williams

United Kingdom

Paul Williams

United Kingdom

Stuart Williams

United Kingdom

Victoria Williams

United Kingdom

Mark Williamson

United Kingdom

Nicola Williamson

United Kingdom

Roy Willis

United Kingdom

Roy Willis

United Kingdom

J R Wilson

United Kingdom

M P Wilson

United Kingdom

Steven Wilson

United Kingdom

Steve Winney

United Kingdom (South West)

Dr Stephen Wintersgill

United Kingdom

Nick Wojdyló

United Kingdom

Alan Wollaston

United Kingdom

Peter Wood

United Kingdom

Samantha Wood

United Kingdom

Daniel Woodford

United Kingdom

Ruth Woods

United Kingdom

Diana Woods-Jeram

United Kingdom

Michael Worswick

United Kingdom

A Wright

United Kingdom

John Wright

United Kingdom

Rebecca Wright

United Kingdom

Karianne Ylvisaker

Norway

Eliot York

United Kingdom

Andrew Young
United Kingdom

Beverley Young
United Kingdom

Gaynor Young
United Kingdom

Graham Young
United Kingdom

Jeremy Young
United Kingdom

Martin Zeipelt
Germany

STAES Bart OFFICE

From: CORA Imperial Tobacco Belux <CORA.ITB@belux.imptob.com>
Sent: 08 July 2013 09:57
To: STAES Bart
Cc: barbara.redant@groen.be
Subject: illegale handel neemt nog steeds toe
Attachments: 130704 krantenknipsels illegale handel Ghlin - luchthaven Zaventem.pdf

Geachte heer Staes,

Naar aanleiding van onze eerdere communicatie willen wij u er langs deze weg op wijzen dat illegale productie en handel van tabaksproducten in België nog steeds toeneemt (zie krantenknipsels in bijlage).

Zo werd 2 weken geleden een illegale fabriek ontdekt in Ghlin waar maar liefst 25 ton tabak in beslag werd genomen, goed voor de productie van 50 miljoen namaaksigaretten. Op de luchthaven van Zaventem werden dan weer 2 pakketten onderschept met daarin 135.000 lege namaakverpakkingen voor tabaksproducten en afzonderlijk nog eens 700 kg tabak om verpakkingen te vullen.

Wij menen dat irrationele wetgeving enorme mogelijkheden creëert voor criminelen die de wetgeving niet respecteren en producten die aan geen enkele norm voldoen, aan lage prijzen kunnen aanbieden.

Dat tabaksproducten gereguleerd moeten worden staat buiten kijf. Maar irrationele en disproportionele wetgeving mist zijn doel en zal de illegale handel alleen maar doen toenemen. Zo zijn wij van oordeel dat ook bepaalde elementen uit het voorstel tot herziening van de Europese Tabaksproductenrichtlijn (zoals eenvoudig te kopiëren grote gezondheidswaarschuwingen of gestandaardiseerde verpakkingen) of extreme accijnsverhogingen dit in de hand kunnen werken.

Uiteraard zijn wij steeds bereid om u hierover verdere informatie te bezorgen of ons standpunt toe te lichten.

Met oprechte achting,

Christine De Baets
Legal & Cora Manager

Imperial Tobacco Belgium
Schaliënhoedreef, 20H
B-2800 Mechelen
Belgium

Tel: +32 (0)15 29 99 11
Fax: +32 (0)15 26 24 47



From: CORA ITB,
Sent: Tuesday, May 07, 2013 2:27 PM
To: 'bart.staes@europarl.europa.eu'
Cc: 'barbara.redant@groen.be'
Subject: Commissievoorstel COM(2012) 788 - bespreking in het Europees Parlement

Geachte heer Staes,

Graag contacteer ik u omtrent het Commissievoorstel COM(2012) 788 tot herziening van de richtlijn van het Europees Parlement en de Raad betreffende “de onderlinge aanpassing van de wettelijke en bestuursrechtelijke bepalingen van de lidstaten inzake de productie, de presentatie en de verkoop van tabaks- en aanverwante producten” dat momenteel besproken wordt binnen de Raad en het Europees Parlement.

Als tabaksproducent hebben we uiteraard het volste begrip voor het feit dat u en andere politici in Europa bepaalde elementen uit de bestaande Richtlijn willen wijzigen. Toch willen we u verzoeken om bij de besluitvorming rekening te willen houden met een aantal objectieve elementen. Dit zal, ons inziens, niet alleen de uitvoerbaarheid, maar ook de democratische grondslag van de aangepaste Richtlijn ten goede komen.

Vanuit die optiek wil ik u graag een aantal concrete voorstellen doen. **Deze voorstellen maken het nog steeds mogelijk om de doelstelling van de Europese Commissie** - het minder aantrekkelijk maken van tabaksproducten en tabaksgebruik - **te verwezenlijken**, terwijl een aantal fundamentele problemen zoals de werkbaarheid en legitimiteit van het huidige voorstel worden opgelost.

In bijlage kan u een kopie vinden van de brief en bijlagen die u ook per post zal ontvangen.

Indien u in tussentijd vragen zou hebben omtrent onze voorstellen, mag u mij uiteraard steeds contacteren.

Met oprechte achting,

Christine De Baets
Legal & Cora Manager

Imperial Tobacco Belgium
Schaliënhoevedreef, 20H
B-2800 Mechelen
Belgium

Tel: +32 (0)15 29 99 11
Fax: +32 (0)15 26 24 47



Imperial Tobacco Limited and Group Companies

www.imperial-tobacco.com

This email is confidential and may contain information that is privileged and exempt from disclosure by law. If you have received it in error, please contact the sender immediately by return email and then delete it from your system; you should not copy it or disclose its contents to anyone. Imperial Tobacco Limited and Group Companies reserve the right to monitor all email communications through their networks. Emails are not secure and cannot be guaranteed to be error free as they can be intercepted, amended, lost or destroyed, or contain viruses. Anyone who communicates with us by email is taken to accept these risks.

STAES Bart OFFICE

From: Sofia Ravara <sbravara@fcsaude.ubi.pt>
Sent: 08 July 2013 00:38
Subject: URGENT-ENVI vote on the Tobacco products Directive on 10 July
Attachments: SFP Mythbusting Briefing EN.pdf; ENVI Voting Recommendations - final-July-2013.pdf

Dear Member of the Committee on the Environment, Public Health and Food Safety

RE: ENVI vote on the Tobacco products Directive on 10 July

Ahead of the Wednesday 10 July vote on the draft report on the Tobacco Products Directive, we are contacting you as representatives of the health community in your country.

We are extremely concerned about the opinions that have emanated from other European Parliament Committees. We are aware that your colleagues in most of these Committees do not have people's health as their first priority. But as a member of the ENVI Committee, your priority is the health of all citizens of the EU.

We are calling on your support for a strong Tobacco Products Directive.

In particular, we call on two crucial votes from you:

- Please **vote in favour of compromise amendment 39** which maintains the size of **75% of the front and the back of the pack**.
- Please **vote against compromise amendment 38** which reduces the size of warnings to **65% of the front and the back of the pack**.

Why?

- 70% of smokers start before the age of 18 and 94% before the age of 25 years.
- Pictorial warnings of 75% or more are not just proven to be more **effective in reducing the attractiveness of tobacco products to children and young people**; they are also in force in several countries around the world where significant reductions in youth smoking were registered after their introduction.
- Pictorial warnings covering 75% of the front and the back of the pack **have NOT been legally challenged anywhere in the world**.
- **75% of all European citizens are in favour** of this measure

The Tobacco Products Directive is one of the **last major pieces of EU regulation that will be adopted before next year's elections** to the European Parliament. The directive has the potential to stop young people from taking up the deadly habit of smoking, with its devastating effects that we witness in our everyday work. That is why **your vote on this crucial piece of legislation will be your legacy to Europe's**

young people and your contribution to reducing death and disease from chronic diseases such as cancer, heart attacks, respiratory illness and diabetes.

We also urge you to make sure that **flavours that make cigarettes more attractive and palatable are not allowed** and that the so-called “**slim**” **cigarettes are no-longer on the market** to seduce young girls, in particular.

Also, we call on you to vote for amendments that **include standard packs and the strengthening of traceability and security features for combating illicit trade.**

The attached document provides a more comprehensive list of the amendments and compromise amendments which we consider as the most important.

The public health community in your country and in the whole of Europe counts on your support and look forward to your vote for a Tobacco Products Directive that places the health of European citizens above the interests of the tobacco industry.

PS: It has come to our attention that a number of arguments against the tobacco products are not backed up by the evidence. To that end we have attached the [leaflet](#) that distinguishes between facts and fiction-briefing Smokefreepartnership.

Yours sincerely,

Sofia Belo Ravara

Sofia Ravara, medical doctor, chest physician
Tobacco Control Committee, European Respiratory Society
University of Beira Interior
CHCB University Hospital
Covilhã, Portugal
sbravara@fcsaude.ubi.pt



STAES Bart OFFICE

From: Clive Bates <clivedbates@gmail.com>
Sent: 08 July 2013 00:16
To: MCAVAN Linda; FLORENZ Karl-Heinz; RIES Frédérique; SCHLYTER Carl; CALLANAN Martin; ANDERSON Martina; ROSSI Oreste
Cc: AYALA SENDER Inés; BLOOM Godfrey; BORSELLINO Rita; BUSOI Cristian Silviu; CHRYSOGELOS Nikos; VAN DALEN Peter; DE VEYRAC Christine; FERNANDES José Manuel; FOSTER Jacqueline; FRANCO Gaston; GARCÍA-HIERRO CARABALLO Dolores; GIEREK Adam; GIRLING Julie; HARMS Rebecca; HAUG Jutta; HERRANZ GARCIA Esther; JORDAN Romana; JUVIN Philippe; KACZMAREK Filip; KALINOWSKI Jarosław; KOUMOUTSAKOS Georgios; KOZLIK Sergej; MANDERS Toine; MASTALKA Jiri; MERKIES Judith A.; MIKOLASIK Miroslav; McGUINNESS Mairead; NICHOLSON James; ORTIZ VILELLA Eva; PALECKIS Justas Vincas; PAULSEN Marit; PETERLE Alojz; PRODI Vittorio; REIMERS Britta; RIVASI Michèle; RIVELLINI Crescenzo; SCHALDEMOSE Christel; SCHNIEBER-JASTRAM Birgit; SCOTTA' Giancarlo; SOMMER Renate; STADLER Ewald; STEVENSON Struan; TABAJDI Csaba; TAYLOR Rebecca; THEOCHAROUS Eleni; ULVSKOG Marita; URUTCHEV Vladimir Andreev; VAN BREMPT Kathleen; DE VILLIERS Philippe; ZANONI Andrea; ZABORSKA Anna; BÁNKI Erik; CLIVETI Minodora; DEMESMAEKER Mark; FERREIRA João; FJELLNER Christofer; FORD Victoria Grace; IVAN C t lin-Sorin; MIZZI Marlene; PAKARINEN Riikka; SOPHOCLEOUS Sophocles; SOUSA Alda; STAES Bart; elenaona.antonescu@europarl.europa.eu; ARSENIS Kriton; AUCONIE Sophie; AYUSO Pilar; BARTOLOZZI Paolo; BERLATO Sergio; BOKROS Lajos; BÉLIER Sandrine; CHILDERS Nessa; COCHET Yves; CYMA SKI Tadeusz; DAVIES Chris; DELVAUX Anne; EICKHOUT Bas; EVANS Jill; GARDINI Elisabetta; GERBRANDY Gerben-Jan; GRIFFIN Nick; GROOTE Matthias; GROSSETETE Francoise; GUTIERREZ-CORTINES Cristina; HASSI Satu; HIBNER Jolanta Emilia; JØRGENSEN Dan; KADENBACH Karin; KLASS Christa; KORHOLA Eija-Riitta; KRAHMER Holger; DE LANGE Esther; LEINEN Jo; LEPAGE Corinne; LIESE Peter; LIOTARD Kartika Tamara; MAZEJ KUKOVI Zofija; radvile.morkunaite@europarl.europa.eu; NUTTALL Paul; OUZKY Miroslav; PANAYOTOV Vladko Todorov; PARGNEAUX Gilles; PARVANOV Antonia; PERELLO RODRIGUEZ Andres; PIRILLO Mario; POC Pavel; ROSBACH Anna; ROTH-BEHRENDT Dagmar; SCHNELLHARDT Horst; SEEBER Richard; SONIK Boguslaw; SARBU Daciana Octavia; TATARELLA Salvatore; T N Sescu Claudiu Ciprian; ULMER Thomas; WEISGERBER Anja; WESTLUND Asa; WILLMOTT Glenis; WILS Sabine; YANNAKOUDAKIS Marina; ŠADURSKIS K rlis; Martin Jarvis; Jacques Le Houezec; Karl Fagerström; Prof. Dr. Michael Kunze; Tony Axéll; Lars Ramström; Karl Erik Lund
Subject: Letter from 8 public health experts on snus / oral tobacco ban - unethical and unscientific
Attachments: EP - snus letter - final.pdf

To: Linda McAvan MEP, Karl-Heinz Florenz MEP, Frédérique Ries MEP, Martin Callanan MEP, Oreste Rossi MEP, Martina Anderson MEP, Carl Schlyter MEP

CC: ENVI MEPs & substitutes

8 July 2013

Dear Ms McAvan and colleagues

Please find attached a letter from eight public health experts regarding the intention to ban snus (oral tobacco) in the Tobacco Products Directive. There is no evidence to support this, and much to suggest it is harmful to health and unethical to deny smokers this option. We urge the Members of the European Parliament to rethink and recognise the great potential health benefits that could arise from wider use of this low risk alternative to cigarettes in the European Union - exactly the beneficial effect seen in Sweden and Norway.

Yours faithfully,

Professor Martin Jarvis
Professor Karl Olov Fagerström
Professor Michael Kunze

Dr Karl Erik Lund
Dr Jacques Le Houezec
Dr Tony Axell
Dr Lars Ramström
Mr Clive Bates

STAES Bart OFFICE

From: Scott C <squizc@hotmail.com>
Sent: 06 July 2013 13:34
To: POC Pavel; RIES Frédérique; ROSBACH Anna; ROSSI Oreste; ROTH-BEHRENDT Dagmar; ŠADURSKIS K rlis; SARBU Daciana Octavia; SCHNELLHARDT Horst; SEEBER Richard; SKYLAKAKIS Theodoros; SONIK Boguslaw; T N Sescu Claudiu Ciprian; TATARELLA Salvatore; ULMER Thomas; WEISGERBER Anja; WESTLUND Asa; WILS Sabine; ARIAS ECHEVERRIA Pablo; AUKEN Margrete; AYALA SENDER Inés; BĀNKI Erik; BORSELLINO Rita; frieda.brepoels@europarl.europa.eu; BUSOI Cristian Silviu; CHRYSOGELOS Nikos; CLIVETI Minodora; VAN DALEN Peter; DE VEYRAC Christine; FERNANDES José Manuel; FERREIRA João; FJELLNER Christof; FORD Victoria Grace; FOSTER Jacqueline; FRANCO Gaston; GARCÍA-HIERRO CARABALLO Dolores; GIEREK Adam; GIRLING Julie; HARMS Rebecca; HAUG Jutta; HERRANZ GARCIA Esther; IVAN C t lin-Sorin; JORDAN Romana; JUVIN Philippe; KACZMAREK Filip; KALINOWSKI Jarosław; KOUMOUTSAKOS Georgios; KOZLIK Sergej; McGUINNESS Mairead; MANDERS Toine; PAKARINEN Riikka; MASTALKA Jiri; MERKIES Judith A.; MIKOLASIK Miroslav; ORTIZ VILELLA Eva; PALECKIS Justas Vincas; PAULSEN Marit; PETERLE Alojz; PRODI Vittorio; REIMERS Britta; RIVASI Michèle; RIVELLINI Crescenzo; SCHALDEMOSE Christel; SCHNIEBER-JASTRAM Birgit; SCICLUNA Edward; SCOTTA' Giancarlo; SOMMER Renate; SOPHOCLEOUS Sophocles; SOUSA Alda; STADLER Ewald; STAES Bart; TABAJDI Csaba; THEOCHAROUS Eleni; THYSSEN Marianne; ULVSKOG Marita; URUTCHEV Vladimir Andreev; VAN BREMPT Kathleen; VIGENIN Kristian; DE VILLIERS Philippe; ZABORSKA Anna; ZANONI Andrea
Subject: ENVI committe vote and the TPD

Dear Sir or Madam,

I would like to talk to you about the ENVI committee vote on 10/11 July on e-cigarettes. I have some points I would like to put across to you about why medicines regulation is a bad idea now and in the long term.

1. Medicines regulation is grossly excessive, and in any case these products are not medicines, either legally or as a matter of common sense.

2. Why make it harder to sell e-cigarettes than cigarettes? Why impose more red tape, costs and restrictions on the products that can free people from smoking (which is proven to kill)? We should at least make e-cigarettes as available as tobacco cigarettes.

3. Why use a form of regulation that will destroy the very things that has made e-cigarettes a success - innovation, diversity, niche products and consumer enthusiasm? Medicines regulation will stop innovation dead in it's tracks because of the high costs associated with getting a product approved (if this is even currently possible). An approved product would be so different than what is already available that the success rate would fall dramatically.

4. Banning flavour is totally counterproductive - e-cigs are basically flavoured nicotine products, and it is good you can get them in flavours other than tobacco as the whole idea is to get tobacco users to forget/leave tobacco.

5. There are virtually no risks to children or any other downsides associated with e-cigarettes - they are always better and far less risky than cigarettes. People smoking tobacco is the gateway to children smoking tobacco not e-cigarettes. The ASH studies have already confirmed e-cigarettes are not a gateway to children taking up tobacco.

Please DO NOT support any approach that is or looks like medicines regulation.

Please DO support any approach that provides a sensible level of protection but leaves it to

consumers market to decide which products are good for them.

There are virtually no risks to children or any other downsides associated with e-cigarettes - they are always better and far less risky than cigarettes.

I am also extremely unhappy to learn of the MHRA reaching their decision on the basis of some research from British American Tobacco. I am also unhappy at the fact the MHRA are mostly funded by the pharmaceutical companies. This to me is a huge conflict of interest.

After seeing numerous stories popping up lately about corruption with the whole TPD and former EU commissioner John Dalli taking bribes from tobacco companies I literally feel sick from the thought of this unnecessary regulation on e-cigarettes getting passed.

This is my life at risk as well as millions of others. I know that medicines regulation will place a de-facto ban on what I currently use to avoid tobacco. An e-cigarette that has been approved for medicinal use cant possible work like they currently do and because of that I would be forced back to tobacco. Innovation would stop and public health costs would again rise.

This is the first real chance for the public to leave tobacco use, to stop it in it's tracks like what is being proposed is just simply inhuman. This does not just effect the current population but also the billions of new lives which could of had the opportunity not to smoke a tobacco cigarette which kills 1 in 2 and instead use a e-cigarette which recent studies have found is safe.

Yours sincerely,

Scott Chambers

STAES Bart OFFICE

From: Interessengemeinschaft E-Dampfen - M. Calvetti <mc@ig-ed.org>
Sent: 05 July 2013 23:28
To: STAES Bart
Subject: A last Plea before the ENVI-Voting

Dear Mr STAES,

shortly before the votings on July 10 and 11, 2013 we contact you again to emphatically draw your attention once more to the concerns of the IG-ED in terms of the Commission proposal and the amendments which are known so far, representing many EU citizens.

A regulation within the Tobacco Product Directive, which is legally obligated to implement the standards of the WHO-FCTC (Framework Convention of Tobacco Control) is highly inadequate for nicotine containing products like the e-cigarette.

An expansion according to WHO FCTC on apparently related products which are much less dangerous is by no means in agreement with the objectives of the proposal with regard to public health. A number of scientists already pointed out in front of the ENVI Committee that e-cigarettes are less harmful and - in their current or an only mildly regulated form - a very effective harm reduction.

There are existing EU regulations in place already which create sufficient safety for us consumers, particularly as the dangers of nicotine are often depicted considerably exaggerated.

We would welcome a proprietary regulation, combining the existing rules, for the E-Cigarette. The objections entered by JURI (particularly No. 74) show very clearly that completely sufficient rules and standards are in existence already.

So again we strongly request: Use the opportunity to establish and support a considerably less dangerous alternative to tobacco consumption. You can do this best with a proportionate regulation focusing on the existing market and on the people.

This open letter will also be published on our website.

Sincerely

Interessengemeinschaft E-Dampfen e. V.

Monika Calvetti

2. Vorsitzende

Web: <http://www.ig-ed.org>

E-Mail: mc@ig-ed.org

Vereinsanschrift:

1. Vorsitzender

Sven-Christian Meyhöfer

Mail: s-c.meyhoefer@ig-ed.org

Karlsbader Str. 76

D-75196 Remchingen

STAES Bart OFFICE

From: Clive Bates <clivedbates@gmail.com>
Sent: 04 July 2013 18:45
To: MCAVAN Linda; FLORENZ Karl-Heinz; RIES Frédérique; SCHLYTER Carl; CALLANAN Martin; ANDERSON Martina; ROSSI Oreste
Cc: AYALA SENDER Inés; BLOOM Godfrey; BORSELLINO Rita; BUSOI Cristian Silviu; CHRYSOGELOS Nikos; VAN DALEN Peter; DE VEYRAC Christine; FERNANDES José Manuel; FOSTER Jacqueline; FRANCO Gaston; GARCÍA-HIERRO CARABALLO Dolores; GIEREK Adam; GIRLING Julie; HARMS Rebecca; HAUG Jutta; HERRANZ GARCIA Esther; JORDAN Romana; JUVIN Philippe; KACZMAREK Filip; KALINOWSKI Jarosław; KOUMOUTSAKOS Georgios; KOZLIK Sergej; MANDERS Toine; MASTALKA Jiri; MERKIES Judith A.; MIKOLASIK Miroslav; McGUINNESS Mairead; NICHOLSON James; ORTIZ VILELLA Eva; PALECKIS Justas Vincas; PAULSEN Marit; PETERLE Alojz; PRODI Vittorio; REIMERS Britta; RIVASI Michèle; RIVELLINI Crescenzo; SCHALDEMOSE Christel; SCHNIEBER-JASTRAM Birgit; SCOTTA' Giancarlo; SOMMER Renate; STADLER Ewald; STEVENSON Struan; TABAJDI Csaba; TAYLOR Rebecca; THEOCHAROUS Eleni; ULVSKOG Marita; URUTCHEV Vladimir Andreev; VAN BREMPT Kathleen; DE VILLIERS Philippe; ZANONI Andrea; ZABORSKA Anna; BÁNKI Erik; CLIVETI Minodora; DEMESMAEKER Mark; FERREIRA João; FJELLNER Christofer; FORD Victoria Grace; IVAN C t lin-Sorin; MIZZI Marlene; PAKARINEN Riikka; SOPHOCLEOUS Sophocles; SOUSA Alda; STAES Bart; elena.antonescu@europarl.europa.eu; ARSENIS Kriton; AUCONIE Sophie; AYUSO Pilar; BARTOLOZZI Paolo; BERLATO Sergio; BOKROS Lajos; BÉLIER Sandrine; CHILDERS Nessa; COCHET Yves; CYMA SKI Tadeusz; DAVIES Chris; DELVAUX Anne; EICKHOUT Bas; EVANS Jill; GARDINI Elisabetta; GERBRANDY Gerben-Jan; GRIFFIN Nick; GROOTE Matthias; GROSSETETE Francoise; GUTIERREZ-CORTINES Cristina; HASSI Satu; HIBNER Jolanta Emilia; JØRGENSEN Dan; KADENBACH Karin; KLASS Christa; KORHOLA Eija-Riitta; KRAHMER Holger; DE LANGE Esther; LEINEN Jo; LEPAGE Corinne; LIESE Peter; LIOTARD Kartika Tamara; MAZEJ KUKOVI Zofija; radvile.morkunaite@europarl.europa.eu; NUTTALL Paul; OUZKY Miroslav; PANAYOTOV Vladko Todorov; PARGNEAUX Gilles; PARVANOV Antonia; PERELLO RODRIGUEZ Andres; PIRILLO Mario; POC Pavel; ROSBACH Anna; ROTH-BEHRENDT Dagmar; SCHNELLHARDT Horst; SEEBER Richard; SONIK Boguslaw; SARBU Daciana Octavia; TATARELLA Salvatore; T N Sescu Claudiu Ciprian; ULMER Thomas; WEISGERBER Anja; WESTLUND Asa; WILLMOTT Glenis; WILS Sabine; YANNAKOUDAKIS Marina; ŠADURSKIS K rlis
Subject: MEPs briefing - 10 things to consider before voting on the Tobacco Products Directive

To: Linda McAvan MEP, Karl-Heinz Florenz MEP, Frédérique Ries MEP, Martin Callanan MEP, Oreste Rossi MEP, Martina Anderson MEP, Carl Schlyter MEP
CC: ENVI MEPs & substitutes
From: Clive Bates
4th July 2013

As you decide how to vote on amendments to the Tobacco Products Directive or how to form compromises, please consider the following points:

1. Keep your eye on the prize - e-cigarettes. By far the most important decisions you will take relate to low risk alternatives to smoking - e-cigarettes, smokeless tobacco, and novel non-combustible tobacco products. The measures related to packaging, warnings and cigarette design are at best second order. Even the European Commission believes these will only reduce consumption by 2 percent - equivalent to 0.5 percent reduction in the number of smokers - and that is with a weak evidence base. This is so small it is 'statistical noise'. On the other hand, Sweden has by far the lowest rates of smoking - less than half the EU average - because it is the only country that has widespread use of low-risk (95-99% lower) alternatives to cigarettes, snus. Some [Wall Street analysts](#) believe that e-cigarettes will *overtake cigarettes within 10 years* - that would be a stunning transformation and major public health success. Even if that sounds optimistic, no other tobacco policy intervention comes remotely close to this scale of transformation - but the wrong regulation would put it at risk.

2. Support rather than obstruct pro-health disruptive technology. E-cigarettes are a true disruptive technology, with amazing revolutionary potential. And the great thing is that they will disrupt the established cigarette business model. But regulating e-cigarettes as medicines will throttle this new industry with costs, regulatory compliance burdens and all manner of restrictions. It will constrain and slow innovation, reduce diversity of products and limit the appeal of these products to users. The true public health goal here is to let the e-cigarette category compete effectively with the entrenched cigarette oligopoly. Why would the European Parliament send these emerging companies into an ultra-competitive marketplace laden with red tape, unnecessary costs, and a restrictive regime guaranteed to make the product unappealing? It amounts to protecting cigarettes.

3. Do not vote for regulation of e-cigarettes as medicines. [E-cigarettes are not medicines](#): not in law nor as a matter of common sense. Medicines must have the purpose of treating or preventing disease. E-cigarettes will dramatically reduce smoking if they are a pleasurable and appealing alternative to cigarettes, not a medicalised quitting aid. The effect will be more people stopping smoking and great reductions in harm, but the purpose for the user and the vendor is to have a better way to take the popular and legal recreational drug, nicotine - which is about as harmful as caffeine. If you doubt that medicines regulation will harm the e-cigarette category, ask why the NRT inhalers have failed to capture the imagination of 'vapers'? You can see why by looking at the '[Patient Information Leaflet](#)' for one. Boring, worthy, miserable and unappealing.

4. Do vote for rigorous regulation of e-cigarettes as consumer products. Start by asking what problems regulation is trying to address? What is the problem with e-cigarettes that cannot be addressed in consumer product legislation? The EU is obliged under the treaties ([Art 5 TEU Protocol 2](#)) to use the least burdensome form of regulation to achieve the policy objective. So what is it that requires medicines regulation? And how would medicines regulation deal with whatever it is? [Consumer product regulations consist of about 15 directives](#) that protect EU citizens from thousands of potentially dangerous products. *This is enough if properly applied and enforced.* If standards are needed - have standards. If warnings are needed - have warning labels. Why should these products be barred from the market subject to medical authorisation, when cigarettes are allowed easy universal access?

5. Don't try to ban flavours in e-cigarettes. These products are comprised of only three main ingredients: the drug nicotine; a vaporising substance; and flavours to make them palatable and appealing. Take away the flavours and you might as well ban the product. In fact, all you would do is to create a home mixing 'DIY' market in which people mix their own liquids and use whatever flavours they want. So ban flavours and the effect is to ruin a very promising public health technology produced to good commercial standards, and in doing so to drive users into the more risky practice of mixing their own - and there is *nothing* you can do to stop that, other than to ensure alternatives are available.

6. Don't misuse children in policy making. It sometimes appears as though any policy, however perverse or evidence-free, can be justified with reference to hypothetical threats to children. Almost everything attempted to stop teenagers smoking *directly* will fail. This is because teenage smoking is primarily experimentation with adult life, and the key driver of youth smoking is adult smoking. You will hear about 'gateway effects', but this idea exists mostly in the imagination and advocacy literature of campaigners. All the evidence suggests that gateways are out of smoking - and it is possible that products like e-cigarettes could divert kids who would otherwise smoke onto a much less harmful pathway. No discussion of gateways is complete without reference to exit gateways and you can read more about that at: [We need to talk about the children - the gateway effect examined](#).

7. Think again on snus - the ban is negligent and unethical. We know snus is 95-99% less dangerous than cigarettes, and we know it is the reason for much lower levels of smoking in Sweden and Norway - yet there appears to be near consensus that these products should be banned outside Sweden. There is no scientific, ethical or legal basis for a ban, and it has genuinely harmful consequences: see [Death by regulation](#). Ask this: *why would the state intervene to deny a person the option to reduce their own risk at their own expense by freely choosing a lower risk alternative to cigarettes, especially as we know this has worked extremely well in Norway and Sweden?* It is impossible to justify. What other cases do you know where the EU bans a safer product but leaves an alternative 20-100 times more dangerous on the market? There are none. The effect of the ban is to support the cigarette trade and

cause more harm to health by denying people better choices - all supposedly in the name of the internal market. Sorry to sound harsh, but it amounts to [negligence in tobacco policy](#).

8. Don't legislate in haste. Devising a regulatory framework is a painstaking and precise process - but worthwhile when it works. Poorly drafted incomplete 'simplified procedures' will not prove to be simple in practice and would need many additional provisions to make a robust procedure - [The road to hell is paved with good intentions](#). Given that there is no crisis engulfing e-cigarettes (or snus) it is best to ensure that the regulatory job is done properly. Making the existing consumer protection framework apply to e-cigarettes is all that is needed for now.

9. Play a long game. Regulatory systems and standards evolve. The directives covering cosmetics began in the 1970 and were substantially updated in 2009. The [regulation 1223/2009 for cosmetics](#) has many useful features - safety assessment, full disclosure, named responsible persons, quality standards, labelling, traceability, banned substance schedules, a special ISO standard for manufacturing practice ([ISO 22716:2007](#)) etc - these elements and others could be fashioned into a comprehensive framework for regulating nicotine products, including tobacco based products. That need not happen overnight - but could come out of a Commission review, options appraisal and extensive consultation - something that has not happened with the proposal to regulate as medicines. For now, *all that is needed* is for member states to apply and enforce the existing consumer protection legislation.

10. Listen to the users. This directive really matters most to existing or future smokers - 28 percent of EU adults at present. Can anyone find any who think that e-cigarettes are medicines, that the users are patients, or that the vendors of e-cigarettes are health care providers? I am unable to find such people. Many health campaigners will have told you that medicines regulation is the right approach. But experience as a chest physician, epidemiologist or smoking adviser is a poor qualification for making judgements on risk based regulation, product innovation, smoker's preferences, fast moving consumer goods markets etc. The vaping community knows from first hand experience how this works and why it matters. They do not want these products regulated as medicines.

I hope you find these observations useful as you work towards negotiating the best possible directive for public health

Yours sincerely

Clive Bates

Disclosure: no competing interests. I am former Director of Action on Smoking and Health (UK based) and a former civil servant. I now run a small consultancy and the [Counterfactual blog](#). Views expressed do not represent those of any previous employer.

From: Richard Hyslop <richard@endeavourpublicaffairs.co.uk>
Sent: 02 July 2013 13:22
To: "Undisclosed-Recipient;"@ham02.websitewelcome.com
Subject: Open letter to ENVI committee members from public health professionals, academics, and scientists

**Open Letter to Members
of the
European Parliament's Environment, Public Health and Food Safety Committee**

Dear ENVI Committee Members,

We are writing to you concerning the vote taking place in the ENVI committee on amendments to the draft Tobacco Products Directive (TPD) and in particular Article 18 which seeks to regulate nicotine containing products (NCP) – including electronic cigarettes – as a medicinal product.

As public health professionals, academics, and scientists, we have no vested interest in the production, promotion, or sale of electronic cigarettes; our only interest is in the public health of European citizens.

The smoking of tobacco cigarettes kills one smoker globally every 45 seconds. Every year in the EU:

- 700,000 people die of smoking related illnesses;
- 13 million people suffer from the main tobacco-related diseases; and
- €25.3 billion is spent every year in healthcare;

In revising the TPD MEPs should be guided by one key principle: lowering the rates of death and disease caused by smoking tobacco cigarettes.

Electronic cigarettes

Electronic cigarettes deliver clean nicotine – without the tar, carbon monoxide, and volatile hot gasses of tobacco cigarettes. For people who switch from tobacco cigarettes, they hugely reduce risk, while satisfying the need for nicotine and some of the behavioural aspects of smoking.

Electronic cigarettes represent a market-based, user-driven public health insurgency. The electronic cigarette market has already overtaken the market in nicotine replacement therapy (NRT) products – this itself is a telling comment on the attraction of electronic cigarettes over medicinal nicotine treatments. No public money has been spent, yet smokers are quitting, switching, and cutting down through using e-cigarettes.

For seven million smokers in the EU, electronic cigarettes have and continue to provide a viable alternative to smoking tobacco cigarettes. They have enabled those using them to leave smoking behind, either on a full or part-time basis. These people are now smoking far fewer or no cigarettes. This should be a cause for celebration, not a cause for concern.

Proposed regulation as a medicinal product

Despite almost uniform opposition from the users of these products, a number of MEPs seem determined to regulate electronic cigarettes as though they are medicines.

The key health benefit of electronic cigarettes is determined by how many smokers switch to them or use them as a staging post to quitting completely. In our opinion, a medicines regulatory regime will impose limitations on electronic cigarettes, making them less attractive relative to tobacco cigarettes, and will limit availability, raise costs, and reduce innovation. Compliance burdens would cause many smaller and more innovative manufacturers to go out of business, perversely giving market advantage to a few large manufacturers (such as tobacco companies) who can afford the costs of putting their products through medicines regulation.

Excessive regulation will not be in the best interests of consumers, as it would have the perverse effect of maintaining tobacco smoking, and current consumers deprived of these products would revert back to smoking cigarettes. The risk adverse regulation of nicotine will help perpetuate the cigarette market. Indeed the proposed health warning for NCPs under Article 18 – “this product contains nicotine and can damage your health” is questionable, and a more accurate statement might be “this product contains nicotine and may be addictive but presents substantially lower risks to health than tobacco cigarettes.”

Since these products are consumer products, regulators do not have to ensure that the product is an effective smoking cessation aid. Unless the maker makes a claim for some beneficial effect, there is no need for a medicines regulator to become involved in determining efficacy. Many smokers have found brands that have worked for them and competition will sort out the reliable products from the rest. Good regulation would build confidence in safety and quality and allow effective communication of the benefits.

TPD threshold levels for nicotine

The proposal in Article 18 to allow products below a certain concentration of nicotine to be on the market is unhelpful, both because that level is set so low, and also because setting nicotine levels for these products (except at the very highest level) is a leading misunderstanding of how these products are used (and indeed how tobacco cigarettes are smoked). The concentration of nicotine in the unit is largely irrelevant as people puff to achieve the level of nicotine that they desire. This has long been known by smoking researchers.

Addiction

Compulsive use of nicotine, at the dosage obtained by electronic cigarette users, is not known to be harmful to health. Thousands of former smokers in the EU use nicotine gums compulsively, often in large quantities and for months or even years, and this is not known to be harmful to their health.

One may dislike the idea that some people use a substance compulsively, but unless this is harmful to their health or family life or to society, this is not sufficient to prohibit all products that are used compulsively.

Regulation as consumer products

Good regulation of an NCP must ensure the product is safe, correctly described, including nicotine concentration, that the device works, and provide science-based accurate consumer information (including the decreased risk in comparison with the on-going smoking of tobacco cigarettes).

It is untrue to say that these electronic cigarettes are currently unregulated, or that the only option is medicines regulation or an unregulated market. As a consumer product electronic cigarettes are regulated at the EU level by at least 17 directives and by a variety of other legislation at the Member State level. What problem do MEPs see that requires further regulation?

Cigarettes are incredibly harmful, yet their toxicity is barely regulated with only peripheral measures regarding additives and flavours. Over-regulating the low-risk alternatives will protect the cigarette industry from competition and contribute to death and disease.

Twin track regulation

In our opinion, the TPD is the wrong place for any further regulatory framework for NCPs. The framework of the TPD – of controlling access to harmful tobacco products – is not the correct place for devices that have the potential for huge public health gains. The framing for NCPs must surely be to facilitate and encourage their uptake as competitors to tobacco cigarettes, at the same time ensuring safety.

In our opinion the way forward is twin track regulation. In this model, NCPs such as electronic cigarettes shall be sold as either (a) consumer products in compliance with the General Products Safety Directive and other relevant consumer protection as above, or (b) in the case where a manufacturer wanted to make a therapeutic claim in terms of the product being a smoking cessation aid, the manufacturer should have the option (as now) to seek to have the product approved as a medicinal product in terms of the relevant sections of the Medical Devices Directive.

Public health gains

We have such a massive opportunity here. It would be an appalling paradox if MEPs, in the name of safety, ended up smothering the electronic cigarette market with red tape, and so tip the competitive balance back in favour of tobacco cigarettes. We are only making small progress in further reducing the prevalence of tobacco cigarette smoking – encouraging current smokers to switch to electronic cigarettes has the potential to speed up the process with consequent major public health gains.

Do policy makers really want to protect an industry that kills 700,000 people at the expense of a market-based, consumer-led public health revolution that has the potential to save millions of lives?

Yours sincerely

Clive Bates

Former Director Action on Smoking and Health UK (1997-2003)
Now Counterfactual Consulting Ltd (no competing interests)

Dr Lynne E. Dawkins

Senior Lecturer in Psychology
Co-ordinator of the Drugs and Addictive Behaviours Research Group
School of Psychology, University of East London

Professor Jean-François Etter, PhD

Professor of public health, Faculty of Medicine, University of Geneva, Switzerland

Dr Konstantinos Farsalinos, M.D.

Researcher, Onassis Cardiac Surgery Centre, Athens Greece
Researcher, University Hospital Gathuisberg, Leuven, Belgium

Jacques Le Houezec, PhD

Consultant in Public Health, Rennes, France
Honorary Lecturer, UK Centre for Tobacco Control Studies, University of Nottingham, United Kingdom

Professor Lynn T. Kozlowski, PhD

Dean
Professor of Community Health and Health Behaviour
School of Public Health & Health Professions, University at Buffalo

Professor Riccardo Polosa
Full Professor of Internal Medicine, University of Catania
Scientific advisor for LIAF – Italian League for Anti-Smoking

Professor Gerry Stimson
Emeritus Professor, Imperial College London
Visiting Professor, London School of Hygiene and Tropical Medicine

Professor David T. Swenor J.D.
Adjunct Professor of Law, University of Ottawa
Honorary Lecturer, School of Community Health Sciences, University of Nottingham

STAES Bart OFFICE

From: Deborah Arnott <Deborah.Arnott@ash.org.uk>
Sent: 02 July 2013 11:39
To: Deborah Arnott
Subject: TPD and e-cigarette regulation: The ASH position

Dear ENVI committee member

I'm emailing you with respect to the regulation of e-cigarettes and the TPD.

ASH in the UK would prefer all e-cigarettes and other novel nicotine products to be require authorisation under the medicines directive but as a compromise we would support the general approach agreed by the Council of Ministers at its meeting on Friday 21st June, which was also the approach adopted in the Commission's proposal for the TPD. This requires all nicotine containing products above a certain threshold to be authorised as medicinal products.

Sales of e-cigarettes are rapidly expanding, indeed some analysts think they could be challenging cigarettes for market share in the near future and we need a proper regulatory framework in place. Having looked at this in detail I don't see how the TPD or GPSD can provide a proper regulatory framework while medicines regulation can and should.

1. Medicines regulators are already regulating nicotine products effectively so it seems more sensible to ensure that medicines regulation is adapted to regulate these products appropriately. E-cigarettes are being used by smokers primarily for the same purposes as NRT – to quit, to cut down, as an alternative to smoking and to use where they can't smoke – all purposes that NRT is licensed for in the UK and can be elsewhere. The industry has to say they're for recreational purposes because otherwise they get caught by medicines regulation, but smokers themselves freely admit they're using them to help them quit smoking.
2. All Member States should allow e-cigarettes to be on general sale and widely available in the transposing of the TPD. Even if this is not the case if they are licensed they will be on sale in pharmacies – and available – maybe in some jurisdictions not as freely as cigarettes but smokers will be able to get hold of them, just as consumers get hold of the medicines they need. Furthermore cigarettes are far too widely available which is part of the problem. There is growing pressure to limit where and when cigarettes can be sold in jurisdictions round the world. This is already being discussed and will be the next new trend in tobacco control after standard packs.
3. I have been involved in the international negotiations on the WHO FCTC since 2003 and there has been growing opposition to e-cigarettes. At the last meeting there was a strong push to have e-cigarettes brought within the FCTC and banned, which we worked hard to resist. See the document that went to the meeting and the decision coming out of it. Lots of countries have already banned e-cigarettes around the world and more are considering it. This pressure will continue and medicines regulation is the best protection against it and the best way of ensuring that e-cigarettes will be available but appropriately regulated.
http://apps.who.int/gb/fctc/PDF/cop5/FCTC_COP5_13-en.pdf
4. Currently the products are extremely variable in quality and reliability and most e-cigarette companies have little understanding of how they work. Medicines regulation along the UK model will ensure that the manufacturers have to know how their products work and what makes them more or less effective. We need to encourage other MS to adopt the same processes as the UK for regulation, which is what the MHRA is doing. Under the UK model it's not expensive, the abridged licence fee is under 35,000 euros, they don't have to carry out expensive randomised controlled trials as is the case for new medicines as the efficacy of nicotine is accepted by the regulator. The costs in bringing products up to scratch in manufacturing standards need to be incurred as many of the current products are not nearly as high a standard as they need to be to be most effective for smokers, as well as not being as safe as they could and should be.
5. The e-cigarette companies say medicines regulation is too expensive but this is a very profitable expanding market. The money is there to make sure they can meet the necessary standards. A recent report by Wells Fargo a US investment analyst came to the conclusion that:
 - Within a decade e-cig sales in the US could overtake cigarettes.
 - While the big 3 tobacco brands in the US are likely to be key players they think independents will continue to have significant market share.
 - Margins are growing on e-cigs as the market grows and evolves: by 2017 they think margins could be higher than current conventional cigarette margins of around 40%
 - Their model doesn't consider new entrants – all of e-cig volume consumption in the model is driven by existing conventional cigarette users
 - Tax rates for e-cigs in the US are currently 0% but they expect this will move to 20% by 2023 (compared to an average in the US for cigarettes of 46% currently increasing to 52% by 2023) [E-cigs attract standard VAT in the EU; licensed NRT in the UK is taxed at the medicines minimum of 5% VAT]

- They don't think regulation will undermine the long-term growth of the e-cig market – it is however likely to entrench existing e-cig players as it increases barriers to entry.
6. E-cigarettes are still a relatively young and rapidly evolving market. As part of normal market evolution there is going to be consolidation and the small companies are going to be swallowed up, largely by the tobacco industry. That is another good reason why we need a strong regulatory framework in place now to help shape how the market develops. The UK model can and should set the standard for how these products should be regulated in other MS too.
7. Medicines regulation is a good fit –it's not at all clear how a new regulatory framework within the TPD can be made to work. In particular:
- The ban on advertising promotion and sponsorship of tobacco products is simple to enforce, controls on marketing of e-cigarettes to ensure they're only being promoted to smokers and not to non-smokers or children and young people would be far more difficult to enforce. Medicines regulation already has a process in place for this.
 - The proposed health warning on e-cigs is very unhelpful – and wouldn't be required under medicines regulation. (We would suggest that any warning needs to be consumer tested before being adopted).
 - There are no mechanisms in place under the TPD to ensure that the products are a good standard in manufacturing and delivery. Such mechanisms are already in place under medicines regulation, while they would be costly and difficult to enforce under the TPD.
 - Medicines regulation also has a system in place for risk management and post-marketing authorization surveillance over the long-term – there's nothing like that in the TPD or the GPSD.

Do let me know if you have any questions.

Regards.

Deborah.

Deborah Arnott FRCP (Hon)
Chief Executive
Action on Smoking & Health
Suites 59-63, 6th Floor, New House
67-68 Hatton Garden
London EC1N 8JY
e-mail: deborah.arnott@ash.org.uk
skype: darnottash
T: 020 7404 0242
M: +44 (0)7976 935 987
F: 020 7404 0850
W: <http://www.ash.org.uk>

Action on Smoking and Health is a company limited by guarantee. Registered in England No. 998971. Registered Charity No. 262067. Registered address as above.

Email Scanned by BBS MessageAngel

STAES Bart OFFICE

From: Richard Hyslop <richard@endeavourpublicaffairs.co.uk>
Sent: 01 July 2013 17:15
To: "Undisclosed-Recipient;"@ham02.websiteswelcome.com
Subject: Banning flavours will lead to more smoking
Attachments: Banning flavours will lead to more smoking.pdf

Dear ENVI committee member,

Please find attached a one page briefing paper that very clearly sets out why our client, Totally Wicked Ltd, concludes that banning flavours in the context of electronic cigarettes will only lead to more people smoking tobacco cigarettes.

We hope that you will take the time to read this short briefing.

If you have any questions please do not hesitate to contact us.

Richard Hyslop
Director
Endeavour Public Affairs Ltd

T: + 44 (0) 7974 133 651
E: richard@endeavourpublicaffairs.co.uk
W: www.endeavourpublicaffairs.co.uk

Follow us on Twitter: <https://twitter.com/EndeavourPA>

STAES Bart OFFICE

From: Weidenhammer Packaging Group <Ralf.Weidenhammer@weidenhammer.de>
Sent: 01 July 2013 12:08
To: STAES Bart
Subject: Tobacco Products Directive 2 (TPD2), amendments to chapter 2, article 13
Attachments: Weidenhammer_Packaging_Group_Support_Amendments_2013_07_01.pdf

Dear Mr Staes,

Please allow me to introduce myself and my company, the Weidenhammer Packaging Group, based in Hockenheim, Germany. My name is Ralf Weidenhammer, Managing Director of our family-owned and managed business founded in 1956. Since its foundation, the Weidenhammer Packaging Group has become European market leader in the manufacture of spirally wound composite cans for consumer products. Our website www.weidenhammer.de gives a full breakdown of our business activities.

My reason for contacting you is the European Commission Directive Ref. COM (2012) 788 Final dated 19/12/2012 – also known as **Tobacco Products Directive 2 (TPD2)** – that is currently being reviewed by the ENVI committee. As you know, ENVI members have submitted a high number of amendments for TPD2, including several amendments that particularly suggest a **revision of chapter 2, article 13: amendments N° 872-879 and N° 881**.

Article 13 regulates the packaging of fine-cut tobacco products and could have dramatic consequences not only for the European packaging industry, but also for the end consumer. In its most recent version, this article clearly states that pouches are the only form of packaging allowed for such a tobacco product. As a consequence all other types of packaging – including composite cans – would no longer be allowed for fine-cut tobacco. This would have a severe impact on our business since a considerable part of our production is dedicated to composite cans for fine-cut tobacco.

There is no scientific evidence at all that our packaging has any more negative effect or impact on smoking trends (or on prohibiting youth smoking, which is the target of TPD2) compared to pouch packaging. During the past few months we have therefore been in contact with many MEPs inside and outside the ENVI committee, and have asked them to support a revision of article 13. Almost all of them agreed that this respective article should be amended to allow it is to be changed.

Meanwhile, the AGRI committee of the European Parliament has already suggested deleting article 13. **Several members of the ENVI committee, including MEP Linda McAvan, have further signalled that they would support a revision**, that would allow the future use of the composite can.

This is why I would like to ask you today to support the **amendments N° 872-879 and N° 881 for article 13** in the final vote of the ENVI committee, therefore ensuring that composite cans will continue to be allowed for the packaging of fine-cut tobacco.

Please find attached a leaflet that sums up all important information. It explains why we think it is necessary that article 13 should be amended and the change adopted.

If you have any questions regarding this topic, I am very happy to answer them personally. I would be very grateful if you could support our concerns in additional debates of the ENVI committee and if you could inform me about your further steps in this matter. My contact details are recorded below.

Yours sincerely

Ralf Weidenhammer
Managing Director
Weidenhammer Packaging Group GmbH

Phone: +49 6205 203 177 | Fax: +49 6205 203 131
e-mail: Ralf.Weidenhammer@weidenhammer.de

Weidenhammer Packaging Group GmbH, 1. Industriestraße 26, 68766 Hockenheim
Sitz Hockenheim, Registergericht Amtsgericht Mannheim HRB 421663
Vertreten durch die Geschäftsführer: Arthur Weidenhammer, Ralf Weidenhammer

STAES Bart OFFICE

From: ÖGB Europabüro <office@oegb-eu.at>
Sent: 01 July 2013 12:06
To: STAES Bart
Subject: ÖGB position on the EU Tobacco Products Directive
Attachments: ENVI - Pos. Neg. Amendments.pdf



Dear Members of the European Parliament,

The Austrian Trade Union Federation (ÖGB) is gravely concerned that in the implementation process of the new EU Tobacco Products Directive, this Directive – despite our full understanding of the Commission’s efforts with regard to health policy – will lead to severe distortions of structural and industrial policy.

Particularly, this affects some highly specialised production plants in Austria, where the management and union representation see their medium-long-term existence at risk in the event of the implementation of this Directive. The tragic aspect is that it has to be feared that in the medium term these highly-specialised enterprises will migrate and around 800 workers will lose their jobs – yet the tobacco products will then be imported or smuggled from countries with fewer restrictions.

We therefore ask you to oppose the negative industrial and labour market policy implications of this Directive.

With respect to the contents, the attached proposed amendments relate to:

- Deletion of the greatly extended powers of the EU Commission (“Delegated acts”), to prevent future decisions of the Commission in the framework of the Tobacco Products Directive from leading to reduction and displacement of production and the loss of highly-qualified jobs without the Austrian Government having any further involvement;
- That no reduction and displacement of production and the loss of highly-qualified jobs takes place in the highly specialised Austrian production companies as a result of the technical specifications in the Directive or the prohibitions envisaged (menthol, slim, flavours and various warning notices).

The Austrian Trade Union Federation explicitly states that a negotiating outcome that failed to take account of these views – even if funds from the Globalisation Fund were concurrently made available in compensation – would not be defensible.

We kindly asks the Members of the European Parliament, in particular of the Environment, Public Health and Food Safety Committee, to support our position in the upcoming legislative process. Please find enclosed the related amendments with respect to our key demands.

For any further question, please, do not hesitate to contact us.

Yours sincerely,

Oliver Röpke
Head of Office

ÖGB-Europabüro
Permanent Representation of Austria to the EU
Avenue de Cortenbergh 30
B-1040 Brussels
Tel. +32 (0)2 230 74 63
Fax +32 (0)2 231 17 10

www.oegb-eu.at

STAES Bart OFFICE

From: Richard Hyslop <richard@endeavourpublicaffairs.co.uk>
Sent: 27 June 2013 23:55
To: "Undisclosed-Recipient;"; @ham01.websiteswelcome.com
Subject: Why regulating electronic cigarettes as a medicinal product actually constitutes a ban
Attachments: Why regulating electronic cigarettes as a medicinal product actually constitutes a ban.pdf

Dear ENVI committee member,

Please find attached a one page briefing paper that very clearly sets out why our client, Totally Wicked Ltd, concludes that regulating electronic cigarettes as a medicinal product actually constitutes a ban, a position supported by the European Parliaments own Legal Affairs committee.

We hope that you will take the time to read this short briefing which is based on significant experience in the electronic cigarette industry, legal advice, and a relevant case study.

If you have any questions please do not hesitate to contact us.

Richard Hyslop
Director
Endeavour Public Affairs Ltd

T: + 44 (0) 7974 133 651
E: richard@endeavourpublicaffairs.co.uk
W: www.endeavourpublicaffairs.co.uk

Follow us on Twitter: <https://twitter.com/EndeavourPA>

STAES Bart OFFICE

From: Richard Hyslop <richard@endeavourpublicaffairs.co.uk>
Sent: 27 June 2013 23:01
To: STAES Bart
Subject: Request for a meeting

Dear Mr Staes

Millions of lives depend on MEPs doing the right thing when revising the Tobacco Products Directive

You should have received in the post, a sample electronic cigarette and a short [briefing paper](#) regarding electronic cigarettes and the Tobacco Products Directive from our client Totally Wicked Ltd. If you have not received this, it should arrive within the next few days.

Ahead of the vote in the ENVI committee in July on the Commission's proposals to revise the Tobacco Products Directive, our client would very much like to meet with you to discuss this issue in more detail and to answer any questions that you may have regarding electronic cigarettes. We are happy to come to Brussels and to meet at a time of your convenience.

I look forward to hearing from you.

Richard Hyslop
Director
Endeavour Public Affairs Ltd

T: + 44 (0) 7974 133 651
E: richard@endeavourpublicaffairs.co.uk
W: www.endeavourpublicaffairs.co.uk

Follow us on Twitter: <https://twitter.com/EndeavourPA>

STAES Bart OFFICE

From: George Yiangou <G.Yiangou@AESGP.eu>
Sent: 26 June 2013 19:02
To: STAES Bart
Subject: Tobacco Products Directive - Regulation of nicotine containing products - Social media analysis
Attachments: AESGP response to EC proposal for TPD.PDF; Social media analysis.docx

Dear Mr Staes,

As you may know, the Association of the European Self-Medication Industry (AESGP) represents the manufacturers of non-prescription medicines, food supplements and self-care medical devices in Europe, including world leaders in the manufacture and marketing of Nicotine Replacement Therapy products.

In light of the debate on the revision of the Tobacco Products Directive, we would like to share with you our related position paper, as well as an analysis of social media activity demonstrating how nicotine containing products such as e-cigarettes are promoted. The key issues raised by the two documents are summarised below:

- There is a need for a single regulatory framework for all nicotine-containing products classifying them as medicines.
- A differentiation between medicinal and non-medicinal nicotine containing products based on dosage/concentration is not justified by evidence or based on experience in how these products are marketed.
- AESGP supports the objective set by the European Commission's proposal that: "The proposal removes current legislative divergence between Member States and the differential treatment between Nicotine Replacement Therapies and Nicotine Containing Products".

We would also like to bring to your attention that the AESGP position is in line with the policy of the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA), which [decided on 12 June 2013](#) that: "*All nicotine-containing products (NCPs), such as electronic cigarettes, are to be regulated as medicines in a move to make these products safer and more effective to reduce the harms of smoking.*"

Sincerely,
George Yiangou



Dr George Yiangou

AESGP - Association of the European Self-Medication Industry

7 avenue de Tervuren, B-1040 Brussels | Tel: +3227355130 | Fax: +3227355222

E-mail: g.yiangou@aesgp.eu URL: <http://www.aesgp.eu>